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Granulomatosis with polyangiitis (GPA, formerly known as Wegener’s 
granulomatosis) is a rare and sometimes fatal systemic autoimmune disease.  
Anti-neutrophil cytoplasmic antibodies (ANCAs) specific for proteinase 3 (PR3) 
are associated with GPA.  However, the pathogenesis of GPA is not yet clear.  
Our aim was to investigate the local autoimmune response, circulating immune 
modulatory cells and cells expressing the immune suppressor molecules 
programmed death 1 (PD-1) and its ligands in GPA.   
In mucosa from GPA patients, activated B cells were observed located alongside 
PR3 expressing cells and B cell survival factors BAFF and APRIL, which was 
produced by the granulomas and giant cells.  B cells were proliferating and 
persistent in biopsies.  However no evidence of B cell clones from the mucosal 
biopsies circulating in peripheral blood was observed in GPA.   
An increased frequency of circulating TFH cells and a reduced frequency of Treg 
cells was observed in peripheral blood from GPA patients on conventional 
therapies compared to healthy controls.  No such difference was found in GPA 
patients treated with rituximab.  The frequency of circulating TFH and Treg cells 
was found to be inversely correlated in human peripheral blood. 
No difference in the relative quantity of mRNA encoding PD-1 in lymphocytes 
and monocytes was found in GPA patients compared with healthy controls.  
Lower percentage of CD14+ monocytes expressing PD-1 was observed in GPA 
patients.  Lower relative quantity of mRNA encoding PD-1 ligands PD-L1 and 
PD-L2 in T cells and monocytes was observed in GPA patients.   
In conclusion, data in this thesis identifies activated B cells alongside 
auto-antigens and B cell survival factors in the mucosa in GPA.  A negative 
correlation between TFH and Treg cells is observed that implies the balance 
between T cell subsets and its B cell dependence are associated with disease 
activity in GPA.  The deficiency of PD-L1 and PD-L2 mRNA in lymphocytes and 
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BAFF B-cell activating factor 
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1.1 Granulomatosis with polyangiitis (GPA) 
Granulomatosis with polyangiitis (GPA) was formerly known as Wegener’s 
granulomatosis [1].  It is a chronic inflammatory granulomatous autoimmune 
disease characterized by upper and/or lower airways disease and 
glomerulonephritis [2-5].  It can affect all ethnicities with an equal male to 
female ratio and higher prevalence in Caucasians (more than 90%) [6, 7].  It is 
one of the most common systemic vasculitic diseases in the UK and the annual 
incidence of GPA in the UK has been reported to be 8.5 cases per million [8].   
GPA is a part of a spectrum of vasculitic syndromes that affect small and 
medium-sized vessels.  The clinical symptoms of GPA are variable and many 
organs can be affected, such as the upper airways, lungs, kidneys, ears, skin, gut 
and the central and peripheral nervous systems [3]. The condition may be 
life-threatening and 75% of patients with GPA will eventually develop renal 
involvement, for example rapidly progressive glomerulonephritis and 
necrotizing crescentic glomerulonephritis which, if not recognized and treated 
early, can lead to end-stage renal disease or death [2, 3].  More than 80% of GPA 
patients suffer from nasal symptoms, such as pain, stuffiness, nosebleeds, rhinitis 
nasal bridge tenderness and crusting [3, 9].  Some patients have distinctive 
nasal septal perforations and a saddle-nose deformity, as shown in figure 1.1.1.  
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Figure 1.1.1 Saddle-nose deformity of GPA patient: left picture of an example of 
saddle-nose deformity in a patient with GPA [3];  right magnetic resonance imaging 
(MRI) of an example of saddle-nose deformity in a patient with GPA.  The loss of nasal 
conchae and destruction of the nasal septum is indicated by triangle; the inflammatory 
tissue around is indicated by arrows [10]. 
GPA can also cause pulmonary manifestations such as pulmonary nodules, 
infiltrates, cavitary lesions and alveolar hemorrhage (Figure 1.1.2).  Ear 
symptoms include ear pain, otitis externa and otitis media hearing loss.  Other 
non-specific manifestations include oral mucosal ulcerations, skin lesions and 
arthralgia [3].  Central and especially peripheral nerve involvement with 
vasculitic neuropathies and peripheral nerve lesions can be disabling and there 
is a wide spectrum of ophthalmologic manifestations including orbital 
granulomas, scleritis, peripheral ulcerative keratitis, retinal vasculitis and visual 
loss [3].    
                                                                               
Figure 1.1.2 Multifocal cavitary nodules in lungs of patient with GPA [3] 
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To be classified as GPA, a patient has to fulfill a minimum of 2 of the 4 criteria: 
nasal or oral inflammation resulting in ulcers, purulent or bloody nasal discharge; 
chest radiographic abnormalities such as nodules, fixed pulmonary infiltrates or 
lung cavities; urinary sediment and granulomatous inflammation on tissue 
biopsies [11, 12].  These are not diagnostic criteria but are useful in classifying 
anti-neutorphil cytoplasmic antibody (ANCA) associated vasculitis as GPA.  
ANCA has been reported to have a specificity of 92% and a sensitivity of 88% in 
GPA diagnosis [13].  The diagnosis of GPA is primarily based on clinical 
manifestations of systemic vasculitis since some patients may be ANCA negative 
despite having clinical evidence of GPA.  This small group of ANCA-negative 
GPA patients tend to have limited disease rather than severe systemic 
manifestations of GPA [14]. 
It is important to ascertain the level of disease activity in systemic vasculitis in 
order to devise the best treatment strategies for patients and monitor clinical 
response to therapy.  The Birmingham Vasculitis Activity Score (BVAS) is a 
disease assessment instrument which provides a computer generated numerical 
score of vasculitis disease activity that can be applied directly to management of 
patients with GPA [15].  The extent of damage as a result of the granulomatous 
or vasculitic aspects of this disease can be measured annually with a vasculitis 
damage index score (VDI) [16].  The BVAS and VDI are instrumental in 
predicting possible disease outcome and prognosis.   
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If untreated severe GPA has a mortality rate at 1 year of approximately 80% with 
the major causes of death including severe necrotising glomerulonephritis, 
severe pulmonary haemorrhage and infection.  The introduction of 
immunosuppressive therapy has greatly improved the morbidity and mortality 
of GPA patients and at present the 5 year survival rate is approximately 75% [17].  
Induction and maintenance of remission in GPA may be achieved using standard 
immunosuppressive drugs.  Cyclophosphamide (CYC) in combination with 
corticosteroids has been used via either as intravenous pulsed therapy or oral 
therapy in remission induction therapy for moderately-severe to severe 
manifestations of GPA [18].  Mild or localized GPA may be treated with 
Methotrexate (MTX) via the oral or subcutaneous route [19].  MTX and 
Azathioprine have also been reported to be effective for remission maintenance 
in GPA [20, 21].  Apart from standard immunosuppressive drugs, rituximab, an 
anti-CD20 monoclonal antibody, was licensed for the management of the 
ANCA-associated vasculitides, GPA and microscopic polyangiitis, by the United 
States Food and Drug Agency (FDA) in 2011 [22].  Rituximab has been shown to 
be effective in treating GPA patients (details described in section 1.9 and chapter 
4) [23, 24].    
In this thesis, various aspects of the immunology of GPA have been investigated.  
Before introducing what is known about the immunology of GPA from the 
literature, the relevant aspects of basic immunology will be described. 
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1.2 B cell maturation and Antibody production 
1.2.1. Overview of B cell development 
B cells producing antibodies (Abs) against antigen (Ag) play an important role in 
the humoral immune response of adaptive immune system [25].  They originate 
from stem cells in bone marrow [26].  In bone marrow, progenitor B cells go 
through immunoglobulin heavy chain gene rearrangement (pro-B cell stage) 
followed by light chain gene rearrangement (pre-B cell stage) and then become 
immature B cells [27, 28] (details described in section 1.2.2).  CD20 is expressed 
on the surface of B cells from the late pro-B cell stage and is useful as a marker 
for B cells [28, 29].  The first checkpoint for autoreactive B cells occurs at this 
stage which only allows cells with low affinity to self Ags to survive [28, 30] 
(details described in section 1.2.3).   
Immature B cells then leave bone marrow and enter peripheral blood.  B cells at 
this stage are called transitional B cells [31].  It has been reported that there are 
three consecutive stages of transitional cells in human based on expression of 
transitional markers CD21, CD24, CD38, CD10, IgD and CD45RBMEM55 [31, 32].  
The second checkpoint for autoreactive B cells in which B cells expressing Abs 
against self Ags are deleted occurs at this stage though what contributes to this in 
humans is not known [33, 34].  B-cell activating factor (BAFF) has been 
reported to play an important role in B cell survival at this checkpoint [35] 




Figure 1.2.1 Overview of B cell development in bone marrow and periphery [36].  
 
When the peripheral tolerance process is complete, B cells become fully mature 
and named naïve B cells [31].  They then recirculate through peripheral blood 
to secondary lymphoid tissues such as lymph nodes, spleen and Peyer’s patches 
where they encounter Ags and may form germinal centres (GC) with help from 
activated T cells if they encounter specific Ag [37].  Activation of B cells 
resulting in GC formation requires the presence of Ag, interaction between CD40 
on B cells and CD40ligand (CD40L) on T cells and cytokine stimulation [31, 38, 
39].  The activated B cells then proliferate rapidly and form germinal centres 
where B cells undergo somatic hypermutation (SHM) and class switch 
recombination (CSR) to generate high affinity Abs and Ab diversity [40, 41] 
(details described in section 1.2.4).   Activated B cells with low affinity to Ags 
are deleted while cells expressing high affinity Abs survive and leave GCs develop 
35 
 
into Ab-secreting plasma cells or memory B cells [42, 43].  CD20 is expressed on 
memory B cells, but is lost before terminal plasma cell differentiation [28, 29].  
The overview of B cell development is shown in Figure 1.2.1. 
Alternatively, B cells can be activated in a T cell independent manner.  It has 
been suggested that the second signal provided by T cells in T cell dependent B 
cell response is replaced by either recognition of microbial constituents or 
cross-linking of BCRs by Ag with repeating epitopes [28] (details described in 




1.2.2 Antibody production 
1.2.2.1 Structure of Antibodies 
The basic functional unit of antibody (Ab), also known as immunoglobulin (Ig), is 
a ‘Y’ shaped molecule which contains two identical antigen-binding sites at the 
tips of the arms of the ‘Y’.  Each Ab molecule contains two identical heavy chains 
and two identical light chains combined together by disulfide bonds.  Both 
heavy and light chains are composed of two different functional domains: 
variable (V) domains encoding the antigen binding site and constant (C) domains 
determining different isotypes.  There are five isotypes of Ig that differ in their 
functional properties in mammals: IgM, IgD, IgG, IgA and IgE.  Flexible hinges in 
IgD, IgE and IgA connect the branch and stem together, while in IgM and IgE, 
there is an extra C region instead of hinge, as shown in Figure 1.2.2 [28]. 
          
Figure 1.2.2 Different Ig isotypes are encoded by identical heavy chain C 
regions. IgD, IgG and IgA are encoded by three Cδ, Cγ and Cα gene segments 
respectively.  IgM and IgE are encoded by four Cμ and Cε segments respectively.  An 




The angle between two antigen-binding sites can be dramatically different 
according to the flexibility of the hinge, which enables Ab to recognize and bind 
to different antigens (Ags) [44].  Antigen-binding sites consist of V domains 
from both light chains and heavy chains.  In the V domain of each polypeptipe 
chain, there are three segments having much higher variability termed 
complementarity determining regions (CDRs).  CDRs determine binding ability 
to Ags.  The regions between CDRs are termed framework regions (FRs) as they 
provide the structural framework of the antigen-binding site.  There are three 
FRs in each germline V domain: FR1, FR2 and FR3, and an FR4 after the 
rearranged CDR3 [45]. 
1.2.2.2 Generation of Antibodies 
Antibody diversity in the primary Ig repertoire is generated by gene 
rearrangement. Diversity by gene rearrangement can be combinatorial due to 
multiple alternative rearranging segments in germline or junctional because the 
joints between segments are not precise.  Light chain consists of variable (V), 
joining (J) and constant (C) regions, while heavy chain has an extra diversity (D) 
segment between V and J segments.  As many alternatives of V, D and J 
segments are present in germline DNA, approximately random selection of gene 
segment from each type makes V(D)J combination highly variable, and ensures 
the combinatorial diversity of gene rearrangement.  Random deletion of 
nucleotides by exonuclease and addition of nucleotides in the joint of gene 
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segments in each chain guarantees junctional variability that also contributes to 
the diversity resulting from V(D)J recombination [28].  
B cell development starts by rearrangement of Ig heavy chain loci [27, 46].  
When gene rearrangement occurs in the heavy chain, one D segment combines 
randomly with one J segment by pairing of recombination signal sequences (RSSs) 
with opposite orientation and everything between is deleted.  Then the joined 
DJ segments combine with one of the upstream V segments at random while 
nucleotides are added to the junction by Terminal deoxynucleotidyl transferase 
(TdT).  After the VDJ junction is formed, the DNA strand is transcribed to 
primary transcript RNA which has an intron between VDJ junction and C region.  
Finally, messenger RNA (mRNA) is produced by splicing out the intron between 
VDJ junction and C segment [28].  B cells undergoing Ig heavy chain gene 




                          
Figure 1.2.3 Gene rearrangement in heavy chain and light chain [28]: Ig heavy 
chain gene rearrangement (right) starts from random combination of one D 
segment with one J segment, then DJ junction combines with one randomly selected 
V segment.  Gene sequences between the selected gene segments are deleted.  
Then template DNA is transcribed into mRNA containing an intron between VDJ 
junction and C segment which will be spliced out at the final stage.  Ig light chain 
gene rearrangement (left) starts with random combination of one V segment with 
a J segment.  DNA is then transcribed into mRNA which contains an intron 
between VJ junction and C segments.  The intron is then spliced out when the light 
chain gene rearrangement is completed. 
When the heavy chain rearrangement is completed, pro-B cells develop to pre-B 
cells at which stage Ig light chain gene rearrangement occurs [48, 49].  The 
process of VJ recombination in light chain is similar to that in heavy chain.  As 
there is no D segment in light chain, rearrangement starts from the random 
combination of a V segment and a J segment, and the subsequent steps are the 
same as in heavy chain [28].  The sequence of Ig gene rearrangements is shown 




1.2.3 Autoreactive B cells in early B cell development 
It has been reported that the rearranged Ig heavy chain can be expressed on the 
surface of pre-B cells to form pre-B cell receptor (pre-BCR) [50].  At this stage, a 
Vpre-B and λ5 encoded surrogate protein replaces the conventional light chain 
by binding to rearranged heavy chain [51].  The expression of pre-BCR has been 
reported to play an important role in the transition from pro-B cell to pre-B cell.  
First checkpoint for autoreactive immature B cells occurs when light chain is 
rearranged.  This tolerance is known as central tolerance [52, 53].  
Traditionally, autoreactive B cells that bind to self Ags were thought to be 
eliminated at the immature B cell stage during central tolerence [54, 55].  
However, recent studies indicate that autoreactivity is necessary for B cell 
development at early stages [56, 57].  The recent hypothesis proposes that a 
low level of immature B cell expansion will be induced by pre-BCR which is not 
autoreactive, while pre-B cells with autoreactivity will encounter self-Ag and 
undergo a proliferative burst.  Autoreactivity of newly developed pre-B cells 
can be removed subsequently by rearranging light chain genes.  This process is 





1.2.4 T cell dependent B cell activation 
1.2.4.1 Germinal centre responses 
After maturation in bone marrow and maturation systemically from transitional 
B cells, naïve B cells expressing surface IgM and IgD circulate in the blood and 
migrate through secondary lymphoid organs, such as spleen, lymph nodes and 
tonsil [59].  B cells enter secondary lymphoid tissue via high endothelial venule 
(HEV) in the T-cell zones, and then migrate towards the B cell follicles [28].   
If naïve B cells passing by the border between T-zone and B-zone do not 
encounter a specific Ag, they would leave the lymphoid organ by efferent lymph 
vessel, return to the peripheral blood and continue circulating [28].   
If naïve B cells encounter Ags and pre-activated CD4+ T cells on the border 
between the T-zone and B-zone, they would be activated and form or migrate 
into germinal centre (GC) to proliferate and generate B cells expressing diverse 
Abs through somatic hypermutation (SHM) and class switch recombination (CSR) 
[60].  Firstly naïve B cells that have encountered Ags and received cognate T cell 
help move to the dark zone of GCs and form centroblasts which are rapidly 
proliferating.  Then progeny of those rapidly dividing centroblasts termed 
centrocytes, express surface Ig and move to the light zone of the GC to test their 
affinity to Ags [37, 59].   
The selection of high affinity B cells in the light zone of GCs has been reported to 
depend on several signals [61].  Signal through BCR has been demonstrated to 
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play an important role in selecting high affinity B cells, as well as signals through 
CD40 and CD40L interaction delivered by T follicular helper (TFH) cells in GCs 
(details described in section 1.3.3) [61-64].  B cells with high affinity Abs then 
differentiate into memory B cells [65, 66] or long-lived plasma cells [67, 68] or 
continue to cycle in the GC and undergo further rounds of mutations and 
selection [69].   GC B cell differentiation has been reported to be mediated by 
many signals [61].  Signaling through CD40 has been demonstrated to favour 
memory B cell development [70, 71].  IL-2, IL-10, CD40L and IL-21 have been 
found to promote the generation of memory B cells, while IL4 partially inhibits it 
[61, 72].  IL-10 has also been reported to promote the generation of plasma 
cells [73], while IL-24 has been reported to inhibit this differentiation [74].  B 
cells with low affinity for Ags will either go apoptosis or recycle through the GC 
[69].  
 
1.2.4.2 Somatic hypermutation and class switch recombination 
Diversity of Abs in mature B cells after activation with T cell help is generated by 
somatic hypermutation (SHM) and class switch recombination (CSR) of the Ig 
genes.  SHM alters the Ab affinity to Ag through mutating individual nucleotide 
in the variable region of both light and heavy chains, while CSR produces 
functional diversity by switching to different isotypes of antibody harboring the 
same antigen-binding sites by changing the constant regions of heavy chains. 
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Activation-induced cyditine deaminase (AID) is a DNA cytidine deaminase that is 
expressed by activated germinal centre B cells [75].  AID has been reported to 
be essential for both SHM and CSR [76-78].  Further studies have reported that 
AID initiates SHM and CSR by deaminating cytosine (C) to uracil (U) [76, 79].   
In terms of SHM, it has been reported that following AID deamination, the U-G 
pair can be transcribed and replicated into a transition mutated T-A pair [76, 79].  
Alternatively, the U residue can be removed by uracil-DNA glycosylase (UNG) 
[80].  The abasic site created by excising of U can either be filled by a C, in which 
case the AID and UNG attacked point is repaired and no mutation occurs [80];  
or be filled randomly by the other three types of nucleotides by translesion 
polymerases, in which case  SHM from C to G or A, or T occurs [28].  The U-G 
mismatch can also be recognized by MSH2-MSH6 complex instead of UNG [81].  
In the presence of MSH2-MSH6, exonuclease I and low fidelity polymerase η has 
been reported to trigger the mutation of upstream and downstream A-T [28].  
In the case of CSR, AID initiates the recombination by deaminating C in switch (S) 
regions, which are located upstream of each C region [82].  Similar to SHM, the 
produced U residues are then removed by UNG.   Instead of refilling the abasic 
residue directly, the apurinic/apyrimidinic endonucleases (APE1 and APE2) 
generate double strand breaks (DSBs) which are essential for CSR [83].  Then 
donor and acceptor S regions containing double strand breaks align and 
recombine together [82].  
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1.2.5 T cell independent B cell activation 
Although T cells are required for B cell responses involving GC formation, some 
microbial constituents, can support B cell responses in the absence of cognate T 
cell help [28].  According to different stimulating mechanism, 
thymus-independent (TI) Ags are divided into two classes, TI-1 and TI-2.   
It has been reported that high concentration of TI-1 Ags can activate nonspecific 
B cell responses , which is known as polyclonal activation [84].  
Lipopolysaccharide (LPS) a TI-1 Ag in mice that can bind to TLR-4 on B cells [85].  
It has been reported that B cell IgA CSR is up-regulated by DCs when stimulated 
with LPS and native choleva toxin (nCT) during TI-1 response [86].  
TI-2 Ags include bacterial capsular polysaccharides that contain highly repetitive 
structures [87].  It has been reported that TI-2 Ags activate mature B cells 
through cross-linking many BCRs that are specific for the Ag [88].  Some studies 
have demonstrated that both recirculating B cells and B cells from GCs can 
differentiate into cells that can respond to TI-2 Ags [89].  It has been 
demonstrated that DCs and macrophages can support TI-2 Ag induced B cell 
activation by producing B cell survival factors, such as BAFF and a 






1.2.6 B cell survival factors  
1.2.6.1 B cell activating factor (BAFF) 
B cell activating factor (BAFF), which is also known as B Lymphocyte Stimulator 
(BLyS) and TNF- and APOL-related leukocyte expressed ligand (TALL-1), is a 
cytokine that belongs to the tumor necrosis factor (TNF) ligand family [92].  
BAFF is encoded by the TNFSF13B gene on chromosome 13q32-34 in human [92, 
93].  In the human BAFF encoding gene, there are 6 exons: exon 1 encodes the 
transmembrane domain; exon 2 encodes the furin processing site; and exons 3 to 
6 encode the TNF homology domain binding to receptors [94].  In human, BAFF 
can be either expressed on the cell surface or released as a soluble trimeric 
ligand [94].  BAFF can be expressed on a range of different cells, including 
monocytes, activated neutrophils, DCs and T cells [95-97].  There are three 
receptors for BAFF: transmembrane activator-1 and calcium modulator and 
cyclophilin ligand-interactor (TACI), B cell maturation antigen (BCMA) and BAFF 
receptor (BAFF-R) [35].   
1.2.6.2 A proliferation-inducing ligand (APRIL)  
A proliferation-inducing ligand (APRIL), also known as tumor necrosis factor 
ligand superfamily member 13 (TNFSF13), is a protein that belongs to the TNF 
ligand family [98].  APRIL is encoded by the TNFSF13 gene on chromosome 17 
in human [94].  It is a 250aa protein which contains an extracellular domain 
(encoded by exons 2 to 6), a hydrophobic transmenbrane domain (encoded by 
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exon 1) and a predicted cytoplasmic domain in human [98].  Similar to BAFF, 
APRIL can either be expressed on the cell surface or released as soluble trimers 
[94].   
In contrast to BAFF, APRIL can only bind to TACI and BCMA, but not BAFF-R in 
human [94, 99].  Although BAFF and APRIL can both bind to BCMA, the binding 
affinities are different [99].  It has been reported that the APRIL: BCMA 
interaction has higher affinity than BAFF: BCMA interaction [100, 101].  TACI 
has been demonstrated to interact with BAFF and APRIL with similar affinity 
[101, 102].  However, the mechanisms of binding of TACI to BAFF and APRIL 
are different, as TACI can bind to both BAFF trimers and BAFF multimers [103] 
and APRIL does not form multimers [104].  Recently, some studies have 
reported that APRIL can also interact with heparan sulphate proteoglycan (HSPG) 
[105]. 
1.2.6.3 Function of BAFF and APRIL  
BAFF and APRIL have been shown to play an important role in B cell survival and 
proliferation [35, 94].  The interaction between BAFF and BAFF-R on B cells is 
essential for B cell survival and differentiation at immature stages [103, 106, 
107].  It has been reported that immature transitional B cells require BAFF 
signaling to develop into mature B cells [108].  APRIL has been shown to play a 
critical role for later-staged B cells and plasma cells through reaction with its 
receptors TACI or BCMA [109, 110].  Huard, et al (2008) demonstrated that 
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APRIL upregulates the expression of anti-apoptotic factors Bcl-2 and Bcl-XL [111].  
It also has been shown that over-expression of Bcl-2 and Bcl-XL can rescue B cells 
in BAFF-R deficient mice demonstrating that interaction between BAFF and 
BAFF-R encourages B cell survival through preventing apoptosis [112, 113].   
Moreover, BAFF and APRIL have been reported to induce class switch 
recombination (CSR) in human without help from T cells [95].  Some studies 
have reported that BAFF-R and TACI can initiate Ig isotype switching in B cells 
[114, 115].  The interaction between BAFF and BAFF-R has been reported to 
support T cell proliferation as well [116, 117].   
Increased levels of serum BAFF have been detected in patients with autoimmune 
diseases [35].  Antibody to BAFF (Belimumab) is a new therapeutic option for 
treatment of autoimmune diseases [118], implying that BAFF plays important 





1.3 T cell development  
1.3.1 T cell maturation 
Naïve T cells develop in the thymus from stem cells that originate in bone 
marrow.  Similar to B cells, T cell maturation progresses alongside 
rearrangement of the genes encoding the T cell receptor (TCR) in thymus [28].  
The development of T cells in thymus is divided into three stages: double 
negative (DN), double positive (DP) and single positive (SP) [119].  The DN 
stage can be subdivided into 4 stages according to the expression of CD25 and 
CD44: DN1 (CD44+CD25-), DN2 (CD44+CD25+), DN3 (CD44-CD25+) and DN4 
(CD44-CD25-) [120, 121] .   
It has been reported that TCR rearrangement of ɣ, δ or α and β loci occurs at the 
DN3 stage and after this stage cells successfully rearranged TCR ɣ and δ chains 
will express ɣδ TCRs and then proceed along the ɣδ lineage pathway [120, 122].  
In contrast, cells that successfully rearrange TCR β chain express pre-TCR, which 
is formed by a rearranged β chain and a surrogate α chain while cells that failed 
TCR β chain rearrangement die in DN4 stage [119, 120].  This pre-TCRs lead T 
cells to stop rearranging β chain but further proliferate and express both CD4 
and CD8 on their surfaces, which are termed double positive (DP) T cells [28].  




Figure 1.3.1 Overview of T cell development in thymus [123]. 
When α chain rearrangement is completed, DP T cells expressing TCRs which are 
low affinity to self major histocompatibility complex (MHC) and peptide complex 
can go through positive selection (less than 5%) and develop to either CD4 or 
CD8 SP T cells.  The others die [119, 120].  To prevent potential auto-reactivity, 
T cells with TCR with too high affinity to self MHC: peptide complex will be 
eliminated through negative selection and die [120].  It has been suggested that 
negative selection can occur throughout all stages of T cell development, and 
may not be sequential to the process of positive selection [28].  The overview of 
T cell development is shown in Figure 1.3.1. 
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1.3.2 Effector T cell subsets 
After differentiation and migration to lymphoid tissue, naïve T cells may be 
activated by antigen presenting cells that express suitable peptide: MHC complex 
and then become effector cells.  There are many types of effector T cells divided 
by the different cytokines they produced.  
Cytotoxic T cells are CD8+ T cells that recognize MHC-I molecules.  It has been 
reported that CD8+ T cells can release Fas ligand (Fas-L) which can trigger 
apoptosis in target cells, INF-ɣ and TNF-α [124]. 
In CD4 T cells, there are several different effector cells, for example T helper 1 
(Th1) cells, T helper 2 (Th2), T helper 3 (Th3) cells, T helper 9 (Th9) cells, T 
helper 17 cells (Th17), T follicular helper (TFH) cells, regulatory T (Treg) cells 
and T regulatory 1 (Tr1) cells.   
Th1 cells activate macrophages.  The main cytokine TH1 cells produce is IFN-ɣ, 
which can stimulate infected cells and promote inflammation [28].    
Th2 cells are involved in immune responses to parasites, and allergy.  Th2 cells 
can support B cell activation by producing cytokines important for B cell 
proliferation, such as IL-4, IL-5 and CD40-L [28].   
Th9 cells have been reported to induce inflammation in animal models [125, 
126].  Some studies have reported that Th9 cells are able to produce IL-9, IL-10 
and IFN-ɣ [127, 128]. 
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Th17 cells have been reported to promote acute inflammation by producing 
cytokines to recruit neutrophils to the infected tissues.  Cytokines produced by 
Th17 cells are mainly IL-17 family and IL-6.  Th17 cells have been reported to 
be associated with autoimmune diseases, such as multiple sclerosis and 
rheumatoid arthritis [129].   
TFH cells are T cells found in GCs to provide help for B cell activation and high 
affinity Ab production.  They have been reported to express high levels of 
chemokine receptor CXCR5 and produce IL-21 and IL-4 [130] (details described 
in section 1.3.3).   
Treg cells have been reported to down-regulate immune response by secreting 
suppressive cytokines TGF-β and IL-10 [131, 132] (details described in section 
1.3.4).      
Th3 cells and Tr1 cells have been reported to be subsets of inducible Treg cells 
[133].  Th3 cells can produce TGF-β in mice [134, 135], while Tr1 cells have 







1.3.3 Follicular helper T (TFH) cells 
1.3.3.1 TFH cell differentiation 
T follicular helper (TFH) cells are a CD4+ T cell subset that resides in GCs in B cell 
follicles of secondary lymphoid tissues [59].  It has been reported that TFH cells 
can differentiate either from naïve T cells directly once activated or from Th2 
cells [136].   
When naïve T cells are pre-activated by DCs, they up-regulate B-cell lymphoma 6 
(Bcl-6) which is a transcriptional repressor that has been reported to be 
important for GC formation and to limit differentiation to other CD4+ T cell 
subsets, such as Th1, Th2, and Th17 cells [137, 138].  Bcl-6 expression has been 
reported to be essential for TFH cell differentiation and function, although the 
mechanism is not clear yet [136, 138-140].  It has been reported that Bcl-6 can 
down-regulate expression of CCR7 and P-selectin glycoprotein ligand-1 (PSGL-1), 
which guide cells to localize to T cell zones, and up-regulate CXCR5 expression on 
TFH cells, which allow them to migrate to GCs [140-143].  Interaction between 
inducible co-stimulator ligand (ICOS-L) expressed on B cells and DCs and ICOS 
expressed on TFH cells has been reported to support TFH cell differentiation and 
function by activating phophatidylinositol-3-kinase (PI3K) signaling [144, 145].  
In addition, cytokines such as IL-21, IL-6 and IL-27 have been reported to be able 
to promote TFH differentiation [144, 146, 147]. 
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Some studies have reported that differentiation of TFH cells from activated naïve 
T cells is independent of other CD4+ T cell subsets [148].  Other studies have 
demonstrated that TFH cells can be derived from Th2 cells in mice [149].  This 
differentiation has been shown to be GC dependent which implies that B cells 
and other GC specific molecules play important roles in TFH cell differentiation 
from Th2 cells [149].  
It has been reported that clones of TFH cells disseminate widely and circulate as a 
minority subset of T cells in the blood [150].  CD4+ T cells expressing CXCR5 in 
human peripheral blood have been found to be able to migrate to GCs [151].  
Although circulating CD4+ CXCR5+ T cells in peripheral blood may have similar 
functions to TFH cells from GCs, the precise relationship between these cells is not 




1.3.3.2 Markers for TFH cells  
It has been reported that TFH cells express CXCR5 which is the receptor for 
CXCL13 produced in follicles of secondary lymphoid tissues [152, 153].  Some 
studies have reported that TFH cells express ICOS [154].  Other studies have 
demonstrated that programmed death-1 (PD-1) which is an inhibitory molecule 
of CTLA-4 family (details described in section 1.7.1) is up-regulated on TFH cells 
[155].  CD57 expression by TFH cells have been found in GCs of human tonsils, 
lymph nodes and spleen [130, 156].  However, it has been reported that CD57 is 
not expressed on all TFH cells in GCs [157].  Therefore, TFH cells are identified as 
CD4+CXCR5hiICOShiPD-1hi [130]. 
A small subset of circulating T cells has the phenotype and functional properties 
of TFH cell.  A recent study has identified CD4+CXCR5hiICOShi or 
CD4+CXCR5hiPD-1hi circulating TFH cells in peripheral blood from SLE patients by 
comparing with TFH cells in tonsils [158].  Cells in the blood with phenotype and 
properties of TFH cells are referred as circulating TFH (cTFH) cells.  
1.3.3.3 Function of TFH cells 
The direct contact between TCR on TFH cells and peptide: MHC-II complex on B 
cells, the binding of CD40L and CD40, ICOS and ICOS-L, and cytokines secreted by 
activated TFH cells, including IL-21 and IL-4, are all essential for activation and 
proliferation of B cells in germinal centres [130].  IL-21 secreted by TFH cells has 
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been reported to induce B cell differentiation and to regulate GC responses and 
Ig production [159-162].  TFH cells have also been reported to produce IL-4 and 
IFN-ɣ which can induce Ig CSR [130, 163, 164].  Other studies have reported 
that TFH cells can produce IL-17 which contributes to GC formation in 
autoimmunity [165].  Interaction between PD-1 expressed on TFH cells and PD-1 
ligands expressed on GC B cells has been reported to regulate B cell survival and 
generation of plasma cells [67, 166].  
 
1.3.4 Regulatory T (Treg) cells  
1.3.4.1 Treg cell differentiation 
Regulatory T (Treg) cells are a subset of CD4+ T cells found in peripheral blood 
that can down-regulate immune responses by suppressing cell proliferation and 
cytokine production [167].  Treg cells can be derived from either thymocytes 
during early development in thymus (termed natural Treg cells, nTreg) or from T 
cells in the periphery (termed inducible Treg cells, iTreg) [168]. 
It has been reported that the differentiation of Treg cells in thymus is mediated 
by intermediate strength TCR signal, FoxP3 expression, NF-κB signaling and 
cytokines [168].  Studies of mice have observed Treg cell expansion in thymus 
when TCR signaling is enhanced [169].  A major subset of Treg cells is defined 
by the expression of transcriptional factor FoxP3 that regulates the Treg 
56 
 
suppressor function and differentiation in thymus [168].  Some studies have 
reported that FoxP3 expressing Treg cells will survive while FoxP3 negative Treg 
cells will be eliminated when receiving the same TCR signal [170].  Increased 
FoxP3 expression on Treg cells has been found in thymus of mice when the signal 
strength of NF-κB pathway is enhanced [171].  It has also been demonstrated 
that deficiency in IL-2, IL-15 and IL-7 results in depletion of FoxP3+ Treg cells in 
thymus [172, 173].   
 The gut-associate lymphoid tissues (GALT) and mesenteric lymph nodes have 
been reported to be the places where inducible Treg cells are generated [168].  
In contrast to natural Treg cells, inducible Treg cells have been reported to be 
generated more efficiently under stimulation of high affinity TCR signaling in the 
periphery [174].  Transforming growth factor beta (TGF-β) has been reported 
to promote the differentiation from naïve T cells to inducible Treg cells [175, 
176].   
1.3.4.2 Markers for Treg cells 
When first identified, Treg cells were characterized by high expression of CD25, 
which is the α-chain of IL-2 receptor, on activated CD4+ T cells [167, 177].  
Then transcription factor FoxP3 was identified as a specific marker for Treg cells 
by further studies as it is only expressed on Treg cells but not other CD4+ T cell 
subsets [178, 179].  Recently, Miyara et al have divided FoxP3+ CD4+ Treg cells 
into three distinct populations based on expression of CD25 and CD45RA, which 
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represent different stages of differentiation including: naïve or resting Tregs 
expressing CD45RA and intermediate levels of FoxP3 and CD25; memory Tregs 
expressing intermediate levels of FoxP3 and CD25 and lacking expression of 
CD45RA; and activated Tregs expressing high levels of FoxP3 and CD25 and 
lacking expression of CD45RA [180].   
1.3.4.3 Function of Treg cells 
The molecular mechanisms of Treg cells induced immune suppression are not 
fully understood [168].  It has been reported that Treg cells suppress immune 
responses through secreting anti-inflammatory cytokines, such as IL-10 and 
TGF-β [131, 132].   IL-10 produced by Treg cells has been demonstrated to 
down-regulate immune responses at environmental interfaces [181], and to 
inhibit the production of IL-12 therefore down-regulate Th1 responses [182].  
TGF-β has been reported to inhibit Th1 cell differentiation while promoting Th17 
cell differentiation in animal models [183].   
In addition, Treg cells have been reported to induce cell apoptosis in T responder 
cells and antigen presenting cells [184, 185].  Recently, some studies have 
reported that Treg cells in GCs play an important role in controlling germinal 
centre responses [186, 187]. 
It has been reported that CD25 expressed on Treg cells can bind to IL-2 therefore 
inhibit effector T cell differentiation [188].  Cytotoxic T-lymphocyte antigen 4 
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(CTLA-4) has also been considered to contribute to Treg suppressive activity as 
it has been reported that Treg cells in CTLA-4 deficient mice lose their 




1.4.1 Innate immunity 
The innate immune system forms the earliest immunological barriers to 
infection.  In contrast to the adaptive immune system, innate immune 
responses to pathogens are fast but without long-term immunological memory 
[191].   When microorganisms invade tissue, they could be recognized 
immediately by dendritic cells (DCs), macrophages which are continuously 
matured from monocytes and neutrophils, [28].  Cells in innate immune system 
recognize microorganisms through pattern recognition receptors (PRRs) 
expressed on the cell surface.  PRRs recognize repetitive patterns termed 
pathogen-associated molecular patterns (PAMPs) expressed only on 
microorganisms surface but not on the self cells.  Once activated through PRRs, 
DCs can activate naïve T cells therefore induce an adaptive immune response. 
Toll-like receptors (TLRs) are a type of PRRs.  TLRs expressed by DCs have been 
shown to be an important link between innate and adaptive immunity.  TLR 
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pathways have been shown to regulate the production of IL-12 and IL-18 which 
signal naive T-cells to mature into type 1 helper T cells, and to upregulate the 
expression of costimulatory molecules, such as CTLA-4, PD-1 and PD-Ls (details 
described in section 1.7), which play essential roles in T-cell activation. 
Regulated recognition of self and non-self by cells of innate immune system 
therefore plays an important role in prevention of autoimmune diseases.   
1.4.2 Monocytes 
Monocytes are part of innate immune system.  They develop from precursors in 
bone marrow, and can further differentiate into macrophages and dendritic cells 
(DCs) [192].  Monocytes can be divided into subsets by expression of different 
chemokine receptors and surface markers [193, 194].   
In mice, monocytes have been identified as CD115+CD11b+ cells.  They can be 
subdivided into two functional subsets according to the expression of Ly6C, 
which is a glycosylphosphatidylinositol-anchored molecule [192, 194].  It has 
been reported that CD115+Ly6C+ monocytes in mice express high levels of CCR2 
and low levels of CX3CR1.  They have been reported to be recruited to 
inflammatory tissues and produce pro-inflammatory cytokines, such as TNF-α 
and IL-1 [194, 195].  Another subset of monocytes in mice has been identified 
as CD115+Ly6C- cells which express low level of CCR2 while high level of 
CX3CR1 [192, 194].  These monocytes have been demonstrated to patrol blood 
vessels, and to be involved in repairing damaged tissues [196, 197].   
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In humans, monocytes have been characterized by the expression of CD14 and 
CD16.  It has been reported that CD14 expression identifies over 90% of 
monocytes in humans [194].  CD14+ monocytes can be further divided into 
three subsets in humans by their expression of CD16: the majority classical 
monocytes which are CD14hiCD16- cells expressing high level of CCR2 while low 
level of CX3CR1; the intermediate monocytes which are CD14hiCD16+ cells 
expressing low level of CCR2 and high level of CX3CR1; and the non-classical 
monocytes which are CD14+CD16hi cells expressing low level of CCR2 and high 
level of CX3CR1 [192, 194].  It has been reported that the classical monocytes 
resemble murine CD115+Ly6C+ monocytes [194]; the intermediate monocytes 
produce pro-inflammatory cytokine TNF [198]; while non-classical monocytes 





1.5 Tissue specific lymphocyte migration 
After activation, lymphocytes migrate to different target tissues through 
peripheral blood [28].  This migration is site specific and guided by adhesion 
molecules, chemokines selectively produced in different organs and chemokine 
receptors expressed on lymphocyte surface [200, 201].   
Integrins, selectins, Ig superfamily members and vascular addressins are the 
main classes of adhesion molecules that play important roles in lymphocyte 
trafficking [202].  Interactions between selectins expressed on lymphocytes and 
vascular addressins on the endothelium allow lymphocytes to roll along the 
endothelium of blood vessels.  Then lymphocytes adhere to the endothelium by 
firmer interaction between integrins on lymphocyte surface and adhesion 
molecules expressed on endothelium.  Subsequently lymphocytes migrate into 
tissue by diapedesis [203].   
Integrin molecules α4β7 and α4β1 expressed on lymphocyte surface have been 
reported to identify two different populations homing to mucosal organs [204, 
205].  Lymphocytes expressing high levels of α4β7 are guided to the 
gastrointestinal tract through binding to endothelial adhesion molecule 
MadCAM-1 [204].  In addition, mucosal thymus-expressed chemokine (TECK) 
(also known as CCL25) is expressed predominantly by small bowel epithelium 
and mucosae-associated epithelial chemokine (MEC) (also known as CCL28) by 
colonic epithelium.  These chemokines attracts cells expressing chemokine 
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receptors CCR9 and CCR10 to the small bowel and colon respectively.  Most of 
these cells are α4β7hi [205-208].  In contrast, most α4β7low lymphocytes highly 
express α4β1 integrin which is a receptor for vascular cell adhesion molecule 1 
(VCAM-1), which mediates migration to non-gastrointestinal sites [205].  
Chemokine receptor CCR10 can also be expressed on α4β7low cells that home to 
skin, bronchi, nasal and oral mucosa through interaction with cutaneous 
T-cell-attracting chemokine (CTACK) (also known as CCL27) [205, 209].  In 
addition, cutaneous lymphocyte antigen (CLA) which is a lymphocyte receptor 
for E-selectin has been reported to facilitate lymphocyte movement to inflamed 




1.6 Important pathways in Autoimmunity 
1.6.1 B cells and Autoantibodies 
It has been known for a long time that antoantibodies produced by auto-reactive 
B cells are a consistent feature of autoimmune diseases [212].   
The autoantibody response has different targets in different diseases and 
consequences of autoantibody production vary [28].  For example, 
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autoantibodies that bind red blood cells can lead to red cell destruction and 
autoimmune hemolytic anemia [213].  It has been reported that autoantibodies 
against the thyroid-stimulating hormone receptor stimulate the hormone 
production constantly in Graves’ disease [214, 215].  In other autoimmune 
diseases, autoantibodies have been reported to cause tissue damage through 
binding to extracellular self-Ags [216]. 
The mechanisms driving autoantibody production are not clear yet.  It has been 
suggested that TFH cells helping B cells in GCs would play an important role in 
regulating autoantibody production [217, 218] (details described in section 
1.3.3). 
As B cells can be Ag presenting cells as well, they are also considered to have the 
potential to play a role in activating auto-reactive T cells in autoimmune diseases 
[28]. 
 
1.6.2 Self-reactive T cells 
Apart from helping autoreactive B cells to produce autoanibodies, self-reactive 
effector T cells have also been reported to damage tissues directly in some 
autoimmune diseases [219].  Specific cytotoxic T cells targeting 
insulin-producing β cells have been reported in type I diabetes [220].  
Auto-reactive CD4+ T cells have been observed in central nervous system 
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producing inflammatory cytokines therefore promoting lymphocyte infiltrating 
in patients with multiple sclerosis [28].  Similarly, it has been reported that 
auto-reactive CD4+ T cells can be activated by DCs and produce 
pre-inflammatory cytokines and chemokines therefore cause tissue damage in 
patients with rheumatoid arthritis (RA) [221].  
 
1.6.3 TFH cells in autoimmunity 
Germinal centre TFH cells are involved in the progression of autoimmunity in a 
mouse model of SLE by lowering the threshold for B cell survival in GCs [222].  
This lack of stringency in T cell mediated B-cell selection supports the evolution 
of autoreactive antibody secreting clones of cells.  Thus, dysfunctional or 
excessive numbers of TFH cells in germinal centres have been implicated in the 
pathogenesis of autoimmune diseases by permitting the survival of autoreactive 
B cells [222].   
ICOS is expressed on TFH cells at high levels.  Decreased autoantibody 
production and organ injury in ICOS deficient mice has been observed which 
again implies an important role of TFH cells in autoimmunity [218].  Cytokines 
produced by TFH cells have also been reported to contribute to autoimmune 
diseases.  Studies have reported that IL-21, IFN-ɣ and IL-4 produced by TFH cells 
play an important role in autoantibody production and tissue injury in mouse 
models for SLE [217, 223].   
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There is evidence that TFH cells may be involved in autoimmune responses in 
humans in a subset of patients with severe SLE, where the proportion of 
circulating TFH cells,  which were defined as CXCR5+CD4+ T cells expressing 
high levels of ICOS or PD-1, was significantly higher than that in healthy controls 
[158].  
 
1.6.4 Immune suppression by Treg cells and autoimmunity 
As described above, the function of Treg cells is to suppress immune responses.  
Treg cells have been thought to be differentiated from self-reactive T cells in 
thymus that then develop strong suppressive function to suppress self reactivity 
[28].  Therefore a defect in Treg function would be likely to play an important 
role in the pathogenesis of autoimmune diseases.  Immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX) which is a disease first 
described in 1982 that often includes autoimmune symptoms such as diabetes.  
It has been reported to be due to a defect in Treg cells caused by FoxP3 
mutations [224, 225].   
Defect in Treg cell function can be caused either by a change in Treg cell 
frequency or a deficiency in suppressive capacity or a functional failure of cells 
that respond to Treg cells.  There are many examples of Treg deficiency in 
autoimmune diseases.  For example, studies have observed normal numbers of 
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Treg cells with deficiency in suppressive capacity in patients with multiple 
sclerosis [226].   It has been reported the frequency of Treg cells in peripheral 
blood is associated with disease activity in patients with rheumatoid arthritis 
(RA) [227], while other studies have reported defective Treg cell suppressive 




1.7 Programmed death-1 and its ligands 
1.7.1 Co-stimulatory molecules 
In addition to Ag-specific signals, co-stimulatory molecules are required to fully 
activate B cells and T cells [28].  In absence of second signal from 
co-stimulatory molecules, T cells activated through TCR-MHC complex 
interaction will be turned into anergy.  It has been reported that co-stimulatory 
molecules CD28, CTLA-4, ICOS and PD-1 and their ligands play important roles in 
immune responses.  The expression, function and interaction of co-stimulatory 
molecules and their ligands is shown in figure 1.7.1 [229].  Co-stimulatory 
molecules can regulate T cell responses through different mechanisms.  For 
example, expression of CTLA-4 on T cells has been reported to enhance T cell 
movement and therefore stop T cells interacting with APCs for too long during 
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activation in GC [230, 231].  It has also been suggested by other studies that 
CTLA-4 can inhibit CD28 co-stimulatory signal by trans-endocytosing the ligands 
CD80 and CD86 which are shared with CTLA-4 (Figure 1.7.1) [232].  In addition, 
CTLA-4 deficiency has been demonstrated to impair Treg cell suppressive 
function in mouse model [190].   
    
Figure 1.7.1: Expression, interaction and function of co-stimulatory molecules 
[229].  
 
1.7.2 Programmed death-1 (PD-1) 
1.7.2.1 Structure of PD-1 
Programmed death-1 (PD-1) is a member of the immunoglobulin superfamily 
that associated with programmed cell death [233].  It is encoded by the pdcd1 
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gene on chromosome 1 in mice and chromosome 2 (2q37) in human [234, 235].  
Pdcd1 consists of 5 exons: exon 1 encodes signal sequence; exon 2 encodes the 
IgV domain; exon 3 encodes the stalk and the transmembrane domain; exon 4 
and 5 encode the cytoplasmic domain [234].  The mature form of the PD-1 
protein is 268 amino acids (aa).  It contains an N-terminal IgV-like domain, 
followed by an approximately 20 amino acid stalk, then a transmembrane 
domain and a cytoplasmic domain [236].  The cytoplasmic domain of PD-1 
contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an 
immunoreceptor tyrosine-based switch motif (ITSM) which has been shown to 
be essential for PD-1 function in T cells and B cells [236, 237].   
1.7.2.2 Expression of PD-1 
The expression of PD-1 has been reported to be hardly observed on resting cells 
[236].  Some studies have observed PD-1 expression on immature CD4-CD8- T 
cells, and the expression of PD-1 can be induced on activated CD4+CD8+ T cells 
in mice [238].  It has been reported that PD-1 expression can be induced on 
activated T cells and B cells through TCR or BCR signaling [234, 239].  In 
contrast to activated T cells, Treg cells in both mice and human have been 
reported to retain PD-1 intracellularly [240].  It has been reported that the level 
of mRNA encoding PD-1 is not correlated with the level of protein expressed on 
cell surface [239].  In addition, PD-1 has been reported to be inducibly 
expressed on activated antigen presenting cells (APC) in human [241].   
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In other studies, PD-1 has been identified as a marker for T follicular help (TFH) 
cells in germinal centres in human [242, 243].  Recently, the high expression of 
PD-1 together with chemokine receptor CXCR5 has been reported to be able to 
identify circulating TFH cells in human peripheral blood [158].  In addition, the 
increased proportion of PD-1 high expressing circulating TFH cells in peripheral 
blood has been reported to be associated with certain subset of SLE patients.  
This implies that the expression of PD-1 on TFH cells could play a role in 
autoimmune diseases [158].   
1.7.2.3 Signalling through PD-1 
Ligation of PD-1 with its ligand PD-L1 or PD-L2 has been reported to inhibit T 
cell proliferation, cytokine production and impair T cell survival through TCR 
signal [235].  The extent of PD-1 mediated inhibition has been reported to be 
dependent on the strength of the TCR signal; the bigger inhibition is induced by 
the weaker TCR signal [234, 236].  It also has been reported that the PD-1 
pathway can inhibit cytokine production more efficiently than cell proliferation, 
although the mechanism is unclear [234, 236].   
In contrast to the cytotoxic T-lymphocyte antigen 4 (CTLA-4) pathway, 
engagement of PD-1 has been demonstrated to inhibit T cell responses through 
blocking the induction of phophatidylinositol-3-kinase (PI3K) and the 
downstream activation of Akt [244].  Further studies illustrated that tyrosine 
phosphatase 1 (SHP-1) and tyrosine phosphatase 2 (SHP-2) can bind to the ITSM 
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motif in the cytoplasmic domain of PD-1, and play an essential role in the PD-1 
inhibitory pathway [237, 245].  Binding of SHP-1 and SHP-2 with the ITSM 
motif of PD-1 could result in increased expression of phosphatase and tensin 
homolog (PTEN), which can efficiently block the PI3K pathway [236].  As the 
CTLA-4 pathway blocks the Akt signal but does not affect PI3K activity, the 
inhibition induced by PD-1 ligation has been reported to be greater extent than 
CTLA-4 pathway [244].   Some studies have reported the inhibition mediated 
by PD-1 can be overridden by co-stimulating with CD28 or IL-2 [246, 247]. 
1.7.2.4 Function of PD-1 
PD-1 deficiency in animal studies has been shown to affect lymphocyte 
development and functions.  One study reported that PD-1 deficiency results in 
increased double negative T cells in thymus and spleen in mice [248].  Another 
study on PD-1 deficient mice demonstrated that PD-1 negatively regulates the 
transition of double negative T cells to double positive T cells in thymus [249].  
Other studies on PD-1 deficient mice illustrated that lack of PD-1 results in 
impaired peripheral CD8+ T cell tolerance and self-reactive CD8+ T cell 
responses in lymph nodes [250, 251].  Although the percentage of Treg cells in 
CD4+ T cells remained at normal level in mice deficient in PD-1, Treg cells from 
these mice was found to have reduced suppressor function [252].  Other studies 
of PD-1 deficient mice demonstrated that B cell responses are negatively 
regulated by PD-1, which can also influence B cell differentiation [253], while 
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more IgA with reduced bacteria-binding capacity was induced in the gut of PD-1 
deficient mice [254]. 
1.7.2.5 PD-1 polymorphisms in autoimmune diseases 
An association between PD-1 and human autoimmune disease has been 
identified by genomic studies.  A susceptibility locus for SLE was identified on 
chromosome 2q37 by a genomic screen in 2000 [255, 256].  Subsequently, the 
pdcd1 gene encoding PD-1 was located within the region 2q37.3 and was found 
to associate with susceptibility in SLE [257].  PD1.3A allele has been reported to 
associate with renal manifestations in patients with SLE by a Swedish group 
[258].  Another study has found the PD1.3A allele is significantly associated 
with SLE susceptibility in Caucasian patients [259].  Others have found more 
PD1.3A alleles in patients with SLE in Greece [260], but less in SLE patients in 
Spain [261].  Another study reported that the PD1.3A allele is significantly 
associated with SLE in Latin Americans but not in European and African SLE 
patients [262].  In addition to SLE, polymorphisms in pdcd1 have also been 
reported to associate with rheumatoid arthritis (RA) in patients from Iran and 
Taiwan [263, 264], type 1 diabetes in patients from Denmark [265], and 





1.7.3 Programmed death-1 ligand 1 (PD-L1) 
1.7.3.1 Structure of PD-L1 
Programmed death 1 ligand 1 (PD-L1) is one of the ligands of PD-1 which is also 
known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1) [246].  
It is a type I transmembrane protein of the B7 family which is encoded by the 
CD274 gene on chromosome 19 in mice and chromosome 9 in human [234, 267].  
The CD274 gene consists of 7 exons: exon 1 is a non-coding gene; exon 2 encodes 
a signal sequence; exon 3 encodes the IgV domain; exon 4 encodes the IgC-like 
domain;  exon 5 encodes the transmembrane; exon 6 and 7 encode the 
cytoplasmic domain [234].  PD-L1 is a 290 aa protein [234].  It contains a 
IgV-like domain and a IgC-like domain, followed by a transmembrane domain 
and a short cytoplasmic domain [236].  The cytoplasmic domain of PD-L1 is 
approximately 30 aa and found to be conserved in many species [234, 236].  
However, the function of the intracellular part of PD-L1 is still unknown [246, 
267].  One study has reported mutated PD-L1 encoding mRNA lacking IgV-like 
domain in human [268].  
1.7.3.2 Expression of PD-L1 
PD-L1 has been reported to be widely expressed on many different cell types, 
including both hematopoietic and non-hemopoietic cells [236].  Some studies 
have observed PD-L1 expression on T cells, B cells, DCs, macrophages, stem cells 
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and bone marrow derived mast cells in mice [269].  In humans, PD-L1 has been 
found to be expressed in heart, lung, placenta and skeletal muscle [234, 267].  
Studies on cell lines have demonstrated that the expression of PD-L1 is 
dependent on myeloid differentiation primary response gene 88 (MyD88), TNF 
receptor associated factor 6 (TRAF6) and MAPK/ERK kinase (MEK) pathways 
[270].  Another study has reported that blocking phosphatase and tensin 
homolog (PTEN) could result in increased expression of PD-L1 [271].  It has 
been reported that PD-1 expression is dependent on interferon (IFN) regulatory 
factor-1 binding site [272], and can be up-regulated by IFNα and IFNβ 
stimulation [273, 274].  It has been reported that interleukin-2 (IL-2), IL-7 and 
IL-15 can increase the PD-L1 expression on human T cells, while IL-21 can 
increase the expression of PD-L1 on human B cells [275].  In contrast, IL-10 has 
been reported to induce PD-L1 expression on monocytes [234]. 
Apart from hematopoietic cells, PD-L1 can also be constitutively expressed on 
many non-hematopoietic cells, such as vascular endothelial cells, pancreatic islet 
cells, and neurons [234, 236, 267]. 
1.7.3.3 Signaling through PD-L1 
Ligation of PD-1 with its ligand PD-L1 or PD-L2 has been reported to inhibit T 
cell proliferation, cytokine production and impair T cell survival through TCR 
signal [235].  However, apart from affecting immune responses through TCR or 
BCR signaling, PD-L1 can also deliver inhibitory signals to the cells expressing 
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PD-L1 [234].  One study on mice has demonstrated that the over-expression of 
PD-L1 on DCs does not alter T cell response, while ligation of PD-L1 expressed on 
DCs with soluble PD-1 can inhibit the DC activation and increase IL-10 
production suggests there is a reverse signaling by PD-L1 to DCs  [276].    
PD-1 is not the only receptor for PD-L1.  B7-1 co-stimulatory molecule has been 
reported to be another receptor for PD-L1 through their IgV-like domains [277].  
The B7-1: PD-L1 interface has been reported to partly overlap with the PD-1: 
PD-L1 interface [277, 278].  It has been demonstrated that interaction between 
B7-1 and PD-L1 inhibits T cell activation and cytokine production [277].  Since 
PD-L1 and B7-1 are expressed on many different cell types, people hypothesis 
the bidirectional interactions between PD-L1 and B7-1 may have potential 
influence in immune responses [234].   
1.7.3.4 Function of PD-L1 
PD-L1 deficiency in animal studies has been shown to be associated with 
autoimmune diseases.  Studies on mice have shown that PD-L1 deficiency can 
cause expansion of autoreactive T cells with diabetes [279, 280].  Another study 
on PD-L1 deficient mice demonstrated that PD-L1 expressed on T cells, antigen 
presenting cells (APCs) and host tissues negatively regulates the T cell cytokine 
production [281].  Despite inhibiting T cell responses, PD-L1 has also been 
demonstrated to potentially influence T cell differentiation.  Studies on mouse 
models have reported that PD-1/PD-L1 interaction down-regulated the 
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expansion of TFH cells but up-regulated the development of Treg cells [166, 282].  
Moreover, PD-L1 is thought to associate with Treg function as one animal study 
indicating that PD-L1 deficient Treg cells were defective in inhibiting Th1 
responses in mice [283].  Recently, Treg cells were shown to suppress 
autoreactive B cells through a PD-1/PD-L dependent pathway [284].  
Polymorphisms of PD-L1 encoding gene CD274 have been reported to be 
associated with Graves’ disease in Asian and Caucasian cohorts [285, 286], and 
with ankylosing spondylitis in Chinese patients [266, 287].  In contrast, 
polymorphisms of CD274 have been reported to not be associated with RA in 
Taiwan [288] or SLE in many different cohorts [289, 290]. 
 
1.7.4 Programmed death-1 ligand 2 (PD-L2) 
1.7.4.1 Structure of PD-L2 
Programmed death 1 ligand 2 (PD-L2) is one of the ligands of PD-1 which also 
known as cluster of differentiation 273 (CD273) or B7-DC [291, 292].  It is a 
member of the B7 family which is encoded by the pdcd1lg2 gene on chromosome 
19 in mice and chromosome 9 in human [234].  Pdcd1lg2 gene consists of 7 
exons in human: exon 1 is a non-coding gene; exon 2 encodes signal sequence; 
exon 3 encodes the IgV domain; exon 4 encodes the IgC-like domain;  exon 5 
encodes the short stalk, transmembrane and the beginning of the cytoplasmic tail; 
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exon 6 and 7 encode an approximately 30 aa cytoplasmic domain [234].  The 
approximately 30 aa cytoplasmic domain is conserved across many mammals.  
The function of the intracellular tail of PD-L2 is unknown [234, 236].  Studies 
have reported splice variants in PD-L2 encoding mRNA in human [291, 293].  
One mutation results in the loss of the IgV-like domain of the PD-L2 protein 
would result in failure of binding to PD-1 [278, 291].  Another two splice 
variants have been reported to affect the IgC-like domain with or without 
affecting the transmembrane domain in PD-L2 [268].  However, these 
mutations would be expected not to affect the binding capacity to PD-1 as the 
IgV-like domain has been reported to be the domain that has most binding 
activity to PD-1 [278]. 
1.7.4.2 Expression of PD-L2 
In contrast to the wide expression of PD-L1 on many different cell types, the 
expression of PD-L2 is more restricted [234, 236].  Expression of PD-L2 by 
activated cells from peripheral blood in human has been described. One study 
indicated that PD-L2 is inducibly expressed by activated CD4+ and CD8+ T cells 
from human blood [294].  PD-L2 expression by peripheral blood monocytes 
was reported to be up-regulated in multiple sclerosis patients treated with IFN-β 
[295]. 
The expression of PD-L2 in tissues has also been described in autoimmune 
mouse models and human studies.  In human, PD-L2 has been found to be 
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expressed by macrophages and DCs in livers from patients with autoimmune 
liver diseases [296].  Other studies have shown that PD-L2 is expressed by renal 
tubular epithelial cells in the kidneys from patients with lupus nephritis [297].  
Constitutive expression of PD-L2 has been detected in un-stimulated human 
umbilical vein and brain endothelial cells, while the expression was found to be 
up-regulated under inflammatory conditions [298, 299].  PD-L2 expression has 
also been observed on inflammatory cells in rheumatoid synovium from patients 
with rheumatoid arthritis [300].  
There is no agreement on the expression of PD-L2 in tissues of mice.  Some 
studies indicated that PD-L2 was not expressed by activated lymphocytes in the 
spleen, bone marrow and thymus of mice [301].  Another study observed PD-L2 
expression on DCs in thymus from naive mice and on inflammatory infiltrating 
cells in brains from EAE mice [302].  This was supported by an observation of 
PD-L2 expression on DCs from mesenteric lymph nodes in mice [303].  
1.7.4.3 Signaling through PD-L2 
Like the PD-1/PD-L1 pathway, the interaction between PD-L2 and PD-1 has been 
shown to inhibit T cell proliferation and cytokine production in mouse models 
and human studies [291, 304, 305].  Studies have reported the PD-1/PD-L2 
pathway down-regulates CD4+ as well as CD8+ T cell responses in mice [247].  
This was further confirmed by PD-L2 blockade in EAE mice, which results in T 
cell expansion and accelerated and more severe disease [306].  Similar to PD-L1, 
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PD-L2 has also been reported to regulate the generation of inducible Treg cells in 
mice.  One study has demonstrated that PD-L2 deficient DCs induce fewer Treg 
cells in mesenteric lymph nodes in mouse models [303].  In addition, PD-L2 has 
also been reported to be involved in regulating autoreactive B cell responses, as 
the expression of PD-L1 and PD-L2 on Treg cells were both required for 
inhibiting autoreactive B cell proliferation in mice [284].   
Similar to PD-L1, PD-L2 has been reported to deliver inhibitory signal to the cells 
expressing PD-L2 [234].  One study on mice has demonstrated that ligation of 
PD-Ls expressed by DCs with soluble PD-1 can inhibit the DC activation and 
increase IL-10 production suggesting that there is a reverse signaling by PD-Ls to 
DCs  [276].   
1.7.4.4 Function of PD-L2 
PD-L2 deficiency has been shown to result in experimental autoimmune 
encephalomyelitis in a mouse model, with a less severe disease and 
inflammatory cytokines produced in lymph nodes than the PD-L1 deficient mice 
[307].   
Polymorphisms of PD-L2 encoding gene pdcd1lg2 have not been thoroughly 
studied.  It has been reported that polymorphisms of pdcd1lg2 are not 
associated with the occurrence of RA in Taiwan [288].   Another study has 
reported association between pdcd1lg2 polymorphisms and ankylosing 
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spondylitis in patients from Taiwan [287].  It has been reported that the 
polymorphisms of pdcd1lg2 are associated with SLE in patients from Taiwan 
[289], but not SLE patients from Sweden, Mexico or Argentina [290]. 
1.7.5 The PD-1/PD-L pathways 
The PD-1/PD-L pathways have been demonstrated to affect cell maturation and 
proliferation in animal models.  PD-1/PD-L1 interaction has been found to be 
required to induce T cell anergy before T cells migrate from lymphoid organs to 
peripheral blood in mice [308].  Further study of mouse models has indicated 
that blockade of the PD-1/PD-L1 pathway leads to less T cell movement but 
longer interaction between T cells and DCs in lymph nodes [309].  Moreover, 
interaction between PD-1 and its two ligands has been shown to inhibit CD4+ 
and CD8+ T cell responses in mice [247].  Autoreactive B cells in mice have been 
demonstrated to be suppressed by PD-1 ligation through PD-L1 and PD-L2 [284], 
while disruption of PD-1/PD-L pathways in mice have been reported to result in 
fewer plasma cells [67].  DC maturation in mice has been shown to be inhibited 
through PD-1/PD-L pathways as well [276]. 
The effect of PD-1/PD-L pathways on T cell proliferation in human has also been 
reported.  PD-1/PD-L pathways have been reported to down regulate both 
primary and secondary T cell responses in peripheral blood from healthy donors 
[305].  The interaction between PD-1 and PD-L2 has been shown to inhibit T 
cell proliferation as well as cytokine production in human blood [304].  Further 
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study has indicated that PD-1/PD-L pathways negatively regulate T cell 





V-domain Ig suppressor of T cell activation (VISTA) is a newly identified Ig 
superfamily ligand which down regulates T cell responses [311].  VISTA is a 309 
aa type 1 transmembrane protein which contains a IgV-like extracellulcar 
domain, a stalk domain, a transmembrane domain and a cytoplasmic domain.  
The extracellular IgV-like domain of VISTA is homologous to PD-L1.  However, 
VISTA does not bind to PD-1 and the receptor for VISTA is unknown.  The 
expression of VISTA has been observed on many hematopoietic cells, especially T 
cells and APCs, and some organs such as lung, brain and kidney.  It has been 
shown that VISTA expressed on APCs suppresses T cell proliferation and 
cytokine production in mouse models.  Anti-VISTA treatment has been reported 





1.9 Immunology of GPA 
1.9.1 Hypothesis of autoantibody production in GPA 
Friederich Wegener first observed that patients with this disorder almost 
universally had upper airway disease especially affecting the facial sinuses [312, 
313].  As upper airway inflammation is so often the first sign of GPA, infections 
are suspected to trigger the disease.  It has been suggested that Staphylococcus 
aureus infection may be associated with the pathogenesis of GPA and persistent S. 
aureus nasal carriage is associated with a risk of disease relapse [314, 315].  
Anti-neutrophil cytoplasmic antibody (ANCA) has been reported to be closely 
associated with GPA through reacting with proteinase 3 (PR3) [13, 316].  It has 
been shown that rising levels of ANCA in GPA patients’ blood can predict the 
relapse of the disease [13, 316].  Abundant PR3 expression has been detected in 
lung biopsies of GPA patients by immunohistochemistry, where most PR3 
positive cells were macrophages [317].  The increased percentage of 
neutrophils expressing membrane PR3 has been shown to associate with relapse 
of GPA [318].  In addition, Reumaux et al, 1995, demonstrated that membrane 
PR3 on resting neutrophils was two to three times less than neutrophils 
activated by inflammatory factors [319].  Thus, a current hypothesis for the 
mechanism of vessel damage in PR3-ANCA associated vasculitis is that 
monocytes activated by infection release proinflammatory factors, such as IL-1 
and TNF-α, which up-regulate the expression of adhesion molecules on 
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endothelium and stimulate neutrophils to express membrane PR3.  As a 
consequence, activated neutrophils adhere to endothelium of vessel walls.  
Meanwhile, in the presence of PR3 released by activated macrophages, B cells 
activated by pathogen, with T cell help, produce ANCA.  Subsequently, 
neutrophils adhered to endothelium are stimulated by ANCA through PR3-ANCA 
reaction, leading to degranulation and release of reactive oxygen species which 
results in vascular damage [314, 315].  However, how ANCA is produced by B 
cells and how PR3-ANCA reaction induces vasculitis are still not clear. 
  
Figure 1.9.1 Hypothesis of infection triggering PR3-ANCA associated vasculitis 
[314] 
Consistent with this hypothesis, innate and adaptive immune systems have both 
been reported to contribute to the chronic inflammation seen in GPA.  Dendritic 
cells (DCs) have been reported to help T cell responses and potentially 
contribute to granuloma formation in GPA [320].  Another study has 
demonstrated that both macrophages and neutrophils may play a role in the 
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inflammation in GPA [321].  Other studies have observed expansion of T cells 
and B cells in granulomatous lesions from GPA patients [322, 323]. 
 
1.9.2 Current studies of B cells in GPA 
The types of lymphocyte infiltrating in granuomatous lesions from GPA patients 
are various.  Formation of follicle-like B cell infiltrates have been observed in 
granulomatous lesions from GPA patients [324, 325].  Others have reported the 
presence of germinal centre-like structures with follicular dendritic cells in 
granulomatous lesions from GPA patients [326].  Gene analysis of the Ig heavy 
chains of B cells isolated from granulomatous lesions from GPA patients has 
shown mutations [323-325]. This implies that B cells in the lesions are generated 
by germinal centre responses.  Ig gene analysis also identified clonal expansion 
of B cells in lesions from GPA patients [323].  Apart from ANCA against PR3 
[327], B cells in lesions from GPA patients have been found to produce other Abs 
specific to a proinflammatory transmembrane protein [328].   
ANCA has been demonstrated to play an important role in the pathogenesis of 
GPA [329].  Rituximab which is a monoclonal antibody against CD20 has been 
shown to efficiently deplete B cells which could develop into ANCA-producing 
plasma cells [330] and has therefore been considered as a treatment in GPA 
patients [331].  Two large randomized controlled trials have clearly 
demonstrated the clinical benefits of rituximab in GPA patients with active and 
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relapsing disease and this agent has been approved by the Food and Drug 
Administration [24, 332].  Interestingly, B cells have been observed in liver 
lesions from a GPA patient following rituximab treatment while circulating B 
cells were absent from peripheral blood [333].  This implies B cells in the 
lesions of GPA patients might not be a component of circulating B cells in 
peripheral blood. 
 
1.9.3 Current studies of Treg cells in GPA 
Regulatory T cells (Treg) are critical regulators of autoimmune diseases through 
suppressing the proliferation and cytokine production of effector T cells [334, 
335]. The failure of regulatory T cells (Treg) to suppress inflammation, either 
through defects of Treg or the cells that respond to them, may facilitate the 
development of autoimmune pathology. Some studies have shown Treg 
frequencies to be reduced in GPA, and other studies have detected defects in the 
suppressive function of Treg in GPA.  Both of these sets of observations 
implicate Treg in the disease process [336-338]. Interestingly, Treg frequencies 
have been shown to increase in the blood of patients with SLE following 
rituximab treatment [339]. This could be a secondary consequence of clinical 
remission, or if Treg are actually associated with the disease process and are not 




1.9.4 Current studies of PD-1, its ligands and VISTA in GPA 
The expression of PD-1 and its ligands PD-L1 and PD-L2 by different cell types 
from GPA patients had not been reported when the studies in this thesis were 
started.  Polymorphisms in the pdcd1 (PD-1 encoding gene), CD274 (PD-L1 
encoding gene) and pdcd1lg2 (PD-L2 encoding gene) genes have not been 
thoroughly studied in GPA.  One study has reported that polymorphisms in 
pdcd1 were not associated with GPA [340].  No disease association with 
polymorphisms in genes encoding PD-L1 or PD-L2 has been reported in GPA.   
As a newly identified Ig superfamily ligand in mouse, the expression of VISTA in 




1.10 Systemic lupus erythematosus (SLE) 
Systemic lupus erythematosus (SLE) is a chronic multi-systemic autoimmune 
disease with wide range of many different symptoms [341].  SLE can affect all 
ethnicities with a high female to male ratio (approximately 9:1) [342], and higher 
prevalence in Asia and Africa [343, 344]. 
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The clinical features of SLE include photosenstive skin rashes, arthritis, nephritis, 
cardiac and pulmonary disease and central nervous system (CNS) disorders, et al 
[35].  Serologically, SLE is characterized by high autoantibody titers and 
abnormal B cell activation in peripheral blood [345].  It has been reported that 
autoantibody titers in peripheral blood can be detected many years before the 
clinical onset of SLE [346], and reach a peak prior to the onset of illness [347]. 
The pathogenesis of SLE is not fully understood [348].  It is widely agreed that 
genetic and environmental factors together can trigger SLE [35, 349].  
Polymorphisms of many different genes (including genes encoding human 
leukocyte antigen (HLA), Fc receptor, complement components and PD-1) have 
been reported to associate with SLE [257, 349].  There are many theories 
relating to the pathogenesis of SLE.  For example B cells, B cell survival factors, 
cytokines, complements, interferon related pathways and failure in clearance of 
apoptotic debris have all been implicated in the pathogenesis of SLE [35, 
350-352]. 
SLE and GPA are both systemic autoimmune diseases that can induce nephritis 
which is a life-threaten symptom.   The mechanisms of inducing nephritis in 
SLE and GPA are different: membrane attack complex of complement system 
mediated in SLE but vasculitis induced in GPA.  Therefore active SLE patients 
were selected as a disease control for GPA study in this thesis. 
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1.11 Aims of studies in this thesis  
The aims of studies in this thesis were to investigate the immunology in GPA and 
to increase understanding of this disease. 
As the immunological features of the mucosal microenvironment in GPA have not 
been studied extensively, the aim of chapter 3 was to investigate the 
immunological features of biopsies from GPA patients.  It was hypothesised that 
B cell clones identified in the mucosa from GPA patients might also circulate in 
the blood.  To investigate this hypothesis, junctional sequences of Igs that are 
unique to each B cell and its clonal progeny were compared. 
As described in section 1.9.2, rituximab has been reported to be a beneficial 
therapy for GPA patients.  However, the effects of B cell depletion therapy on 
different T cell subsets in general immune system is still unclear.  Therefore the 
aim of chapter 4 was to investigate any difference in frequencies of circulating 
TFH cells and Treg cells from GPA patients on conventional therapies, GPA 
patients following rituximab treatment, healthy and disease controls. 
As introduced in section 1.7, PD-1 and its ligands are immunoglobulin 
superfamily members that could be expressed on many different cell types.  It 
has been reported that polymorphisms in genes encoding PD-1 and its ligands 
are associated with various autoimmune diseases.  PD-1/PD-Ls pathways may 
also affect the generation of different T cell subsets.  Therefore, the aim of 
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chapter 5 was to identify any differences in the expression of PD-1, PD-L1, PD-L2, 


















2.1 Ethics approval 
This study was approved by the National Research Ethics Service (Approval No. 
10/H0715/3) and by the Guys and St Thomas’ Hospital Ethics Committee.  All 
patients donated blood and agreed to allow access to biopsy and tissue samples 
that were surplus to clinical investigation after fully informed written consent. 
 
2.2 Patients 
2.2.1 Patients involved in peripheral blood study 
GPA patients attending the systemic vasculitis clinic in the Louise Coote Lupus 
Unit at St Thomas’ Hospital were invited to participate in this study following 
written informed consent.  SLE patients attending lupus clinic in the Louise 
Coote Lupus Unit at St Thomas’ Hospital were invited to participate as disease 
controls in this study following written informed consent.  GPA patients and 
SLE patients fulfilled the American College of Rheumatology classification 
criteria [11].  Data on disease activity and damage using the BVAS and the VDI 
was collected at the time of venesection for GPA patients.  Data on British Isles 
Lupus Assessment Group (BILAG) was collected at the time of venesection for 
SLE patients.  Information on organ involvement and treatment was also 
collected.  
GPA patients who underwent B cell depletion with rituximab did so based on 
clinical need.  These patients had all failed standard therapies with 
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corticosteroids and immunosuppressive agents and still had active or relapsing 
disease.  All patients gave written informed consent prior to receiving 
rituximab.  Protocol is to discontinue immunosuppressive agents one week 
prior to rituximab but oral corticosteroids are continued.  Patients received 
rituximab 1g at day 1 and day 15 and were followed with clinical parameters, 
BVAS, CD19 counts and serum immunoglobulin levels.  Patients also received iv 
methylprednisolone 100mgs and iv chlorpheniramine 10mgs prior to each 
infusion to minimize the risk of a hypersensitivity reaction.  
Approximately age and gender matched healthy control subjects from hospital 
and laboratory staffs were recruited and gave blood following written informed 
consent. 
The details of clinical information of patients involved in different studies are 
listed in tables in each result chapter. 
 
2.2.2 Patients involved in biopsy study 
Biopsies taken for diagnosis from GPA patients were studied following written 
consent.  The group of patients with orofacial granulomatosis (OFG) were 
considered to be an important control group because this is a chronic 
granulomatous mucosal lesion, but not associated with acute inflammation or 
autoimmunity.  The group of patients with sarcoidosis was considered to be a 
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control group as granuloma is a feature of the disease.  Written consents were 
obtained as appropriate. 
 
2.3 Tissues 
2.3.1 Blood samples 
Peripheral blood samples were collected in universal tubes containing 
spray-coated K2EDTA (BD Vacutainer).  Peripheral blood mononuclear cells 
(PBMC) were isolated with Ficoll-Paque from fresh blood samples.  General 
information of GPA patients and healthy and disease controls involved in each 
chapter is listed in table 2.3.1.  Details of clinical information of GPA patients 
and SLE controls are listed in tables in each chapter.  
Table 2.3.1 General information of patients and controls studied in each chapter 





2.3.2 Paraffin biopsies 
Paraffin blocks of inflamed mucosal biopsies from 8 patients with clinically 
confirmed GPA, were selected to include a range of characteristics from mild 
lymphocytic infiltrates considered within normal histological limits through to 
marked inflammation (Detailed location of the tissue sampled and the diagnoses 
are included in Table 2.3.2).  Specimens were graded according to the 
inflammatory infiltrate present to produce a semi-quantitative score (Nil, Mild 
and Marked).  This was undertaken blind by two authors (PP & EO).  








TBS: 6.05g Trisma base (Sigma), 80g sodium chloride and 38ml 1M HCL were 
dissolved in 10 litres dH2O and mixed well to make a TBS stock.  Concentrated 
HCL was added a drop at a time until the solution was pH 7.6.   
1M Tris: 121.1g Trisma base (Sigma) was dissolved in 800ml dH2O and mixed 
well. Concentrated HCL was added a drop at a time to adjust pH value to 9. 
10x TBE: 108g of trizma base (Sigma), 55g boric acid and 8.3g EDTA (Sigma) 
was dissolved in 1L dH2O by mixing vigorously.  
Ethidium Bromide stock (0.5 µl/ml): 10mg ethidium bromide was dissolved in 
l ml dH2O and 10µl of this was diluted in 200µl of 1x TBE to produce a 
concentration of 0.5µl/ml. 
SOC medium: 2g of Tryptone, 0.5g Yeast extract, 1ml 1M NaCl and 0.25 ml 1M 
KCl were added to 97ml dH2O and autoclaved at 120°C for 20 minutes.  The SOC 
medium was left to cool to room temperature before adding 1ml of 
filter-sterilized 2M Mg2+. 
LB Agar: 1g Tryptone, 0.5g Yeast extract, 0.5 NaCl and 1.5g Bacto agar was 
dissolved in 100ml dH2O and autoclaved at 120°C for 20 minutes.  The Agar was 
allowed to cool for 10 minutes before adding 200µl 0.5µl/ml Ampicillin (Sigma), 
200µl 0.5µl/ml XGAL (Promega) and 0.5ml 0.1M IPTG.  Mix well and pour 20ml 
into each plate while agar is still warm.  To prepare the plate sending out for 
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sequencing, only 200µl 0.5µl/ml Ampicillin was added into the Agar after cooling 
down. 
RPMI-1640 medium:  1640 medium (Gibco) containing 1% L-glutamine was 
supplemented with 1% penicillin (Sigma) and 10% heat-inactivated (56°C for 30 
minutes) fetal calf serum (FCS) (seraLab). 
10x PBS: 80g NaCl, 2g KCl, 14.4g Na2HPO4 and 2.4g KH2PO4 (all from Sigma) 
were dissolved in 800ml distilled water.  pH value was then adjusted to 7.4 with 
concentrated HCl.  Distilled water was added to make up final volume 1 liter.    
FACS buffer:  1ml filtered FCS and 200µl EDTA (Sigma) were added into 
autoclaved PBS (1:10 diluted from 10x PBS) and mixed.  
X-VIVO 15 medium: X-VIVO 15 medium (Lonza) was supplemented with 5% 
heat-inactivated human AB serum (PAA Labs Ltd), 100μl/ml 
penicillin/streptomycin (Invitrogen) and 100μg/ml fungizone (Invitrogen) 
 
2.5 Immunohistochemistry staining (IHC)  
All reagents were from DAKO unless stated.  Paraffin embedded tissue sections 
(5m) were baked at 60°C for 30min.  Then sections were rehydrated with 
Xylene for 2x10 minutes and then IMS for 2x10 minutes, followed by distilled 
water for 10 minutes.  Sections were then submitted to antigen retrieval by 
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heating retrieval solution (DAKO) at 95C for 40 minutes and then cooled down 
on bench for 30min and then washed with TBS unless stated.  After retrieval, 
sections were incubated with Dual Endogenous block or Peroxidase block for 10 
minutes and then washed with TBS.  Sections were then incubated with 
appropriate primary Ab for 1 hour at room temperature unless stated and then 
washed with TBS.  Sections were then incubated with secondary Abs for 30 
minutes, and then washed with TBS.  Choice of secondary Ab was depend on 
different primary Abs: a) Rabbit and mouse Abs were developed with HRP 
envision; b) Goat Ab (PD-1) was developed with a rabbit anti-goat secondary Ab 
(dilution 1:100).   
For single staining, sections were then developed with DAB+ (diluted 1:100 with 
DAB substrate buffer) and then washed with TBS, followed by counter staining, 
and then rehydrating and mounting steps described below.    
For double staining, sections were incubated with Double staining block for 10 
minutes, and then washed with TBS.  Sections were subsequently incubated 
with appropriate primary Abs for 1 hour at room temperature and then washed 
with TBS unless stated.  Then sections were incubated with Rabbit-mouse Link 
for 30 minutes followed by Polymer/AP for 30 minutes, and then washed with 
TBS.  Sections were then developed with red chromogen from DAKO or Vector 
labs, and then washed with distilled water.   
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After developed with DAB+ or red chromogen, sections were counter stained 
with haematoxylin for 5 seconds, and then washed with running water.  
Sections were subsequently re-hydrated with IMS for 2x10 minutes, followed by 
Xylene for 2x10 minutes, and then mounted with Depex Mounting medium. 
Concentrations of each Ab used for IHC experiments are shown in table 2.5.1.  






2.6 DNA and RNA extraction 
DNA samples for IgH gene study in chapter 3 were isolated from paraffin coated 
biopsy sections using DNeasy Blood & Tissue Kit (Qiagen).  Tissues were 
digested by incubating with proteinase k at 56°C for 3 hours.   
RNA samples for IgH gene study in chapter 3 and PD-1/PD-Ls study in chapter 5 
were isolated from blood B cells, different T cell subsets and monocytes sorted 
according to different subsets using miRNeasy Mini Kit (Qiagen).  To prevent 
contamination for RNA isolation, nuclease-free water (Qiagen) was aliquot and 
all instruments including pipettes, tips and racks, and nuclease-free water was 
disinfected under UV light for 20 minutes before each experiment. 
 
2.7 Reverse transcription 
RNA samples were reverse transcribed to cDNA using Oligo dT primer (Promega) 
and M-MLV Reverse Transcriptase kit (Promega).  To prevent contamination, 
nuclease-free water (Qiagen) was aliquot and disinfected under UV light for 20 
minutes as well as all instruments including pipettes, tips and racks before each 
experiment. 
To reverse transcribe RNA into cDNA, 7μl of RNA, 3μl of dH2O and 1μl of primer 
were mixed and incubated at 70°C for 10 minutes.  Tubes were then moved to 
iced water and left on ice for 10 minutes, and then spun down once for 5mins.  
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Then 4.0μl of M-MLV Buffer, 0.5μl of dNTPs (Promega), 0.5μl of RNase inhibitor 
(Promega), 1.0μl of M-MLV Reverse Transcriptase (Promega) and 3.0μl of dH2O 
were added to make a final volume 20μl followed by incubation at 42°C for 1 
hour.  Products were extended at 70°C for another 15 minutes and then held at 
15°C. 
 
2.8 Amplification of Ig gene rearrangements 
2.8.1 General information 
The reverse transcribed cDNA and isolated DNA was amplified by semi-nested 
PCR.  Ig heavy chain gene was amplified from V regions (VH1-6) to C regions 
(Cα, Cγ, Cμ and Cε).  Leader and FR1 primers were performed in semi-nested 
PCR. DNA isolated from paraffin block was amplified from FR3 to J regions.  JH 
external and VLJH internal primers were applied in semi-nested PCR.  To search 
for clonal relationships between cells in biopsies and different circulating blood 
subsets, clone specific primers designed from IgH sequence isolated from biopsy 
were applied to all blood subsets and biopsies from the same patient using the 
FR3-J PCR program.   
In each experiment, 3μl MgCl2, 0.5μl 20mm dNTPs, 10μl 5xBuffer, 0.5μl of each 
20mM primer, 3μl cDNA, and 31.5μl dH2O were added to each tube to make the 
total volume 50μl.    
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2.8.2 PCR Programs 
 IgH-C:  
1) 1st round: 95°C for 10 minutes then hold at 54°C, 2μl Taq DNA 
polymerase (Promega) was added to the tube after holding, 
followed by 30 cycles of 94°C for 40 seconds, 65°C for 45 seconds 
and 72°C for 2 minutes, and then extended at 72°C for 10 minutes.  
2) 2nd round: 95°C for 10 minutes then hold at 54°C, 2μl Taq DNA 
polymerase (Promega) was added to the tube after holding, 
followed by 30 cycles of 94°C for 40 seconds, 55°C for 45 seconds 
and 72°C for 2 minutes, and then extended at 72°C for 10 minutes.  
 IgH-J:  
1) 1st round: 95°C for 10 minutes then hold at 54°C, 2μl Taq DNA 
polymerase (Promega) was added to the tube after holding, 
followed by 7 cycles of 94°C for 60 seconds, 64°C for 2 minutes and 
72°C for 45 seconds, and then 39 cycles of 94°C for 30 seconds, 
62°C for 30 seconds and 72°C for 90 seconds, then extended at 
72°C for 10 minutes.  
2) 2nd round: 95°C for 10 minutes then hold at 54°C, 2μl Taq DNA 
polymerase (Promega) was added to the tube after holding, 
followed by 7 cycles of 94°C for 60 seconds, 66°C for 2 minutes and 
72°C for 45 seconds, and then 35 cycles of 94°C for 30 seconds, 
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54°C for 30 seconds and 72°C for 90 seconds, then extended at 
72°C for 10 minutes.  
 Clone specific (FR3-J):  
Samples were heated at 95°C for 10 minutes then hold at 54°C. 2μl 
1:20 diluted Taq DNA polymerase (Promega) was then added to 
the tube, followed by 35 cycles of 95°C for 60 seconds, 60°C for 60 
seconds and 72°C for 60 seconds, and then extended at 72°C for 10 
minutes. 
 Clone screening:   
Samples were heated at 95°C for 5 minutes and then followed by 
30 cycles of 95°C for 30 seconds for denaturation, 45°C for 30 
seconds for annealing and 72°C for 90 seconds for elongation and 
then extended at 72°C for 5 minutes.  
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2.8.3 Primers used for PCR 
Table 2.8.3 Sequences of PCR primers used for PCR 
 
 
2.9 Gel electrophoresis 
2.9.1 Agarose gel electrophoresis 
PCR products of immunoglobulin heavy chain V to C (size range 300bp to 500bp) 
were detected using agarose gel electrophoresis.  Agarose gel was prepared 
with 6g 3:1 agarose and 200ml TBE buffer.  8 μl of PCR product was mixed with 
2μl of Gel loading dye (New England Biolabs), and then loaded into gel.  8μl of 
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phiX74 DNA markers (Promega) was applied to identify the size of the products.  
Voltage was set to 127V and applied for 60 minutes.  Gels were stained in 
0.5μg/ml ethidium bromide solution for 30 minutes, and then exposed to UV 
light.  The ladder of the DNA marker and the PCR products can be observed 
under UV light.  
2.9.2 10% Polyacrylamide mini-gel 
10% Polyacrylamide mini-gel was used for low molecular weight DNA samples 
(size smaller than 100bp).  13ml of dH2O, 2ml of 10x TBE, 5ml of acrylogel 5, 
200μl of 10% Ammonium Persulphate (freshly made) and 20μl of TEMED were 
added by order, mixed and then pour out quickly to make up new gels.  6 μl of 
PCR product was mixed with 2μl of Gel loading dye (New England Biolabs), and 
then loaded into gel.  5μl of Low Molecular weight marker (Biolabs) was applied 
to identify the size of the products.  Voltage was set to 125V and applied for 60 
minutes.  Gels were stained in 0.5μg/ml ethidium bromide solution for 30 
minutes, and then exposed to UV light.  The ladder of the DNA marker and the 




2.10.1 General information 
Quantitative PCR’s were designed by Applied Biosciences using their Taqman 
Gene Expression Assay.  Five sets of assays were designed for reactions 
covering the PD-1, PD-L1, PD-L2, VISTA and GAPDH gene segments in human 
respectively.  Assays applied for sorted CD19+ B cells, CD4+ T cells, CD8+ T cells, 
CD14+ monocytes and whole PBMC from GPA patients and disease and healthy 
controls.   
2.10.2 Protocol 
In each experiment, 5.0μl TaqMan Universal PCR Master Mix, 0.5μl 20× Assay 
Mix and 4.5μl CDNA diluted to 1/5 or 1/10 in RNase-free water was added to 
each well to make the total volume 10μl.  For each cDNA sample, there were 
three replicates.  Cycling as follow: denature (hold) at 95°C for 10 minutes, and 
then 40 cycles of 95°C for 15 seconds for denature, 60°C for 1 minute for 
annealing and extention. 
2.10.3 Extraction and calculation of quantitative PCR data 
1) Reliability of replicates  
The number of cycles taken for each of 3 replicates of each reaction to cross the 
threshold was read.  Occasionally data was variable within the 3 replicates.  To 
deal with these data, two rules were applied in the study: first, if two values in 
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the replicates have less than 0.3 cycles between them, then remove the third 
value.  Second, if there is a difference greater than 1 full cycle of quantitative 
PCR between replicates, then leave out this experiment because it is inaccurate.  
2) Calculation for each value 
As the data of quantitative PCR shows the amplified cycles of each sample, it was 
calculated to the relative amount of cDNA products.  To relate the data of each 
RT-PCR assay, results of GAPDH was chosen to be the standard, and other results 
were related to it.  
In each individual, after the raw data of GAPDH was chosen to be the standard, 
every other data (PD-1, PD-L1, PD-L2 and VISTA) was calculated in the equation 
Y=2^(X-A) (X=each raw data, A= cycle number of GAPDH).  In this way, the 
standard (GAPDH) was transferred to 1, and other data was relative to it.  
However, the raw data indicated the numbers of PCR amplified cycles, which 
meant that the bigger the data was indicating the smaller amount of original RNA. 
Thus, all data then was applied in the equation of Y=1/(X*100) (X= each data 
from the first step calculation) to make sure the correct value relationship 






2.11.1 Gel extraction & DNA purification 
PCR products with a cluster of different sizes of bands were separated by size on 
gel.  The gel with the right size of the band was extracted applying the QIAquick 
Gel Extraction Kit (Qiagen).  Other PCR products were purified using MinElute 
PCR Purification Kit (Qiagen). 
2.11.2 Ligation 
Ligation reaction was performed in 10μl for each reaction.  Reagents were all 
from Promega.  3μl of PCR product, 1μl of T4 vector, 1μl of T4 ligase and 5μl of 
ligase buffer were added to eppendorf tube, mixed and then incubated at room 
temperature for 2 hours. 
2.11.3 Transfection 
JM109 component cells (Promega) were thawed on ice, then 25μl of cells and 
2.5μl of ligation product were transferred to a new eppendorf tube, mixed and 
then incubated on ice for 20mins.  Samples were subsequently heat-shocked at 
42°C for 45s, and then immediately moved back to ice for 2mins.  Then samples 
were incubated with 950μl of SOC medium at 37°C with shaking at 150rpm for 
2hrs.  Samples were then centrifuged at 200rpm at room temperature for 
10mins and then supernatants were taken off.  Cells were re-suspended in 
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100μl SOC medium and spread on Agar plates, incubated at 37°C upside down 
overnight. 
2.11.4 Picking up colonies 
Bacteria with a vector containing a DNA insert grew as white colonies and the 
bacteria with a vector without a DNA insert grew as blue colonies. The white 
colonies were picked up at random with a pipette tip and transferred to a 
gridded plate. The gridded plate was then incubated at 37°C upside down 
overnight.  The tip was washed off in 15µl dH2O.   
2.11.5 Screening 
2.11.5.1 Protocol 
To release the vector and denature the DNAse, dH2O containing washed off 
bacteria from the tips was boiled for 10mins and then centrifuged at 400g for 
10mins.  5µl of bacterial supernatant was taken off and amplified by PCR using 
M13 forward and M13 reverse primers.  PCR products were then run on a 3% 
agarose gel to screen for inserts of the correct size. 
2.11.5.2 PCR reaction 
Each PCR reaction contained 9.46µl nuclease free dH2O, 4µl 5x flexi buffer 
(Promega), 1.2µl MgCL2 (Promega), 0.2µl 20mm dNTPs (Promega), 0.02µl of 
each 100mm M13 primers, 0.1µl Taq polymerase (Promega).  PCR program has 
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been described in section 2.8.2.  Sequences of M13 primers are shown in table 
2.11.5.  
Table 2.11.5 Sequences of M13 primers used for clone screening 
         
 
2.11.6 DNA sequencing 
Colonies with appropriately size DNA inserts were tapped with clean tips from 
the gridded plate to sequencing plate and then sent for sequencing by Beckman 
Coulter sequencing services. 
 
2.12 Flow cytometry 
2.12.1 Cell surface staining 
Peripheral blood mononuclear cells (PBMC) were isolated from fresh blood or 
buffy coats and then washed with 2ml RPMI-1640 medium.  Samples were then 
spun down at 1200rpm or 400g at 4°C for 10 minutes, and then supernatants 
were taken off.  Samples were re-suspended in 2ml 1640 medium and cells 
were counted under microscope with trypon blue.  Cells (1x106 to 10x106 
depending on different experiments) were transferred into FACS tubes 
(Bioscience) and then washed with FACS buffer.  Samples were then spun down 
at 1200rpm or 400g at 4°C for 10 minutes, supernatants were then taken off.  
Cells were re-suspended with certain amount of FASC buffer (depending on 
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volumes of Abs added in, to make up a final volume 200ul) and incubated with 
fluorochrome-conjugated mAbs on ice for 20 minutes.  After incubation, 
samples were washed once with 2ml FACS buffer, and then spun down at 
1200rpm at 4°C for 10 minutes, and then supernatants were taken off.  Cells 
were re-suspended with 500μl FACS buffer (samples too sticky or containing too 
many cells will be transferred to a new tube through a strainer) and then 
analyzed with the BD FACSAria I cell sorter or BD FACSCanto.  All samples were 
gated and analyzed in a blinded manner. 
2.12.2 Intracellular staining 
In some experiments PBMC were also examined for expression of FoxP3 using 
the FoxP3 Fix/Perm buffer set (eBioscience) according to the manufacturers’ 
instructions. 
After step stained with surface Abs, cells were re-suspended in 1ml FoxP3 
fix/perm buffer (1:4 diluted) and vortex, and then incubated at room 
temperature in dark for 45 minutes.  Cells were then washed with 2ml Perm 
buffer (1:10 diluted) and centrifuged at 400g for 5 minutes.  Supernatants were 
then taken off.  Samples were subsequently re-suspended in 200μl Perm buffer 
(1:10 diluted), and incubated with FoxP3 Ab at room temperature in dark for 30 
minutes.  After incubation, samples were washed with 2ml Perm buffer (1:10 
diluted) and then centrifuged at 400g for 5 minutes.  Supernatants were taken 
off after centrifuge.  Samples were then washed once with 2ml FACS buffer and 
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then centrifuged at 400g for 5 minutes.  Supernatants were then discarded.  
Then cells were re-suspended with 500μl FACS buffer and then analyzed with 
the BD FACSAria I cell sorter or BD FACSCanto.   
2.12.3 Ab panels 
Table 2.12.3.1 Abs for study of CLA expressing B cells  
 
 
Table 2.12.3.2 Abs for study of circulating TFH cells 
 
 




Table 2.12.3.4 Abs for study of FoxP3 staining for Treg cells 
  
 
2.13 Treg cell suppressive function study 
For isolation of cell populations for functional studies, PBMC were stained as 
described above and regulatory (CD4+CD127loCD25hi) and effector 
(CD4+CD127+CD25-/lo) T cell populations isolated using a BD FACS-Aria II flow 
cytometer and FACS Diva Software.  In vitro co-culture suppression assays were 
performed by culturing effector T-cell populations (2.5x103/well) in the 
presence or absence of autologous Tregs at different ratios: 0:1, 1:1, 1:2 or 0:1.  
Cells were activated by the addition of Dynabeads®  Human T-Activator 
anti-CD3/anti-CD28 beads (Invitrogen, Paisley, UK) at a bead:conventional-cell 
ratio of 1:1, 1:2 or 1:4.  All assays were conducted in triplicate.  After 5 days of 
culture, proliferation was assessed by the addition of 0.5 µCi/well 
3[H]-Thymidine (Perkin Elmer, Waltham, MA, USA) for the final 18 hours of 
co-culture in X-VIVO 15 media.  The percentage of suppression was calculated 
using the following formula: %suppression = 100-(counts per minute (cpm) in 
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the presence of Tregs ÷ cpm in the absence of Tregs x 100).  All analyses were 
performed in a paired manner with one GPA and one control individual analyzed 
on a single day.   
 
2.14 Statistical methods 
Data sets are expressed as average and range.  All data has been tested for 
normality.  Some of the data studied in this thesis were not normally 
distributed, therefore nonparametric statistics including Mann Whitney test 
were used to analyze data in this thesis.  Statistical analysis was carried out 






















Study of B cells in lesions and peripheral blood from 






GPA is a rare autoimmune disease characterized by granulomatous vasculitis of 
the upper and lower respiratory tracts and glomerulonephritis [2, 4].  As a 
systemic inflammatory disease, many organs may be affected in GPA such as 
lungs, bronchi, oral or nasal mucosa, eyes, kidneys, nerves, brain, joints and skin 
[3].  However, upper respiratory tract involvement especially the affected facial 
sinuses was observed to be the most characteristic and common feature of GPA 
[3, 312, 313].  Moreover, the nasal mucosa has been reported to often be the 
site of initial disease activity [315, 353].  Therefore it has been proposed that 
the disease is initiated in the upper airways [312, 313].  It has been suggested 
that Staphylococcus aureus infection may be associated with the pathogenesis of 
GPA and persistent S. aureus nasal carriage is associated with a risk of disease 
relapse [314, 315].  
Anti-neutrophil cytoplasmic antibodies (ANCA) against proteinase 3 (PR3) have 
been reported to be highly sensitive and specific in GPA patients [13, 316] .  
Previous studies have found PR3 expressing granulocytes and macrophages in 
lung tissue from GPA patients [317], and an increased proportion of neutrophils 
expressing high levels of PR3 in peripheral blood from GPA patients compared to 
healthy controls [314, 354].  Moreover, an elevated level of PR3 expressed on 
the surface of neutrophils in peripheral blood was observed to be significantly 
associated with an increased disease relapse in GPA patients [318].  The 
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chronological sequence of upper airway symptoms followed by systemic 
manifestations is consistent with the notion that GPA may evolve as a 
consequence of upper airway inflammation and that other systemic, potentially 
life-threatening symptoms are a direct consequence of the activity of pathogenic 
autoantibodies.     
The immunological features of the mucosal microenvironment in GPA have not 
been studied extensively.  Classical features of the disease include a mixed 
infiltration of acute and chronic inflammatory cells, vasculitis, granulomas and 
small numbers of giant cells [3, 4, 355, 356].  B cells in normal oro-nasal mucosa 
and bronchial mucosa have been identified in organized lymphoid structures 
termed nasal-associated lymphoid tissue (NALT) or bronchus-associated 
lymphoid tissue (BALT) respectively [357].   In addition isolated activated B 
cells can be identified beneath the stratified/ pseudo stratified epithelium in oral 
mucosa that are increased in frequency and are associated with plasma cell 
differentiation in local inflammatory responses [358].  B cells and antibody 
producing plasma cell infiltrates were observed to be present in the mucosa of 
endonasal lesions from GPA patients [325].  Analysis of the immunoglobulin 
heavy chain genes from granulomatous lesions has found mutations in their 
immunoglobulin variable regions [323, 325], which is a feature of germinal 
centre origin [59].  However, conventional germinal centre stuctures have not 
been reported as a consistent feature of the inflamed airway mucosa in GPA in 
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previous studies.  One study has reported diffusely infiltrating lymphocytes, T 
cell and B cell infiltrates and germinal centre-like structures with DCs in 
granulomatous lesions of GPA [326]. 
Previous studies of animal models and humans have demonstrated that class 
switch recombination can be induced by BAFF and APRIL in a T cell independent 
way [95, 114, 359].  As a B cell survival factor, BAFF has been shown to prevent 
cell apoptosis and support B cell survival in mouse models [106, 108, 112].  In 
addition, over-expression of BAFF has been shown to lead to autoimmune 
symptoms in mice [35, 360].  Previous studies have observed higher plasma 
levels of BAFF in PR3-ANCA vasculitis patients [361] and an increased level of 
serum BAFF in peripheral blood from GPA patients [362] and activate 
MPO-ANCA vasculitis patients [363], although the correlation between BAFF and 
Ab status is not coincided.   
It has been reported that lymphocytes could migrate to different target organs by 
expressing a panel of chemokine receptors and adhesion molecules [205].  
Certain subsets of T cells have been reported to be recruited to skin and 
contribute to the local inflammation in inflammatory skin diseases [210].  
Another study has observed that a certain subset of T cells disappeared from 
peripheral blood but was found in lesions in activate GPA [314].  This raises the 
question of whether certain subsets of lymphocytes are recruited to 
inflammatory sites from peripheral blood in GPA patients. 
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Therefore the immunological features of the mucosal microenvironment in GPA 
were studied by immunohistochemistry; and B cell clonality in biopsies and 
peripheral blood were investigated by Immunoglobulin heavy chain (IGH) gene 
study in this chapter.  
Aims of this chapter: 
The aim of this chapter is to investigate the immunological features of biopsies 
from GPA patients, and to investigate any possibility that B cell clones identified 
in the mucosa might also circulate in the blood by comparison of junctional 
sequences that are unique to each B cell and its clonal progeny. 
 
3.2 Results 
3.2.1 Study of B cells and autoantibody production in biopsies from 
GPA patients 
B cells and local environment in biopsies from 8 patients with GPA were studied 
through IHC staining.  B cells were found to be consistently present in mucosal 
biopsies from all GPA patients studied.  One nasal biopsy from a patient with 
GPA contained abundant organised mucosa-associated lymphoid tissue (MALT), 
but the affected mucosa in the remaining cases had no evidence of germinal 
centre formation.  B cells in most cases were found not to be components of any 
organized lymphoid structure but were scattered submucosally (Figure 3.2.1 A).  
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Plasma cells were also observed in biopsies from GPA patients.  The plasma cell 
and B cell infiltrates tended to occupy adjacent areas of mucosa.  Plasma cells 
were often observed in the infiltrate that was predominantly B cells, but B cells 
were rare in the plasma cell dominated zones (Figure 3.2.1 B).            
 
Figure 3.2.1: Examples of B cells in paraffin sections of GPA mucosa studied by 
immunohistochemistry.  A. Single staining with CD20 (brown) identified B cells in 
biopsies from GPA patients, original magnification: x400.  B. Double staining with CD20 
(pink) and CD138 (brown) identified B cells and plasma cells occupying adjacent areas 
in GPA, original magnification: x200.  Plasma cells were present in the B cell dominated 
areas while B cells did not tend to infiltrate plasma cell dominated areas.   
 
The B cells in biopsies from GPA patients were large cells with extensive 
dendritic processes that extended and made contact with many adjacent cell 
types (Figure 3.2.1) (observation was made blindly by two researchers).  
Approximately 5% of the B cells were found expressing the Ki67 nuclear 
proliferation antigen (Figure 3.2.2).    
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Figure 3.2.2: Example of proliferating B cells in paraffin sections of GPA mucosa 
studied by immunohistochemistry.  Double staining of cell division antigen Ki67 
(brown nucleus) and surface CD20 (in pink) identified B cells that were proliferating in 
the biopsies (arrow pointing out an example), original magnification: x400.  
 
Neutrophils which are a target of autoantibody ANCA in GPA were observed in 
all biopsies from GPA patients and always located adjacent to B cells (Figure 
3.2.3 A).  Double staining of PR3 which is the target of cANCA that is expressed 
on neutrophils, and CD20 confirmed that PR3+ neutrophils present in biopsies 
from GPA patients were located close to B cells (Figure 3.2.3 B).  The B cell 
infiltrate in GPA was generally intimately mixed with acute inflammatory cells 
that included cells expressing the GPA associated autoantigen PR3 and 
neutrophil elastase.  CD20+ B cells were observed in germinal centres while 
CD3+ T cells were found in T cell zones in tonsil sections (Figure 3.2.3 D).  In 
contrast, although germinal centre structures were not observed as a feature of 
GPA biopsy, CD3+ T cells and CD20+ B cells were observed in adjacent areas in 
biopsies from GPA patients (Figure 3.2.3 C). 
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Figure 3.2.3: Examples of B cells and neutrophils in paraffin sections of GPA 
mucosa studied by immunohistochemistry. A. Double staining of CD20 (pink) and 
neutrophil elastase (brown) identified that activated B cells were adjacent to 
neutrophils (an example is circled), the target of autoantibody ANCA, in GPA biopsies, 
original magnification: x400. B. Double staining of PR3 (brown), the main target of 
ANCA in GPA, and CD20 (pink) original magnification: x600. C. Left: Double staining of 
FoxP3 (brown) and CD3 (pink) on GPA biopsy; Right: Double staining of neutrophil 
elastase (brown) and CD20 (pink) on GPA biopsy.  D. Left: Double staining of FoxP3 
(brown) and CD3 (pink) on tonsil section; Right: Double staining of neutrophil elastase 
(brown) and CD20 (pink) on tonsil section. 
 
To study the isotypes of Abs produced in lesions from GPA patients, biopsies 
were stained IgG, IgM, IgA, IgD and IgE.  The majority of plasma cells expressed 
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IgG, followed by IgA, and then IgM and IgE.  Compared to IgE producing cells 
observed in OFG biopsies under allergic condition, there were not many IgE+ 
cells in GPA biopsies.  No cytoplasmic IgD expression was observed in GPA 
biopsies (Figure 3.2.4). 
 
Figure 3.2.4: Examples of Ig productions in paraffin sections of GPA mucosa 
studied by immunohistochemistry. A. Single staining of IgG (brown) identified IgG 
producing cells in GPA biopsies, original magnification: x400.  B. Single staining of IgA 
(brown) identified IgA producing cells in GPA biopsies, original magnification: x400.  C. 
Single staining of IgM (brown) identified IgM producing cells in GPA biopsies (example 
is pointed out by arrow), original magnification: x400.  D. Left: Single staining of IgE 
(brown) identified IgE producing cells in GPA biopsies (arrow points out an example); 





3.2.2 Study of local B cell clonality in biopsies from GPA patients 
Since one patient with GPA donated surplus tissue following surgical procedures 
in 2004, 2009 and 2010 and a blood sample, IGH gene was studied across these 
biopsies and blood sample.  DNA was prepared from biopsies.  Ten PCR 
reactions to amplify IGH from FR3 to J were carried out from each of the biopsies.  
PCR products were cloned and sequenced.  Clones with the same junctional 
sequence from the same PCR were considered to be the same sequence and were 
counted as one.  A total of 74 different rearrangements were identified; 40 from 
bronchial mucosa 2004, 13 from bronchial 2009 and 21 from nasal mucosa 2010.  
The different numbers were a reflection of different B cell numbers in the 
different sized tissue samples studied.  Clone specific primers were then 
prepared to the V proximal N-D sequence to specifically identify the clone in 
target DNA sample by PCR.  Design ensured that some non-templated sequence 
was present between the clone specific primer and the J segment primer to allow 
confirmation of clonal identity by sequencing.  Of 14 primers designed, 8 were 
found not to amplify non-specifically in a DNA preparation of tonsil cells from an 
unrelated individual and were considered to be potentially clone specific.   
When PCR products of the correct size were generated by clone specific PCR, 





Figure 3.2.5: Immunoglobulin heavy chain VDJ junction sequences from a patient 
with GPA.  A and B. Alignments of sequences of VDJ obtained from different DNA 
samples of a biopsy obtained in 2004. The presence of the same sequence in different 
PCRs confirms B cell division and local presence of members of a B cell clone.   C. One 
VDJ rearrangement was identified in both the 2004 and the 2009 biopsies from this 
patient, implying that this B cell clone was persistent in the lesion for at least 5 years.  
 
Although the B cell population was polyclonal, these methods identified three 
examples of B cell clonal expansion in the inflamed mucosa.  Two different 
sequences were found to be present from different PCRs in the 2009 biopsy 
(Figure 3.2.5 A and B).  Remarkably, one clone was observed to be present in 
bronchial tissue in both 2004 and 2009 (Figure 3.2.5 C).  
The same method was also applied to detect circulating B cell subsets (details 
described in section 3.2.4) isolated from blood, using primers designed to the 
CDR3 sequences observed in the biopsy taken from the patient at the same time.  
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However, no evidence was observed that B cell clones identified in the affected 
mucosa circulated in peripheral blood in any sorted subsets.   
 
3.2.3 Study of local production of B cell survival factors in biopsies 
from GPA patients 
Since local B cell division and sustained clonal expansion was found in GPA 
biopsies as described above, the local distribution of B cell survival factors APRIL 
and BAFF and the BAFF receptor was investigated by IHC staining.  B cells 
expressing the BAFF receptor and cells producing BAFF were identified in the 
mucosa in GPA indicating that this pathway of promoting B cell survival is also 
relevant to the local response in GPA (Figure 3.2.6).                                        
 
Figure 3.2.6: Examples of BAFF and BAFF-R in paraffin sections of GPA mucosa 
studied by immunohistochemistry.  A. Single staining of BAFF-R (brown) identified 
the distribution of B cells that expressed receptor for survival factor BAFF in biopsies 
from GPA patients, original magnification: x400.  B. Single staining of BAFF (brown) 




APRIL was found to be produced abundantly in the B cell microenvironment in 
GPA and in other control mucosal biopsies.  It was observed that granulomas 
and giant cells, both of which are features of most cases of GPA, contained 
abundant APRIL (Figure 3.2.7 A).   Granulomas in orofacial granulomatosis and 
sarcoid were also found to produce APRIL (Figure 3.2.7 B and C).  Granulomas 
in GPA are therefore a previously unrecognized source of APRIL that may 
contribute to the support of the local B cell response.   
 
Figure 3.2.7: Examples of APRIL in paraffin sections of GPA mucosa and controls 
studied by immunohistochemistry.   A. single staining of APRIL (brown) illustrated 
the B cell survival factor APRIL production in GPA. Giant cells producing APRIL were 
observed in GPA, original magnification: x400.  B. Single staining of APRIL (brown) in 
OFG.  A granuloma containing a giant cell producing APRIL is shown here, original 
magnification: x200.  C. Double staining of APRIL (brown) and CD68 (pink) illustrated 
the APRIL was produced by the macrophages that comprise the granulomas in 
sarcoidosis, original magnification: x200.  D. single staining of APRIL (brown) in tonsil 






3.2.4 Study of circulating B cells expressing different regional homing 
receptors in peripheral blood from GPA patients   
Lymphocyte subsets can localize to different tissues by expressing different 
combinations of adhesion molecules and chemokine receptors.  The possibility 
that the potential lymphocyte homing patterns may be distracted in GPA was 
investigated.  Previous studies have illustrated that cells expressing α4β7 tend 
to migrate to gastrointestinal mucosa [205].  Other studies indicated a potential 
role of CLA and CCR10 in guiding cells localize in skin [209, 211].  Table 3.2.1 
that is adapted from a previous review [205] describes combination of adhesion 
molecules and chemokine receptors that would contribute to lymphocytes 
migration to skin and airway mucosa.  Cells co-expressing both the antigen CLA 
that binds the endothelial antigen E-selectin, and the chemokine receptor CCR10 
have the potential to re-localize to skin.  Cells expressing only CLA but not 
CCR10 tend to home to nasal and oral mucosa, while cells expressing CCR10 but 
not CLA tend to localize in bronchial mucosa.  Therefore, B cells expressing 
these molecules in peripheral blood from GPA patients were studied to 
investigate whether the chronic expansion of B cells in the mucosa was 






Table 3.2.1: Regional homing receptors involved in guiding lymphocyte migration 
from human peripheral blood into target tissues in GPA  
            
 
Staining in biopsies from GPA patients indicated the expression of E-selectin by 
flat endothelium in mucosa (Figure 3.2.8 A).  Double staining of E-selectin and 
CLA in biopsies from GPA indicated CLA+ cells interact with E-selectin 
expressing vessel endothelium in GPA biopsies (Figure 3.2.8 B).  This supports 
the concept that cells expressing CLA might migrate from blood to lesions in GPA 
patients.  
  
Figure 3.2.8: Examples of E-selectin and CLA in paraffin sections of GPA mucosa 
and controls studied by immunohistochemistry.  A. Single staining of E-selectin 
(brown) illustrated E-selectin expression in GPA mucosa, original magnification: x200.  
B. Double staining of E-selectin (brown, pointed out by open arrow) and CLA (pink, 
pointed out by closed arrow) illustrated CLA+ cells interact with E-selectin expressing 




Therefore cells expressing CLA, either amongst B cells or in the total lymphocyte 
in peripheral blood from 16 GPA patients and 11 age and gender matched 
healthy controls were studied by flow cytometry.  Patients’ clinical information 
is shown in table 3.2.2.  Gating strategy is shown in figure 3.2.9.  
 
Table 3.2.2: Clinical information of GPA patients  
 
* IgH chain gene analysis used to study biopsies and blood sample.   
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Figure 3.2.9: Gating strategy of circulating B cells expressing different homing 
receptors in peripheral blood from GPA patients and healthy controls.  
Lymphocytes identified by their forward and side scatter properties were gated for 
CD19+ expression and then examined for negative expression of α4β7, and then studied 
for CLA and CCR10 expression. 
 
Firstly, the frequencies of CD19+α4β7- B cells, which could potentially migrate to 
non-gastrointestinal mucosa, in total circulating CD19+ B cells from GPA patients 
and healthy controls were investigated.  No difference in the percentage of 
α4β7- B cells in total B cells was found between GPA patients and healthy 




       
Figure 3.2.10: Analysis of α4β7- cells in CD19+ B cells in peripheral blood from 
GPA patients and healthy controls.  A. Gating strategy of α4β7- cells in CD19+ B cell 
population.  B. Percentage of α4β7- cells in CD19+ B cells in peripheral blood from GPA 
patients (average: 26.29, range: 5.76 to 48.1) and healthy controls (average: 25.5, range: 
7.8 to 35.72) (P=0.94). 
Further study found no difference in the proportion of CLA+CCR10- cells in 
CD19+α4β7- B cell population between GPA patients (average: 8.19, range: 0.51 
to 20.38) and healthy controls (average: 6.6, range: 1.79 to 15) (Figure 3.2.11, 
P=0.57).                
      
      
Figure 3.2.11: Analysis of CLA+CCR10- cells in α4β7- B cells in peripheral blood 
from GPA patients and healthy controls.  A. Gating strategy of CLA+CCR10- cells in 
α4β7- B cell population.  B. Percentage of CLA+CCR10- cells in α4β7- B cells in 
peripheral blood from GPA patients (median: 6.01, range: 0.51 to 20.38) and healthy 
controls (median: 3.57, range: 1.79 to 15) (P=0.57). 
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There were very few CLA and CCR10 double positive cells observed in the 
CD19+α4β7- B cell population.  No difference was found between GPA patients 
(average: 0.025, range: 0 to 0.2) and healthy controls (average: 0.0055, range: 0 
to 0.05) (Figure 3.2.12, P=0.49).   
        
Figure 3.2.12: Analysis of CLA+CCR10+ cells in α4β7- B cells in peripheral blood 
from GPA patients and healthy controls.  A. Gating strategy of CLA+CCR10+ cells in 
α4β7- B cell population.  B. Percentage of CLA+CCR10+ cells in α4β7- B cells in 
peripheral blood from GPA patients (average: 0.025, range: 0 to 0.2) and healthy 
controls (average: 0.0055, range: 0 to 0.05) (P=0.49). 
No difference in the proportion of B cells expressing CCR10 but not CLA in the 
CD19+α4β7- B cell population was observed between patients with GPA 
(average: 0.57, range: 0 to 5.3) and healthy controls (average: 0.25, range: 0 to 
0.42) (Figure 3.2.13, P=0.96).   
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Figure 3.2.13: Analysis of CLA-CCR10+ cells in α4β7- B cells in peripheral blood 
from GPA patients and healthy controls.  A. Gating strategy of CLA-CCR10+ cells in 
α4β7- B cell population.  B. Percentage of CLA-CCR10+ cells in α4β7- B cells in 
peripheral blood from GPA patients (median: 0.22, range: 0 to 5.3) and healthy controls 
(average: 0.25, range: 0 to 0.42) (P=0.96). 
CLA could be expressed on other cell types.  Accumulation of CLA+ T cells has 
been reported to be associated with various skin diseases [210].  The 
percentage of CLA+ cells in total lymphocytes from GPA patients and healthy 
controls were therefore studied.  However, as shown in figure 3.2.14, no 
difference was found in the proportion of CLA+ cells in total lymphocytes 
between GPA patients (average: 10.32, range: 1.37 to 19.6) and healthy controls 
(average: 9.45, range: 2.7 to 19.04) (P=0.54). 
                  
Figure 3.2.14: Analysis of CLA + cells in total lymphocytes in peripheral blood 
from GPA patients and healthy controls.  Percentage of CLA+ cells in total 
lymphocytes in peripheral blood from GPA patients (average: 10.32, range: 1.37 to 19.6) 




3.2.5 Main findings in this chapter 
- B cells and plasma cells surrounded by PR3 expressing cells and 
abundant B cell survival factors were present in biopsies from GPA 
patients. 
- Approximately 5% of those B cells were observed dividing in lesions 
from GPA patients. 
- B cell clonal expansion was observed in biopsies from GPA patients 
through analysis of IgH gene.  
- B cell clonity was observed to be persistent in the bronchial lesion for 
five years in one GPA patient. 
- No evidence of B cell clones presented in lesions circulating in 
peripheral blood was observed in GPA patients. 
- No difference in the percentages of circulating B cell subsets that have 
potential to migrate to skin and non-gastrointestinal mucosa in GPA 





3.3.1 Microenvironment in lesions from GPA 
The microenvironment in biopsies from GPA patients has been described in this 
chapter.  Chronically activated B cells and PR3 expressing cells have been 
observed in biopsies from GPA patients.  These findings are consistent with 
previous studies of patients with GPA [317, 325]. 
Inflamed mucosa containing chronically activated B cells intimately mixed with 
cells expressing PR3, a characteristic target of autoantibodies, has been observed 
in most biopsies from GPA patients in this thesis.  The most common Ig isotype 
observed in biopsies from GPA patients was IgG, consistent with the profile 
observed in the diverse set of control tissues.  Granuloma is a common feature 
present in both GPA and OFG patients [3, 364].  Similar to the subepithelial 
dendritic B cells identified recently in oral mucosa from OFG patients [358], B 
cells observed in lesions from GPA patients were activated cells that lack IgD.  
Consistent with a previous study [323], proliferating B cells were found to 
compose approximately 5% of those B cells in biopsies from GPA patients.   
Moreover, these B cells were observed to have irregular cytoplasmic processes 
that extend and contact diverse adjacent cells.  They are not necessarily 
associated with any follicular structures but exist alongside a plasma cell 
component in inflammation.  Such cells are not known to be a general feature of 
the physiological process of plasma cell differentiation from B cells.  For 
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example the lamina propria of the normal gut, a site of plasma cell differentiation, 
does not have a significant population of proliferating cells that resembles those 
observed in the mucosa described here.  
Abundant expression of B cell survival factors APRIL and BAFF in biopsies from 
GPA patients has been described in this chapter.  BAFF and APRIL have been 
reported to support B cell survival [94, 103].  Previous studies have reported 
increased levels of plasma and serum BAFF, but no difference in serum APRIL 
level in peripheral blood from GPA patients [361-363].  The relevance of serum 
BAFF to ANCA status and vasculitis remains unclear, in a study of GPA serum 
BAFF varied inversely with ANCA levels [361, 362].  Studies have not observed 
any correlation between concentrations of APRIL in serum and ANCA titers [363]. 
Animal studies have demonstrated that BAFF plays an important role in 
regulating B cell maturation during transitional checkpoint [108].  Other 
studies have indicated that over-expression of BAFF could lead to autoimmune 
symptoms reminiscent of SLE and Sjogren syndrome [360].  Therefore the 
abundant expression of BAFF and APRIL observed in lesions from GPA patients 
may contribute to the survival of B cells and local auto-antibody production in 
GPA.  It is not known if BAFF and APRIL produced in mucosa acts locally or if it 
may contribute to the serum pool of B cell survival factors. 
In addition to supporting B cell survival, BAFF has also been reported to support 
T cell proliferation through interaction with BAFF-R [116, 117].  Therefore 
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BAFF production observed in biopsies from GPA patients may contribute to the 
pathogenesis of the disease by multi-pathways.   
Giant cells have been observed in the lesions of the respiratory tract from 
patients with GPA [356].  The expression of APRIL by granulomas and giant 
cells has been described in this thesis for the first time.  It is possible that the 
granulomas, which are also linked to macrophage fusion and giant cell formation, 
may subsequently provide a source of factors to support an aberrant B cell 
response.  This observation is relevant to granulomatous diseases other than 
GPA and is therefore not restricted to this autoimmune condition.  However, the 
combination of mixed acute and activated chronic inflammatory cells, alongside 
survival factors including APRIL produced by granulomas and giant cells was 
only seen in GPA.   
 
3.3.2 B cell clonality study in biopsies from GPA patients 
The B cell clonality in different biopsy sections donated at different time points 
and paired blood sample from one GPA patient has been studied in this chapter.  
Consistent with a previous study [323], clonally related cells were detected in a 
single bronchial biopsy section in a polyclonal B cell background by comparison 
of Ig gene CDR3 sequences, implying local B cell clone expansion.  This finding 
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is also supported by the observation of proliferating B cells by 
immunohistochemistry in this thesis.   
B cell clonality in biopsies of the same bronchial lesion from one patient collected 
for diagnosis at different time points has been described for the first time in this 
thesis.  A clonal population of B cells has been found to be present in two 
biopsies obtained from the same site in one GPA patient in 2004 and 2009 
respectively.  This presence of the B cell clone persisting for 5 years in one 
patient suggests that B cell stimulation in GPA is chronic.   In this chapter, the B 
cells in biopsies from GPA patients were observed to be often intimately 
associated with cells expressing PR3.  Previous studies have reported PR3 
expression in lesions from GPA patients [317].  Consistent with this study, some 
of the PR3 positive cells observed in this thesis were clearly neutrophils, but not 
all.   It is possible that the abundance of PR3 antigen locally provides an 
immunological stimulus to potentially initiate or sustain the chronic B cell 
anti-PR3 response.  However some cases studied in this thesis were negative 
for autoantibodies to PR3.  This demonstrates that although the presence of 
PR3 positive cells adjacent to B cells in lesions of GPA could possibly support the 
generation of autoantigen reactive B cells, this does not necessarily occur.  A 
population of neutrophils that support B cell responses has recently been 
described suggesting that neutrophils activating B cell responses may be 
involved in pathogenesis of GPA [365]. 
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Consistent with previous studies [323, 325], the IGH sequences obtained from 
biopsies from GPA patients contained mutants which generated by somatic 
hypermutation (SHM) (data not shown).  In normal condition, this suggested 
that these B cells were driven from germinal centres.  However, although CD3+ 
T cells and CD20+ B cells were observed in adjacent area in GPA biopsies, 
germinal centres were not found as a common feature in GPA mucosa.  It has 
been reported that B cell responses that result in germinal centre formation are 
generally T cell dependent [59].  T cell involvement places stringent regulation 
on the discrimination between self and non-self as a consequence of thymic 
education [158, 222].  However, in most cases studied in this thesis, no 
organized lymphoid structure was observed in GPA.  There is one study 
reporting germinal centre-like structures and also diffusely infiltrating 
lymphocytes in granuloma lesions from GPA [326].  Previous studies on mice 
have demonstrated that CSR in BAFF-transgenic mice is T cell independent [359].  
Further studies on human blood and mice demonstrated that BAFF and APRIL 
could induce CSR [95, 114].  Therefore the chronic B cell activity but lack of 
germinal centre formation in most disease relevant mucosal microenvironments 
in GPA might indicate that the anti-PR3 response in the mucosa could be driven 
in a T cell independent way.   
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Moreover, the mutants found in IGH gene in lesions from GPA patients might be 
induced by the presence of abundant BAFF and APRIL in the microenvironment 




3.3.3 Study of circulating lymphocytes that may migrate to upper 
airway lesions in GPA  
The B cells in mucosal lesions in GPA have been observed to have mutated IgHV 
genes, yet in the majority of cases no GC formation was observed in the mucosa.  
We therefore considered that the B cell fraction that localizes to the mucosa 
might be expanded as a population in blood and lymph nodes in GPA as part of a 
migratory continuum.  It is also possible that recruitment to an inflammatory 
site might result in depletion of a subset of inflammatory cells from the blood.  
When we analyzed the subsets of total lymphocytes or B cells in blood that 
expressed markers associated with tissue specific homing, no differences 
between GPA and healthy controls were apparent. 
Although other studies have observed that CD4+CD45RO+CCR7- T cells 
disappeared from peripheral blood but appeared in lesions in patients with 
activated GPA [314], no difference was observed in subsets of B cells and T cells 
that might be guided to migrate towards skin and non-gastrointestinal mucosa in 
GPA patients in this thesis.  In addition, no evidence of that B cell clones 
identified in biopsies were circulating in the paired peripheral blood in GPA 
patients was found through IgH gene study in this thesis.  These data together 
suggest that B cells in the lesion from GPA patients would be not a component of 
circulating B cells in the peripheral blood.  This hypothesis is supported by one 
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published study reporting B cell presence in lesions from rituximab treated GPA 
patient when B cells in peripheral blood has been depleted [333].  
 
3.3.4 Conclusion 
- Chronic activated B cells observed in lesions from GPA patients could be 
stimulated by sustained PR3 expression and supported by local 
production of BAFF and APRIL. 
- B cell clonal expansion in the lesion of GPA might be a result from T cell 
independent response but supported by abundant BAFF and APRIL in 
the micro-environment as no organized lymphoid structure was 
observed in most cases. 
- B cells present in the lesion might not be a component of any circulating 
B cell subsets that might have the potential to migrate to the target 
tissue as no evidence was found in B cell clonality study and the study of 


















Rituximab is a chimeric monoclonal antibody against B cell surface marker CD20 
[330] that is used as a B cell depletion therapy to treat different autoimmune 
diseases [366].  Although some studies have reported that rituximab lacks 
efficiency in treating patients with GPA [367, 368], rituximab is considered to be 
a beneficial therapy for GPA patients by many clinicians [369-371].  Recently, 
rituximab was approved for use in GPA patients by the Food and Drug 
Administration in the USA, based on two successful non-inferiority randomized 
controlled clinical trials [23, 24].  Although the pathology in autoimmune 
diseases may be autoantibody mediated, it is considered unlikely that disease 
remissions achieved by rituximab are a consequence of autoantibody depletion 
alone [372].  The relative importance of B cells and T cells in the pathogenesis 
of autoimmune diseases has been debated.  Whilst autoimmune rheumatic 
diseases are consistently linked with the production of autoantibodies, 
implicating B cell involvement, T cells are generally associated with the 
generation of autoimmune pathology [222].  The success of B cell depletion 
therapy in alleviating the symptoms of autoimmune diseases has highlighted the 
importance of B cells [339, 373-375].  There is increasing evidence from animal 
models and patient studies indicating that rituximab treatment also influences T 
cell subsets which directly affect disease development.  Studies on the EAE 
mouse model identified a decreased frequency of CD4+ T cells in spleen and 
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lymph nodes from rituximab treated mice [376].  Other studies on SLE patients 
following B cell depletion therapy demonstrated down-regulated CD40L on the T 
cell surface [377], increased Th1 but not Th2 cells [378]. 
Certain T cell subsets may be intrinsically dependent on T-cell dependent B-cell 
responses.  T follicular helper (TFH) cells, for example, are a T cell subset that 
normally resides in the germinal centres in the B cell zones of secondary 
lymphoid tissues [59].  Clones of TFH cells are known to disseminate widely and 
to circulate as a minority subset of T cells in the blood [150].  In human 
peripheral blood, CD4+ T cells expressing CXCR5, which is receptor for 
chemokine CXCL13 produced in the germinal centres, were found to be able to 
migrate to B cell follicles [151].  Other studies subdivided the CD4+CXCR5+ T 
cell population into Th1, Th2 and Th17 cells and indicated that Th2 and Th17 can 
provide help to naïve B cells to differentiate and produce Abs [379].  Although 
circulating CD4+ CXCR5+ T cells in peripheral blood may have similar functions 
as TFH cells from germinal centres, the relationship between those cells is not 
clear yet.  Whereas TFH cells are defined by their microanatomical location in 
the germinal centres in tissues, a small subset of CD4+ T cells in human blood 
was described as circulating TFH cells by their high levels co-expression of CXCR5 
and cell surface antigen PD-1 [158].   
Germinal centre TFH cells are involved in the progression of autoimmunity in a 
mouse model of SLE by lowering the threshold for B cell survival [222].  This 
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lack of stringency in T cell mediated B-cell selection supports the evolution of 
autoreactive antibody secreting clones of cells.  There is evidence that TFH cells 
may be involved in autoimmune responses in humans in a subset of patients with 
severe SLE, where the proportion of circulating TFH cells,  which were defined 
as CXCR5+CD4+ T cells expressing high levels of ICOS or PD-1, was significantly 
higher than that in healthy controls [158]. 
Regulatory T (Treg) cells are critical regulators of autoimmune diseases through 
suppressing the proliferation and cytokine production of effector T cells [334, 
335].  The failure of Treg cells to suppress inflammation, either through defects 
of Treg cells or the cells that respond to them, may facilitate the development of 
autoimmune pathology.  Some studies have shown Treg cell frequencies to be 
reduced in GPA, and other studies have detected defects in the suppressive 
function of Treg cells in GPA - both sets of observations implicate Treg cells in 
the disease process [336-338].  Interestingly, Treg cell frequencies have been 
shown to increase in the blood of patients with SLE following rituximab 
treatment [339].  This could be a secondary consequence of clinical remission, 
or if Treg cells are actually associated with the disease process and are not 
purely bystanders, this data might imply that Treg cells are in some way B cell 
dependent. 
The pathogenesis of GPA is not well understood.  Although GPA patients have 
benefited from B cell depletion therapy with rituximab, the mechanism of 
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remission is not clear.  The effects of B cell depletion on different T cell subsets 
in GPA patients following rituximab therapy have not been studied.  Therefore 
circulating TFH cells and Treg cells from GPA patients following B cell depletion 
therapy with rituximab, GPA patients on conventional therapies, healthy and 
disease controls were studied in this chapter. 
Aims of this chapter: 
The aim of this chapter is to investigate any difference in frequencies of 
circulating TFH cells and Treg cells from GPA patients on conventional therapies, 






4.2.1 Study of frequencies of B cells and T cells in peripheral blood 
from GPA patients 
4.2.1.1 Frequencies of B cells in peripheral blood from GPA patients, B 
cell depleted GPA patients and healthy controls 
CD19 expression in PBMC from 18 GPA patients on conventional therapies, 9 
GPA patients following B cell depletion therapy and 11 age and gender matched 
healthy controls were studied by flow cytometry and data was analysed.  As 
shown in figure 4.2.1, the proportion of CD19+ B cells in GPA patients following B 
cell depletion therapy (average: 0.68) was significantly lower than in GPA 
patients  on conventional therapies (average: 15.89) (P<0.0001) and healthy 
controls (average: 13.39). There was no difference in the frequency of CD19+ B 
cells in peripheral blood between GPA patients on conventional therapies and 




            
Figure 4.2.1: Frequencies of B cells in total lymphocytes from GPA patients on 
conventional therapies, B cell depleted GPA patients and healthy controls.  
Percentage of CD19+ B cells in total lymphocytes from healthy controls (median: 10.64, 
range: 3.75 to 30.36), GPA patients on conventional therapies (median: 8.26, range: 2.9 




4.2.1.2 Clinical effect of B cell depletion therapy on GPA patients 
Since there were few B cells in the peripheral blood from GPA patients following 
RTX therapy, the clinical effect of B cell depletion therapy on GPA patients was 
studied by comparing the BVAS scores before and after RTX treatment in the 
same patient cohort.  Clinical information of GPA patients on conventional 






Table 4.2.1: Clinical information of GPA patients on conventional therapies: 
 
 





Clinical information of GPA patients following B cell depletion therapy is shown 
in table 4.2.2, including BVAS scores and antibody titers before and after RTX 
treatment.  7 out of 9 B cell depleted GPA patients included in this study were 
ANCA positive.  The ANCA titers were found not to change after RTX treatment 
in 2 out of 7 B cell depleted GPA patients (Table 4.2.2).  
All GPA patients following B cell depletion therapy were clinically improved.  
BVAS scores after RTX treatment were significantly lower than before the 
treatment (P=0.024) (Figure 4.2.2).     
                                
 
Figure 4.2.2: Disease activity score (BVAS score) change in patients before and 
after RTX treatment.  In the group of patients receiving RTX, BVAS scores were 4 to 




Blood samples from SLE patients were used as disease controls for study in this 
chapter.  Clinical information of SLE patients studied in this chapter is shown in 
table 4.2.3. 
 






4.2.1.3 Frequencies of T cells in peripheral blood from GPA patients, B 
cell depleted GPA patients, healthy and disease controls 
To investigate the influence of B cell depletion on other types of lymphocytes, the 
frequency of T cells in peripheral blood from 18 GPA patients on conventional 
therapies, 9 B cell depleted GPA patients, 10 healthy controls and 7 SLE patients 
was studied by flow cytometry.  The average percentage of CD3+ in total 
lymphocytes was 69.94% in healthy controls.  No significant difference in the 
proportion of CD3+ T cells in total lymphocytes was observed between all groups 
of patients (Figure 4.2.3 A).  The frequency of CD4+ T cells in CD3+ T cells was 
further studied.  No significant difference in the percentage of CD4+ T cells in 
CD3+ T cells was found between all groups (Figure 4.2.3 B).  Moreover, no 
difference was observed between all groups when the proportion of CD4+ T cells 




Figure 4.2.3: Frequencies of circulating T cell subsets in peripheral blood from 
GPA patients on conventional therapies, B cell depleted GPA patients, healthy and 
disease controls.  A. Percentage of CD3+ T cells in total lymphocytes in peripheral 
blood from healthy controls (average: 69.94, range: 52.15 to 79.48), GPA patients on 
conventional therapies (average: 57.69, range: 26.62 to 92.03), GPA patients under B 
cell depletion therapy (average: 73.23, range: 56.35 to 90.56) and SLE patients (average: 
58.59, range: 16.19 to 83.8).  B. Percentage of CD4+ T cells in CD3+ T cells in peripheral 
blood from healthy controls (average: 58.18, range: 47.73 to 67.82), GPA patients on 
conventional therapies (average: 57.28, range: 27.41 to 84.22), GPA patients under B 
cell depletion therapy (average: 44.34, range: 8.65 to 73.33) and SLE patients (average: 
56.34, range: 31.73 to 82.73).  C. Percentage of CD4+ T cells in total lymphocytes in 
peripheral blood from healthy controls (average: 40.49, range: 28.52 to 47.09), GPA 
patients on conventional therapies (average: 34.28, range: 10.57 to 70.91), GPA patients 
under B cell depletion therapy (average: 32.38, range: 5.97 to 61.43) and SLE patients 




4.2.2 Frequencies of circulating TFH cells in peripheral blood from GPA 
patients, healthy and disease controls 
TFH cells have been shown to be involved in the progression of autoimmunity in a 
mouse model of SLE by lowering the threshold for B cell survival [222].  
Therefore the frequency of circulating TFH cells in peripheral blood from 19 GPA 
patients on conventional therapies, 9 B cell depleted GPA patients, 10 healthy 
controls and 8 SLE patients was investigated by flow cytometry.  Circulating TFH 
cells were identified in isolated PBMC as CD3+CD4+ T cells expressing high levels 
of CXCR5 and PD-1 (Figure 4.2.4).   
               
Figure 4.2.4: Gating strategy of circulating TFH cells in peripheral blood from GPA 
patients on conventional therapies, B cell depleted GPA patients, healthy and 
disease controls.  Lymphocytes identified by their forward and side scatter properties 
were gated for CD3+ and CD4+ double expression and then examined for high 
expression of PD-1 and CXCR5 to identify circulating TFH cells in peripheral blood.  
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A significant increase in percentage of CXCR5highPD-1high TFH cells in CD4+ T cells 
was observed in peripheral blood from GPA patients on conventional therapies 
(average: 0.37) compared to age and gender matched healthy controls (average: 
0.19) (P=0. 001) and GPA patients following B cell depletion therapy (average: 
0.23) (P=0. 0051).  In contrast, no such difference was found between healthy 
controls and either B cell depleted GPA patients (P=0.5) or SLE patients (average: 
0.3) (P=0.27) (Figure 4.2.5 A).   
 
Figure 4.2.5: Frequencies of circulating TFH cells in peripheral blood from GPA 
patients on conventional therapies, B cell depleted GPA patients, healthy and 
disease controls.  A. Percentage of circulating TFH cells in CD4+ T cells in peripheral 
blood from healthy controls (average: 0.19, range: 0.03 to 0.33), GPA patients on 
conventional therapies (average: 0.37, range: 0.04 to 0.66) (P=0.001 and P=0.0051 when 
compared to healthy controls and GPA patients under B cell depletion therapy 
respectively), GPA patients under B cell depletion therapy (average: 0.23, range: 0.12 to 
0.32) and SLE patients (average: 0.3, range: 0.11 to 0.69).  B. Percentage of circulating 
TFH cells in total lymphocytes in peripheral blood from healthy controls (average: 0.073, 
range: 0.014 to 0.1), GPA patients on conventional therapies (average: 0.13, range: 
0.0087 to 0.23) (P=0.037 and P=0.044 when compared to healthy controls and GPA 
patients under B cell depletion therapy respectively), GPA patients under B cell 
depletion therapy (average: 0.077, range: 0.0096 to 0.2) and SLE patients (average: 0.11, 
range: 0.021 to 0.26).   
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As the proportion of CD4+ T cells in total lymphocytes varies between 
individuals (7.43% to 69.11% in samples studied in this thesis), the frequency of 
CXCR5highPD-1high TFH cells in total lymphocytes was calculated.  A significant 
increase in percentage of CXCR5highPD-1high TFH cells in total lymphocytes was 
observed in peripheral blood from GPA patients on conventional therapies 
(average: 0.13) compared to age and gender matched healthy controls (average: 
0.073) (P=0.037) and GPA patients following B cell depletion therapy (average: 
0.077) (P=0.0044).  No such difference was found between healthy controls and 
either B cell depleted GPA patients (P=0.66) or SLE patients (average: 0.11) 
(P=0.51) (Figure 4.2.5 B). 
 
4.2.3 Frequencies of PD-1+CD4+ T cells in peripheral blood from GPA 
patients, healthy and disease controls 
As an increased proportion of circulating TFH cells was observed in GPA patients 
on conventional therapies but not B cell depleted GPA patients, CD4+ T cells 
expressing PD-1 in peripheral blood was subsequently investigated by flow 
cytometry.  PD-1 expression was measured on CD3+CD4+ T cells in PBMC 
isolated from 18 GPA patients on conventional therapies, 9 B cell depleted GPA 
patients, 10 age and gender matched healthy controls and 8 SLE patients. The 
Gating strategy is shown in figure 4.2.6.   
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Figure 4.2.6: Gating strategy of PD-1+ cells in CD4+ T cells in peripheral blood 
from GPA patients on conventional therapies, B cell depleted GPA patients, 
healthy and disease controls.  Lymphocytes identified by their forward and side 
scatter properties were gated for CD3+ and CD4+ double expression and then examined 
for expression of PD-1 according to FMO controls to identify PD-1+CD4+ T cells in 
peripheral blood.  
A significant increase in the percentage of PD-1+ cells in CD4+ T cells was 
observed in peripheral blood from GPA patients on conventional therapies 
(average: 1.26) compared to healthy controls (average: 0.69) (P=0.0027) (Figure 
4.2.7 A).  However, no significant difference was found in the frequency of 
PD-1+ cells in CD4+ T cells between GPA patients on conventional therapies and 
those who had clinically responded to B cell depletion therapy (average: 0.95) 
(P=0.18).  No difference was observed between healthy controls and either B 
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cell depleted GPA patients (P=0.28) or SLE patients (0.84) (P=0.83) (Figure 4.2.7 
A).   
 
Figure 4.2.7: Frequencies of PD-1+CD4+ T cells in peripheral blood from GPA 
patients on conventional therapies, B cell depleted GPA patients, healthy and 
disease controls.  A. Percentage of PD-1+ cells in CD4+ T cells in peripheral blood 
from healthy controls (average: 0.69, range: 0.47 to 0.99), GPA patients on conventional 
therapies (median: 0.95, range: 0.7 to 2.85) (P=0.0027 compared to healthy controls), 
GPA patients under B cell depletion therapy (average: 0.95, range: 0.44 to 1.72) and SLE 
patients (average: 0.84, range: 0.42 to 1.71).  B. Percentage of PD-1+CD4+ T cells in 
total lymphocytes in peripheral blood from healthy controls (average: 0.28, range: 0.17 
to 0.42), GPA patients on conventional therapies (average: 0.4, range: 0.18 to 0.87), GPA 
patients under B cell depletion therapy (average: 0.3, range: 0.043 to 0.58) and SLE 
patients (average: 0.34, range: 0.031 to 0.84).  
As the proportion of CD3+ T cells in total lymphocytes varies between 
individuals, the frequency of PD-1+CD4+ T cells in total lymphocytes was further 
calculated.  This time, no significant difference in percentage of PD-1 expressing 
CD4+ T cells in total lymphocytes was observed in GPA patients on conventional 
therapies (average: 0.4) compared to healthy controls (average: 0.28) (P=0.089) 
or B cell depleted GPA patients (average: 0.3) (P=0.32) (Figure 4.2.7 B).  No 
difference in proportion of PD-1+ CD4+ T cells in total lymphocytes was found 
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between healthy controls and either GPA patients following B cell depletion 
therapy (P=0.84) or SLE patients (0.34) (P=0.9) (Figure 4.2.7 B). 
 
4.2.4 Expression of PD-1 in tissues from GPA patients and controls 
PD-1 positive cells were observed in 4 of the 6 biopsies from patients with GPA.  
As PD-1 is reported to be expressed on TFH cells in germinal centres [158], tonsil 
sections were used as control.  As expected, most PD-1 positive cells in tonsil 
controls were found in germinal centres (Figure 4.2.8 A). In contrast, PD-1 
positive cells observed in biopsies from GPA patients tended not to be 
components of any organized lymphoid structure (Figure 4.2.8 B). 
 
Figure 4.2.8: PD-1+ cells in paraffin sections from GPA patients were studied by 
immunohistochemistry.  A. Single staining with PD-1 (brown) identified PD-1+ cells 
in tonsil sections, original magnifications: x100 (left), x200 (right), germinal centres in 
tonsil sections are indicated by circles.  B. Single staining with PD-1 (brown) identified 




4.2.5 Study of Treg cells in peripheral blood from GPA patients, 
healthy and disease controls 
4.2.5.1 Frequencies of Treg cells in peripheral blood from GPA 
patients, healthy and disease controls 
The frequency of Treg cells in peripheral blood from 18 GPA patients on 
conventional therapies, 9 B cell depleted GPA patients, 10 healthy controls and 8 
SLE patients was studied by flow cytometry.  Treg cells were identified in 
isolated PBMC as a subset of CD4+CD14- T cells that are CD25high CD127- (Figure 
4.2.9 A).  The expression of FoxP3 was examined in the Treg cell population 
(Figure 4.2.9 B).  The majority of this population expressed FoxP3.    
 
Figure 4.2.9: Gating strategy of Treg cells in peripheral blood from GPA patients 
on conventional therapies, B cell depleted GPA patients, healthy and disease 
controls.  A. Lymphocytes identified by their forward and side scatter properties were 
gated for CD4+CD14- expression and then examined for expression of CD25 and CD127 
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to identify regulatory T cells in peripheral blood.  B. The expression of Foxp3 in 
CD25+CD127- Treg cells and CD25-CD127+ T effector cells from GPA patients.  
Consistent with other studies [380], Treg cells comprised on average 7.73% of 
CD4+ T cells in healthy controls (Figure 4.2.10 A).  Interestingly, a significantly 
reduced proportion of Treg cells in CD4+ T cells was observed in the peripheral 
blood from GPA patients on conventional therapies (average: 5.03) compared to 
healthy controls (P=0.0017) and B cell depleted GPA patients (average: 8.04) 
(P=0.0043).  No such difference was found between B cell depleted GPA 
patients and healthy controls (P=0.6).  There was no difference observed in the 
percentage of Treg cells in CD4+ T cells in peripheral blood between healthy 
controls and SLE patients (average: 8.73) (Figure 4.2.10 A). 
 
Figure 4.2.10: Frequencies of Treg cells in peripheral blood from GPA patients on 
conventional therapies, B cell depleted GPA patients, healthy and disease controls.  
A. Percentage of Treg cells in CD4+ T cells in peripheral blood from healthy controls 
(average: 7.73, range: 6.07 to 9.2), GPA patients on conventional therapies (average: 
5.03, range: 1.88 to 10.07) (P=0.0017 and P=0.0043 when compared to healthy controls 
and GPA patients under B cell depletion therapy respectively), GPA patients under B cell 
depletion therapy (average: 8.04, range: 4.99 to 12.27) and SLE patients (average: 8.73, 
range: 2.61 to 16.16).  B. Percentage of Treg cells in total lymphocytes in peripheral 
blood from healthy controls (average: 3.09, range: 2.23 to 4.29), GPA patients on 
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conventional therapies (average: 1.92, range: 0.22 to 3.75) (P=0.0027 when compared 
to healthy controls), GPA patients under B cell depletion therapy (average: 2.39, range: 
0.47 to 4.76) and SLE patients (average: 3.25, range: 0.48 to 6.04).   
When the frequency of Treg cells in total lymphocytes was calculated, a 
significant reduction was observed in GPA patients on conventional therapies 
(average: 1.92) compared to healthy controls (average: 3.09) (P=0.0027) (Figure 
4.2.10 B).  There was no difference in the proportion of Treg cells in total 
lymphocytes in peripheral blood between GPA patients on conventional 
therapies and those who clinically responded to B cell depletion therapy 
(average: 2.39) (P=0.3).  No significant difference in Treg frequency in total 
lymphocytes was found between healthy controls and either B cell depleted GPA 
patients or SLE patients (average: 3.25) (Figure 4.2.10 B). 
4.2.5.2 Frequencies of different Treg cell subsets in peripheral blood 
from GPA patients, healthy and disease controls 
As a decrease of Treg cell frequency was observed in peripheral blood from GPA 
patients on conventional therapies but not B cell depleted GPA patients, different 
subsets of Treg cells were further studied.  The Treg cell population was 
divided into 3 sub-populations based on the expression of CD25 and CD45RA, 
which represent different stages of differentiation (Figure 4.2.11 A).  The 
reduction of Treg cell frequency in GPA patients on conventional therapies was 
observed in the memory and activated Treg cells but not resting Treg cells 
(Figure 4.2.11 B to D).  The average proportion of memory Treg cells in CD4+ T 
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cells was 2.52 in GPA patients on conventional therapies compared to 4.72 in 
healthy controls and 4.63 in GPA patients following B cell depletion therapy 
(P=0.0001 and P=0.0022 respectively) (Figure 4.2.11 C).  The average 
proportion of activated Treg cells in CD4+ T cells was 0.24 in GPA patients on 
conventional therapies compared to 0.68 in healthy controls and 0.62 in GPA 
patients following B cell depletion therapy (P=0.0002 and P=0.0022 respectively) 
(Figure 4.2.11 C).   
 
Figure 4.2.11: Frequencies of Treg cell subsets in CD4+ T cells of peripheral blood 
from GPA patients on conventional therapies, B cell depleted GPA patients, 
healthy and disease controls.  A. Delineation of Treg subpopulations:  
CD25+CD127- Tregs were identified in figure 4.2.9 and then divided into resting Tregs 
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(CD25+CD45RA+), memory Tregs (CD25+CD45RA-) and activated Tregs 
(CD25highCD45RA-).  B. Percentage of resting Treg cells in CD4+ T cells in healthy 
controls (average: 2.27, range: 1 to 3.2), GPA patients on conventional therapies 
(average: 2.25, range: 0.44 to 5.3), GPA patients under B cell depletion therapy (average: 
2.27, range: 0.76 to 4.74) and SLE patients (average: 3.3, range: 0.25 to 5.74).  C. 
Percentage of memory Treg cells in CD4+ T cells in healthy controls (average: 4.72, 
range: 3.88 to 5.83), GPA patients on conventional therapies (average: 2.52, range: 0.6 to 
4.96) (P=0.0001 and P=0.0022 when compared to healthy controls and GPA patients 
under B cell depletion therapy respectively), GPA patients under B cell depletion 
therapy (average: 4.63, range: 2.61 to 7.75) and SLE patients (average: 4.74, range: 1.18 
to 9.63).  D. Percentage of activated Treg cells in CD4+ T cells in healthy controls 
(average: 0.68, range: 0.34 to 1.07), GPA patients on conventional therapies (median: 
0.20, range: 0.04 to 0.91) (P=0.0002 and P=0.0022 when compared to healthy controls 
and GPA patients under B cell depletion therapy respectively), GPA patients under B cell 
depletion therapy (average: 0.62, range: 0.25 to 1), and SLE patients (average: 0.63, 
range: 0.088 to 1.78). 
As the frequencies of Treg cells and CD4+ T cells in total lymphocytes differ 
between individuals, the proportion of each Treg subset in total lymphocytes 
was further studied.   No difference was observed in the frequency of resting 
Treg cells in total lymphocytes between GPA patients, healthy controls and SLE 
patients (Figure 4.2.12 A).  The frequency of memory Treg cells in total 
lymphocytes was significantly lower in GPA patients on conventional therapies 
(average: 0.87) compared to healthy controls (average: 1.88) (P<0.0001) and B 
cell depleted GPA patients (average: 1.41) (P=0.033).  No such difference was 
observed between B cell depleted GPA patients and healthy controls (Figure 
4.2.12 B).  The frequency of activated Treg cells in total lymphocytes was 
significantly lower in GPA patients on conventional therapies (average: 0.088) 
compared to healthy controls (average: 0.27) (P<0.0001) and B cell depleted 
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GPA patients (average: 0.18) (P=0.0081).  No such difference was observed 
between B cell depleted GPA patients and healthy controls (Figure 4.2.12 C).  
No difference in any Treg subset was found between SLE patients and healthy 
controls. 
     
Figure 4.2.12: Frequencies of Treg cell subsets in total lymphocytes of peripheral 
blood from GPA patients on conventional therapies, B cell depleted GPA patients, 
healthy and disease controls.  A. Percentage of resting Treg cells in total lymphocytes 
in healthy controls (average: 0.92, range: 0.29 to 1.39), GPA patients on conventional 
therapies (average: 0.93, range: 0.059 to 2.54), GPA patients under B cell depletion 
therapy (median: 0.69, range: 0.081 to 2.88) and SLE patients (average: 1.23, range: 
0.047 to 2.91).  B. Percentage of memory Treg cells in total lymphocytes in healthy 
controls (median: 1.86, range: 1.5 to 2.56), GPA patients on conventional therapies 
(average: 0.87, range: 0.13 to 1.45) (P<0.0001 and P=0.033 when compared to healthy 
controls and GPA patients under B cell depletion therapy respectively), GPA patients 
under B cell depletion therapy (average: 1.41, range: 0.33 to 2.11) and SLE patients 
(average: 1.76, range: 0.23 to 3.79).  C. Percentage of activated Treg cells in total 
lymphocytes in healthy controls (median: 0.26, range: 0.16 to 0.51), GPA patients on 
conventional therapies (median: 0.086, range: 0.00079 to 0.28) (P<0.0001 and P=0.0081 
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when compared to healthy controls and GPA patients under B cell depletion therapy 
respectively), GPA patients under B cell depletion therapy (average: 0.18, range: 0.053 
to 0.32), and SLE patients (average: 0.24, range: 0.02 to 0.68). 
4.2.5.3 Functional study of Treg cells from GPA patients and healthy 
controls 
Suppressive functions of Treg cells from 3 GPA patients on conventional 
therapies and 3 healthy controls were investigated.  Clinical information of 
patients studied for Treg cell function is shown in table 4.2.4.   
Table 4.2.4: Clinical information of GPA patients studied for Treg cell function 
 
As different concentration of stimuli can cause different suppression rate, 3 
different concentrations of anti-CD3/CD28 stimuli were used in the functional 
study.  Consistent with the observation in section 4.2.5.1, a significant reduction 
in Treg cell frequency in peripheral blood from GPA patients on conventional 
therapies (average: 3.3) (P=0. 0087) was detected compared to 3 matched 
healthy controls (average: 6.9) (Figure 4.2.13 A).  Treg cells isolated from both 
GPA patients and matched healthy controls were observed to suppress T effector 
cell proliferation, regardless of the concentration of stimuli (Figure 4.2.13 C and 
D).  No difference in Treg cell-mediated suppression of T effector cell 
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proliferation was found between GPA patients on conventional therapies and 
healthy controls (Figure 4.2.13 B, P=0.23).  
 
Figure 4.2.13: Functional study of Treg cells from GPA patients and healthy 
controls.  A. Percentage of CD25+CD127- Treg cells in CD4+ T cells in 3 GPA patients 
(median: 3.2, range: 2.9 to 3.8) and 3 healthy controls (median: 7.5, range: 5.5 to 7.7) 
(P=0.0087).  B. Suppression rate of Treg cells from 3 GPA patients (median: 76.38, 
range: 63.24 to 77.94) and 3 paired healthy controls (median: 66.05, range: 52.8 to 
69.22) activated at a bead:conventional-cell ratio of 1:1 (P=0.23).  A and B: The 3 pairs 
of GPA patients and healthy controls were represented with circle, square and triangle.  
C. Radioactivity measurement of T effector cells alone or co-cultured with Treg cells (1:1) 
from 1 GPA patient activated at a bead: conventional-cell ratio of 1:1, 1:2 or 1:4.  D. 
Radioactivity measurement of T effector cells alone or co-cultured with Treg cells (1:1) 





4.2.6 Study of FoxP3+ Treg cells in tissues from GPA patients and 
controls 
To study Treg cells in lesions from GPA patients, expression of FoxP3 and CD3 on 
biopsies from GPA patients and tonsil controls was studied.  CD3+ T cells were 
observed in 6 of the 7 biopsy sections from GPA patients and controls.  The 
numbers of CD3+ T cells infiltrating in the biopsies were variable between 
individuals.  FoxP3+ Treg cells were observed in all sections that contained 
CD3+ T cells (Figure 4.2.14).  The proportions of FoxP3+ Treg cells in CD3+ T 
cells in each section were variable. 
       
Figure 4.2.14: Foxp3+CD3+ T cells in paraffin sections from GPA patients were 
studied by immunohistochemistry.  A. Double staining with FoxP3 (brown) and CD3 
(pink) identified Treg cells in tonsil sections, original magnifications: x100 (left), x400 
(right).  B. Double staining with FoxP3 (brown) and CD3 (pink) identified Treg cells in 
biopsies from GPA patients, original magnification: x400.  
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4.2.7 Correlation between TFH and Treg cell frequencies in human 
peripheral blood 
A significantly increased frequency of circulating TFH cells and a significant 
reduction in Treg cell frequency was observed in peripheral blood from GPA 
patients on conventional therapies compared to healthy controls and B cell 
depleted GPA patients in previous sections.  Therefore a numerical relationship 
between frequencies of circulating TFH cells and Treg cells in human blood was 
hypothesised.  Proportions of circulating TFH cells and Treg cells in CD4+ T cells 
in peripheral blood from all GPA patients, healthy controls and SLE patients were 
plotted on an XY graph.  A significant inverse correlation between the 
frequencies of circulating TFH cells and Treg cells in CD4+ T cells was observed 
(Figure 4.2.15 A, P=0.012).   
   
Figure 4.2.15: Analysis of frequencies of TFH cells and Treg cells in CD4+ T cells in 
peripheral blood.  A. Circulating TFH cell frequency and Treg cell frequency from all 
samples studied in this thesis, including GPA patients, BCD GPA patients, SLE patients 
and healthy controls, was significantly inverse correlated in CD4+ T cells (P=0.012, 
r2=0.14).  B. Ratio of circulating TFH versus Treg frequencies in CD4+ T cells from 18 
GPA patients (average: 9.07, range: 0.71 to 30.56) and 10 healthy controls (average: 2.43, 
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range: 0.37 to 4.33) (P= 0.0002); and 9 BCD GPA patients (average: 3.16, range: 1.3 to 
5.61) (P=0.0031).  
Since a mathematical relationship between circulating TFH cells and Treg cells 
was observed, the ratio of these two populations was hypothesised to provide 
better discrimination between GPA patients and healthy controls than circulating 
TFH or Treg frequencies alone.  Therefore the ratio of circulating TFH cells to 
Treg cells in peripheral blood from GPA patients on conventional therapies, GPA 
patients following B cell depletion therapy and healthy controls was further 
investigated.  A clearer discrimination between GPA patients on conventional 
therapies (average: 9.07) and healthy controls (average: 2.43) (P=0.0002) and 
GPA patients following B cell depletion therapy (average: 3.16) (P=0.0031) was 
observed.  No difference in the ratio of circulating TFH cells versus Treg cells 
was found between GPA patients following B cell depletion therapy and healthy 




4.2.8 Main findings in this chapter: 
- Higher frequency of circulating CXCR5highPD-1high TFH cells in peripheral 
blood was observed from GPA patients on conventional therapies 
compared to healthy controls and GPA patients following B cell depletion 
therapy. 
- Higher proportion of PD-1 expressing CD4+ T cells was observed in 
peripheral blood from GPA patients on conventional therapies compared 
to healthy controls. 
- Lower frequency of Treg cells in peripheral blood was observed from GPA 
patients on conventional therapies compared to healthy controls and GPA 
patients following B cell depletion therapy. 
- No difference in the the capacity of Treg cells to suppress T cell 
proliferation was found between GPA patients on conventional therapies 
and healthy controls. 
- The frequencies of circulating TFH and Treg cells in CD4+ T cells were 





4.3.1 B cell depletion therapy in GPA 
GPA is a condition where the pathogenicity of autoantibodies may drive the 
vasculitis and renal pathology directly.  Consistent with previous studies [381], 
cANCA titers from 4 out of 9 patients in our study did not change after B cell 
depletion therapy despite a good clinical response (Table 4.2.2), suggesting that 
B cell depletion alone is unlikely to be the sole basis for the success of rituximab 
in generating favorable clinical outcomes in GPA.  The frequencies of regulatory 
T cell subsets are also likely to impact on disease activity.   
 
  4.3.2 Circulating TFH cells in GPA 
The frequency of circulating TFH cells in peripheral blood from GPA patients on 
conventional therapies and GPA patients following B cell depletion therapies has 
been described for the first time in this thesis.  An increase in circulating TFH cell 
frequencies was observed in peripheral blood from GPA patients on conventional 
therapies.  This finding is consistent with previous studies on patients with 
severe SLE [158]. 
TFH cells are cells expressing high level of CXCR5, located in germinal centres that 
support affinity maturation and the production of high affinity Abs [153, 382, 
383].  The pathway of TFH cell differentiation is not clear yet.  Some studies 
173 
 
indicated that TFH cells are a distinct population developed from activated CD4+ 
T cells in B cell dependent or independent ways [148, 384].  Others indicated 
that TFH cells could develop from Th2 cells [149], while a recent study reported 
that TFH cells can develop into other helper T cells in mice [385].  Despite this 
disagreement, TFH cells have been demonstrated to be involved in autoimmune 
diseases in studies on both animal models and patients.  Studies of mouse 
models have shown that TFH cells are required for germinal centre formation and 
play an important role in generation of systemic autoimmunity from a germinal 
centre microenvironment [222].  Germinal centres have been reported in many 
animal models of autoimmune diseases [386].  TFH like cells have been observed 
in the spleen in mouse models of lupus [387, 388].  In patients with SLE, 
auto-reactive B cells have been observed within germinal centres [389].  
Although there is a large population of CXCR5+CD4+ T cells found in human 
peripheral blood, they may not be the same population as TFH cells in germinal 
centres [136, 390].  Further studies indicated that in addition to high 
expression of CXCR5, co-expression of high levels of ICOS or PD-1 could be used 
to identify circulating TFH cells in human peripheral blood [150].  One study of 
patients with SLE has observed an expansion of CXCR5highPD-1high circulating TFH 
cells in peripheral blood from a subset of patients with the most severe 
presentation of SLE [158].  Consistent with previous studies of SLE, a higher 
frequency of circulating TFH cells has been observed in blood of GPA patients on 
conventional therapies contains compared to controls.  Interestingly, there was 
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statistically no difference observed in the frequency of circulating TFH between 
the group of GPA patients who had responded to B cell depletion therapy and the 
healthy control group.  Since TFH are physiologically associated with B cell 
activation, survival and selection for specificity during the germinal centre 
response, an increase in circulating TFH in active disease could reduce the 
threshold for B cells to produce pathogenic Abs in GPA. 
 
4.3.3 PD-1+CD4+ T cells in GPA 
In this thesis, a significantly increased proportion of PD-1+ CD4+ T cells was 
observed in GPA patients (average: 1.26, range: 0.7 to 2.85) compared to healthy 
controls (average: 0.69, range: 0.47 to 0.99).  Since the experiments for this 
study were completed, a manuscript reporting an increased proportion of PD-1 
expressing CD4+ T cells (average 9.8, range: 6.7 to 17.7), in particular antigen 
experienced CD4+ T cells, in peripheral blood from GPA patients was published 
[391].  In contrast to the published paper, much lower frequencies of PD-1+ 
cells were identified in this thesis, although the trend was the same.  
Differences between the data might due to different staining and gating methods 
used for different patient cohorts.  A reduction in functional suppression 
mediated by PD-1 in GPA patients was also reported by this study, although the 
possible suppressive effect of Treg cells and other immune suppressors was not 
excluded in the experimental protocol [391].  Fewer activated and memory 
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Treg cells in GPA on conventional therapies compared to healthy controls has 
been described in this thesis.  The suppressive capacity per cell in Treg cells in 
GPA was shown to be the same as in healthy controls in this thesis.  Therefore 
the suppression of immune responses in the study of Wilde et al 2012 [391], 
which the authors suggested impaired PD-1 mediated immune suppression in 
GPA, could have been influenced by altered frequency of Treg cells that have 
been identified in this thesis in GPA patients.   
 
4.3.4 PD-1+ cells in lesions of GPA  
Cells expressing PD-1 in biopsies from GPA patients and controls have been 
studied in this thesis.  Consistent with previous studies, PD-1+ cells were 
observed in germinal centres of tonsil controls [392].  In contrast, PD-1+ cells 
were observed without lymphoid tissue structure in biopsies from GPA patients.  
Expression of PD-1 in human tissues has been described and is associated with 
autoimmune diseases.  PD-1 has been observed to be expressed by TFH cells in 
germinal centres, T cells in T cell zones and B cells follicles in human tonsil [392].  
PD-1 expressed by CD4+ T cells and B cells in livers from patients with 
autoimmune liver diseases was observed.  Higher relative quantity of mRNA 
encoding PD-1 was detected in livers with autoimmune liver disease compared 
to normal controls [296].  Increased PD-1 expression by CD4+ T cells and CD8+ 
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T cells in salivary gland from patients with Sjögren’s Syndrome was detected 
[393].  Since the experiments for this study were completed, a manuscript 
reporting a lack of PD-1 expression on T cells in renal biopsies from GPA patients 
has been published [391].  In contrast to their study, few PD-1+ cells were 
detected in biopsies from GPA patients in this thesis.  Difference in the data 
might be due to different organs that were biopsied and different patient cohorts.  
Germinal centre like structures have been described in biopsies from GPA 
patients, although B cells in most samples of mucosa involved in GPA patients are 
distributed diffusely (as described in chapter 3) [326, 394, 395].  However, 
PD-1+ cells detected in biopsies from GPA patients were relatively infrequent 
and not specifically associated with either the B cell infiltrate or organized 
lymphoid structure.  Due to the small size of biopsies and limited numbers of 
lymphocyte infiltrating, it is difficult to determine whether these PD-1+ cells 
generally contribute to local inflammation in GPA patients.  Moreover, as it is 
very difficult to obtain biopsies or lymph nodes from GPA patients when they are 
following B cell depletion therapy, it is difficult to see how B cell depletion could 
affect mucosal cells with the TFH cells in GPA. 
PD-1 has been shown to be expressed on lymphocytes in different organs in 
mouse models.  In contrast to young mice, PD-1 was found to be expressed by 
un-stimulated CD4+ T cells in spleen of aged mice.  Furthermore, more PD-1+ 
CD4+ T cells and higher expression level of PD-1 on CD4+ T cells in spleen was 
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observed from old mice compared with young mice [396].  This is confirmed by 
a study of a mouse model of lupus-like nephritis where PD-1 expressing CD4+ T 
cells were also observed infiltrating the kidney [397].  Another study reported 
that PD-1 is expressed by CD3+ T cells in spleen, thymocytes, and B cells in 
germinal centres from draining lymph nodes in mice.  Additionally PD-1 was 
reported to be up-regulated on infiltrating mononuclear cells from pancreas in 
NOD mice and brain in experimental autoimmune encephalomyelitis mice [302].  
Therefore it would be interesting to study PD-1 expression in more biopsies 
from different organs of GPA patients to see if such variation exists.  Expression 
of PD-1 and its ligands in GPA was considered to be interesting and possibly 
related to disease pathogenesis and will be studied in more detail in chapter 5. 
 
4.3.5 Treg cells in GPA  
The frequency of Treg cells in peripheral blood from GPA patients has been 
studied in this thesis.  A reduction in Treg cell frequency in peripheral blood 
from GPA patients on conventional therapy but not GPA patients following B cell 
depletion therapy was observed compared to healthy controls. 
Previous studies have shown that reduction in frequency of Treg cells or 
impaired suppressive capacity of Treg cells may result in failure to suppress 
immune responses, which may predispose to autoimmunity [398-400].  Some 
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studies have observed a decreased proportion of Treg cells in GPA [338], while 
others found an increase or no difference in percentages of Treg cells between 
GPA patients and healthy controls [336, 337].  The differences might due to 
different gating strategies and different patient cohorts and therapies [1, 2, 401].  
Consistent with the findings of Rimbert et al [338], a significantly reduced 
frequency of Treg cells was observed in GPA patients on conventional therapies 
compared to healthy controls.  Interestingly, this reduction was only found in 
the memory and activated Treg populations, which are generated in vivo as a 
consequence of antigen driven activation and are the Treg populations 
responsible for immune resolution [180, 402].   
One study has reported a decreased proportion of Treg cells in peripheral blood 
but an increase of Treg cell proportion in gut from patients with Crohn’s disease, 
suggesting that the reduction of Treg cells in peripheral blood may due to 
migration to inflamed tissue [403].  Although FoxP3+CD3+ Treg cells were 
observed in 6 out of 7 biopsies from GPA patients in this chapter, the total 
number of CD3+ T infiltrating in biopsies was variable and the percentage of 
FoxP3+ Treg cells in CD3+ T cells was quite different between biopsies.  In 
contrast to biopsies from gut, most biopsies studied in this thesis were from 
upper airways, eyes and bronchi of GPA patients.  Due to the small size of 
biopsies and the small number of infiltrating CD3+ T cells, it is hard to conclude 
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whether the reduction of circulating Treg cells in GPA patients could be due to 
migration to inflamed tissue, though it would seem unlikely.  
Previous studies have reported a normal or increased percentage of Treg cells in 
peripheral blood from GPA patients but with an impaired suppressive efficiency 
compared to healthy controls [336, 337].  In this chapter, the capacity of Treg 
cells to suppress T cell proliferation in 3 GPA patients, two of whom were cANCA 
and PR3 positive, while one was ANCA negative, were studied.  In contrast to 
previous studies, the suppressive efficiency of Treg cells in 3 cases of GPA in this 
study was equivalent to that of healthy controls regardless of the ANCA status of 
the GPA patients.  This may be due to differences in sorting strategy when 
isolating Treg cells and effector T cells.  Sorting strategy used in this thesis had 
higher stringency compared to other studies [336, 337].   
 
4.3.6 Correlation between circulating TFH cells, Treg cells and B cells  
The relative frequencies of circulating TFH cells and Treg cells in peripheral blood 
from GPA patients following B cell depletion therapy and the inverse correlation 
between these two populations in human has been described for the first time in 
this thesis.   
Since the experiments for this study were completed, two studies from a US lab 
reporting expansion of circulating TFH cells in peripheral splenocytes from Treg 
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cell deficient mice have been published [404, 405].  The deficiency of Treg cells 
and expansion of circulating TFH cells in those mice was demonstrated to result 
in a loss of B cell anergy [404, 405].  Consistent with their findings, the 
frequencies of circulating TFH cells and Treg in peripheral blood in this thesis 
were found to be inversely related and potentially dependent on B cells.  
Therefore, Treg cell frequencies in peripheral blood may depend on B cells 
through a link with circulating TFH cells which have the same characteristics as 
TFH cells in germinal centres.  Germinal centre structures have been reported to 
be lost in patients following B cell depletion treatment [406].  This implies the 
expansion of circulating TFH cells and reduction of Treg cells in peripheral blood 
from GPA patients may contribute to the disease pathogenesis.   
Previous studies have indicated a relationship between B cell deficiency and T 
cell activation in an animal model of SLE.  T cell activation was shown to be 
inhibited in B cell deficient mice [407], indicating a potential effect of B cell 
depletion on T cell responses.  Further studies demonstrated that SLE patients 
following B cell depletion therapy have augmented Foxp3 mRNA and more Treg 
cells compared to patients who were not in remission [339, 408, 409].  
Restoration of Treg cell numbers by B cell depletion has been also observed in 
animal models of arthritis [410].  In this chapter, a decreased frequency of Treg 
cells in peripheral blood from GPA patients on conventional therapies was 
observed compared to healthy controls, while this difference was not detected in 
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GPA patients following B cell depletion therapy implying that B cell depletion 
restores Treg numbers.  However, whether the nature of Treg cell restoration to 
normal levels in peripheral blood observed following B cell depletion is a cause 
or consequence of disease resolution is unclear. 
The ratio between circulating TFH cell and Treg cell numbers could be used as a 
means of heightening the sensitivity of a test to detect differences between GPA 
patients and controls or predict clinical outcomes.  Despite the sensitivity of the 
ratio, no difference between GPA patients following B cell depletion therapy and 
healthy controls was observed.  This supports the concept that functional T cell 
equilibrium could be restored by B cell depletion therapy, and therefore implies 
that these T cell subsets could be possibly B cell dependent, though at the 
moment cause and effect are impossible to separate.   
The identification of two regulatory T cell subsets that are inversely related in 
frequency and potentially B cell dependent implies that there may be a 
developmental relationship between them or development of these two cell 
types may be altered during T cell differentiation.  Tsuji et al has suggested that 
TFH cells and Treg cells are linked developmentally in the gut in a B cell 
dependent way in a mouse model [411].  However, other studies in animal 
models have reported that PD-1 ligand PD-L1 could negatively regulate the 
generation of TFH cells while positively regulate the development of Treg cell 
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- Higher frequency of circulating TFH cells and PD-1+ T cells observed in 
peripheral blood from GPA on conventional therapies may contribute to 
the pathogenesis of GPA 
- Although the capacity of Treg cells to suppress T cell proliferation in GPA 
patients was found to be the same as in healthy controls, the lower 
frequency of Treg cells found in peripheral blood from GPA patients on 
conventional therapies may lead to less suppression and contribute to 
autoimmune responses in GPA. 
- The frequencies of circulating TFH cells and Treg cells in peripheral blood 
from GPA patients could be altered by B cell depletion therapy which 
implies these two populations are B cell dependent. 
- It may be possible to consider the ratio between the inversely correlated 
frequencies of circulating TFH cells and Treg cells in peripheral blood as a 

















The immunoglobulin superfamily member PD-1 is expressed by circulating TFH 
cells and therefore antibody to PD-1 was used as a component of a panel of Abs 
to identify circulating TFH cells in peripheral blood in the previous chapter [158].  
However PD-1 and its B7 family ligands PD-L1 and PD-L2 [246, 291] are of 
interest in their own right in the context of the pathogenesis of autoimmune 
diseases [412], and have therefore been studied in more detail in this chapter.  
An association between abnormal PD-1 function and human autoimmune disease 
has been identified by genomic studies.  A susceptibility locus for SLE was 
identified on chromosome 2q37 by a genomic screen [255, 256].  Subsequently, 
the pdcd1 gene encoding PD-1 was located within the region 2q37.3 and was 
found to associate with susceptibility in SLE with a relative risk of up to 3.5 [257].  
Various studies illustrated that the polymorphisms in pdcd1 were associated 
with susceptibility to various autoimmune diseases, including rheumatoid 
arthritis, type 1 diabetes and ankylosing spondylitis, from different ethnic groups, 
as well as SLE [259, 260, 262-266].  Polymorphisms in the CD274 gene which 
encodes PD-L1 were found to be associated with Graves’ disease in Asian and 
Caucasian cohorts [285, 286], and with ankylosing spondylitis in Chinese 
patients [266, 287].  A polymorphism in pdcd1lg2 which encodes PD-L2 was 
found to be associated with SLE and ankylosing spondylitis in Chinese cohorts 
[287, 289].  Polymorphisms in the pdcd1, CD274 and pdcd1lg2 genes have not 
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been thoroughly studied in GPA.  One paper reported that polymorphisms in 
pdcd1 were not associated with GPA [340]. No disease association with 
polymorphisms in PD-L1 or PD-L2 have been reported in GPA. 
The importance of PD-1 in the pathogenesis of autoimmunity has been suggested 
by mouse models.  Deficiency of PD-1 in several mouse models resulted in the 
development of lupus-like autoimmune disease or accelerated the onset of type 1 
diabetes [413, 414].  Some studies indicated that expression of PD-1 alone does 
not trigger cell death, and emphasized the importance of interactions between 
PD-1 and its ligands PD-L1 or PD-L2 [239].  Blockade of the PD-1/PD-L1 
pathway promoted T effector cell proliferation and accelerated type 1 diabetes in 
NOD mice [415, 416].  PD-1/PD-L1 interaction was shown to down-regulate 
immune responses by both inhibiting naïve T cell differentiation into T effector 
cells and also affecting cytokine production [236].  Further study of mouse 
models illustrated that PD-1/PD-L1 interaction down-regulated the expansion of 
TFH cells but up-regulated the development of Treg cells [166, 282].  Moreover, 
PD-L1 is also thought to associate with Treg function as one animal study 
indicated that PD-L1 deficient Treg cells were defective in inhibiting Th1 
responses in mice [283].  Recently, Treg cells were shown to suppress 
autoreactive B cells through a PD-1/PD-L dependent pathway [284].  
As described above, PD-1 and its ligands PD-L1 and PD-L2 are implicated in 
autoimmune pathogenesis and have immune-regulatory functions.  Expression 
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of PD-1 and its two ligands PD-L1 and PD-L2 were investigated in GPA in this 
chapter. 
VISTA is a novel member of the Ig superfamily, which is structurally similar to 
PD-L1 though it does not bind PD-1.  VISTA has been shown to be involved in 
suppressing T cell-mediated immune responses in an autoimmune disease model 
[311].  VISTA was therefore also investigated to see whether there is any 
difference in the level of VISTA mRNA transcripts in different cell types between 
patient groups and healthy controls. 
Aims of this chapter:  
PD-1, its ligands PD-L1 and PD-L2, and VISTA are immune-regulatory molecules 
associated with development of autoimmunity.  The aim of this chapter was to 
identify any differences in the expression of PD-1, PD-L1, PD-L2, and VISTA in 






Some of the data studied in this chapter are not normally distributed, therefore 
nonparametric statistics including the Mann-Whitney U- test were used to 
analyse data in this chapter. Clinical information of patients studied in this 
chapter is shown in table 5.2.1-5.2.3. 
Table 5.2.1 Clinical information of GPA patients on conventional therapies 
 




Table 5.2.3 Clinical information of SLE patients 
 
 
5.2.1 Quantification of PD-1, PD-L1 and PD-L2 expression by PBMC in 
GPA patients, healthy and disease controls 
The relative quantity of mRNA encoding PD-1 and its ligands PD-L1 and PD-L2 
was initially quantified in PBMC by RT-PCR. cDNA was prepared from RNA 
isolated from PBMC of 15 GPA patients on conventional therapies, 13 age and 
gender matched healthy controls, 8 GPA patients under B cell depletion therapy 
and 15 SLE patients.  The method was optimized before application to cDNA 
from all samples.  Primers for all targets were checked with a sorted CD4+ T cell 
sample at two dilutions to ensure that approximately the same relative quantity 
value was obtained after correction for dilutions (Table 5.2.4). All RT-PCR data in 
this chapter is expressed as delta CT, where expression of a target gene is 
standardised according to expression of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), so that expression of GAPDH would be 1. 
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Table 5.2.4: Optimisation of RT-PCR: 
 
 
Patient samples were then studied. Significantly lower relative quantities of 
PD-L1 mRNA were observed in GPA patients both on conventional therapies and 
following B cell depletion therapy compared to healthy controls (Figure 5.2.1 B).  
No significant difference in mRNA encoding either PD-1 or PD-L2 was observed 
across four groups when whole PBMC were analysed (Figure 5.2.1 A, C).  The 
relative quantities of mRNA encoding PD-1, PD-L1 or PD-L2 were compared to 
each other.  Approximately 10 times more PD-1 transcripts were detected 




Figure 5.2.1: Relative quantities of mRNA encoding PD-1 and PD-Ls in total PBMC 
from healthy controls, GPA patients, B cell depleted GPA patients and SLE patients.  
A. Relative quantity of mRNA of PD-1 to GAPDH in total PBMC from healthy controls 
(median=0.002, range: 0.0004 to 0.013), GPA patients on conventional therapies 
(average=0.002, range: 0.0005 to 0.0045), GPA patients under B cell depletion therapy 
(median=0.0016, range: 0.0003 to 0.019) and SLE patients (median=0.0011, range: 
0.0003 to 0.018).  B. Relative quantity of mRNA encoding PD-L1 to GAPDH in total 
PBMC from healthy controls (average=0.00037, range: 7x10-6 to 0.0011), GPA patients 
on conventional therapies (average=0.00017, range: 2.5x10-5 to 0.00058) (P=0.043), 
GPA patients under B cell depletion therapy (median=0.00002, range: 8x10-6 to 0.00039) 
(P=0.015) and SLE patients (median=0.00009, range: 5.1x10-6 to 0.0011).  C. Relative 
quantity of mRNA encoding PD-L2 to GAPDH in total PBMC from healthy controls 
(average=0.00014, range: 1.7x10-5 to 0.00034), GPA patients on conventional therapies 
(median=0.00006, range: 9.8x10-6 to 0.00026), GPA patients under B cell depletion 
therapy (median=0.00003, range: 2x10-5 to 0.00024) and SLE patients (median=0.00011, 
range: 9.1x10-6 to 0.0012).  D. Comparison of relative quantities of mRNA of PD-1, 
PD-L1 or PD-L2 in total PBMC. Relative quantity of mRNA of PD-1 was significantly 
higher than that of PD-L1 in total PBMC (P<0.0001). No difference on relative quantities 
of mRNA of PD-L1 and PD-L2 (P=0.21). 
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5.2.2 Analysis of expression of PD-1, PD-L1 and PD-L2 by lymphocyte 
subsets and monocytes in GPA patients, healthy and disease controls 
5.2.2.1 Experimental strategies for studying the expression of PD-1, 
PD-L1 and PD-L2 in different cell types 
Since mRNA encoding PD-L1 was significantly lower in PBMC from patients with 
GPA, as described above, this was investigated further.  PD-1 and its ligands 
PD-L1 and PD-L2 can be expressed on many different cell types [234] and so the 
expression of PD-1 and its two ligands PD-L1 and PD-L2 on lymphocyte subsets 
was analysed, including CD4+ T cells, CD8+ T cells and CD19+ B cells, and also 
CD14+ monocytes.  Pilot experiments were carried out with blood samples 
from GPA patients on conventional therapies, healthy controls, GPA patients 
following B cell depletion therapy and SLE patients and were studied by flow 
cytometry to see if this method could be used.  The gating strategies tested for 
flow cytometry are illustrated in figure 5.2.2 (lymphocytes) and figure 5.2.3 
(monocytes).  As shown in figure 5.2.2 B, PD-L1 and PD-L2 expression was very 
low on CD4+T cells, CD8+ T cells and B cells, and this data was therefore 
considered unreliable.  Therefore only PD-1 expression on lymphocyte subsets 
and monocytes was analysed in detail by flow cytometry and will be illustrated 




Figure 5.2.2: Expression of PD-1 and PD-Ls on different lymphocyte subsets from 
healthy controls, GPA patients on conventional therapies and B cell deplete GPA 
patients.  A and B. Lymphocytes identified by their forward and side scatter 
properties were gated for CD19+ expression, CD3+CD4+ expression, or CD3+CD4- 
expression and then examined for the expression of PD-1, PD-L1 and PD-L2.  B. The 
expression of PD-1 and PD-Ls on different lymphocyte subsets was measured according 




Figure 5.2.3: Expression of PD-1 on monocytes from healthy controls, GPA patients 
on conventional therapies, B cell depleted GPA patients and SLE patients.  A. 
Monocytes identified by their forward and side scatter properties were gated for CD14+ 
expression to further study the expression of PD-1 on CD14+ monocytes.  B to E. The 
expression of PD-1 on monocytes from healthy controls, GPA patients on conventional 
therapies, B cell depleted GPA patients and SLE patients was measured according to 
FMO controls.  
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RT-PCR was considered reliable for studying the expression of PD-1, PD-L1 and 
PD-L2 according to preliminary data (Table 5.2.4).  The relative quantity of 
mRNA encoding PD-1 and its two ligands PD-L1 and PD-L2 in lymphocyte 
subsets, including CD3+CD4+ T cells, CD3+CD8+ T cells, CD19+ B cells, and 
CD14+ monocytes, was quantified by RT-PCR.  cDNA was prepared from RNA 
isolated from sorted lymphocyte subsets and monocytes of GPA patients on 
conventional therapies, healthy controls, B cell depleted GPA patients and SLE 
patients.  Cell isolation strategy used is shown in figure 5.2.4.  Data obtained is 
described in the sections below.  Significant findings will then be summarised in 
section 5.2.4. 
 
Figure 5.2.4: Sort of different lymphocyte subsets and monocytes from healthy 
controls, GPA patients, B cell depleted GPA patients and SLE patients.  Monocytes 
identified by their forward and side scatter properties were sorted for CD14+ 
expression.  Lymphocytes identified by their forward and side scatter properties were 
gated for CD14- expression and then sorted for expression of CD4+, CD8+ or 
CD4-CD8-CD19+ to isolate CD4+ T cells, CD8+ T cells and CD19+ B cells. 
Efforts were made to ensure that the experiments in this chapter were not biased 
by either sample collection, or runs of the RT-PCR analysis.  Blood samples 
were collected in mixed batches and cells were sorted over a period of three 
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months.  RNA was isolated on freshly sorted cells and prepared into cDNA in 
mixed batches.  Samples to be compared were then located on the same RT-PCR 
plate side by side where possible. 
5.2.2.2 Expression of PD-1, PD-L1 and PD-L2 by CD4+ T cells in GPA 
patients, healthy and disease controls 
PD-1 expression by CD4+ T cells from 6 patients with GPA on conventional 
therapies, 6 healthy controls and 4 GPA patients following B cell depletion 
therapy was studied by flow cytometry.  The average percentage of PD-1+ cells 
in CD4+ T cells was 0.98 % in healthy controls.  No significant difference in 
PD-1 expression by CD4+ T cells from healthy controls, GPA patients on 
conventional therapies or GPA patients following B cell depletion therapy was 
observed (Figure 5.2.5).  
              
Figure 5.2.5: Expression of PD-1 on CD4+ T cells from healthy controls, GPA 
patients and B cell depleted GPA patients.  Percentage of PD-1+ cells in CD4+ T cells 
from healthy controls (average=0.98, range: 0.16 to 1.88), GPA patients on conventional 
therapies (average=1.11, range: 0.64 to 1.66) and GPA patients following B cell depletion 
therapy (average=1.68, range: 1.27 to 2.32). 
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The relative quantity of mRNA encoding PD-1 and its ligands PD-L1 and PD-L2 in 
CD4+ T cells was quantified by RT-PCR.  cDNA was prepared from RNA isolated 
from 16 GPA patients on conventional therapies, 12 healthy controls, 7 GPA 
patients following B cell depletion therapy and 12 SLE patients.  As shown in 
figure 5.2.6 A, the relative quantities of PD-1 mRNA to GAPDH were widely 
spread in all patient groups.  Although the average relative quantity of PD-1 
mRNA in GPA patients following B cell depletion therapy was higher than in 
healthy controls and GPA patients on conventional therapies, there was no 
significant difference detected between these study groups.  
The relative quantity of mRNA encoding PD-L1 in CD4+ T cells from GPA patients 
on conventional therapies was significantly lower than the relative quantity 
observed in cells from age and gender matched healthy controls (Figure 5.2.6 B, 
P=0.0024).  A lower relative quantity of mRNA encoding PD-L1 in CD4+ T cells 
from GPA patients who had responded clinically to B cell depletion therapy 
compared to healthy controls was observed, but this difference was less marked 
than in the difference between conventionally treated GPA patients and healthy 
controls (Figure 5.2.6 B, P=0.046).  Further comparison of the two groups of 
GPA patients demonstrated a significantly lower relative quantity of mRNA 
encoding PD-L1 in CD4+ T cells in the group on conventional therapies compared 
to those who were following B cell depletion therapy (Figure 5.2.6 B, P=0.016).  
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A significantly lower relative quantity of PD-L1 mRNA in CD4+ T cells was also 
detected in SLE patients when compared with healthy controls (P=0.035).   
The relative quantity of mRNA encoding PD-L2 in CD4+ T cells from GPA patients 
on conventional therapies was significantly lower when compared to age and 
gender matched healthy controls (Figure 5.2.6 C, P=0.023).  However, no such 
difference was observed in GPA patients who had responded clinically to B cell 
depletion therapy.  Further comparison of the two groups of GPA patients 
demonstrated a significantly lower relative quantity of mRNA encoding PD-L2 in 
CD4+ T cells in the group on conventional therapies compared to those who 
were following B cell depletion therapy (Figure 5.2.6 C, P=0.025).  No difference 
in the relative quantity of PD-L2 mRNA in CD4+ T cells was detected in SLE 
patients compared with healthy controls.  
The relative quantity levels of mRNA encoding PD-1, PD-L1 and PD-L2 was 
further compared.  As in total PBMC, the level of mRNA encoding PD-1 in CD4+ 
T cells was approximately 10 times more than PD-L1 (P<0.0001), which was 




     
Figure 5.2.6: Relative quantities of mRNA encoding PD-1 and PD-Ls in CD4+ T cells 
from healthy controls, GPA patients, B cell depleted GPA patients and SLE patients.   
A. Relative quantity of mRNA of PD-1 to GAPDH in CD4+ T cells from healthy controls 
(median=0.0025, range: 0.0014 to 0.009), GPA patients on conventional therapies 
(median=0.0036, range: 0.0006 to 0.015), GPA patients under B cell depletion therapy 
(median=0.011, range: 0.0014 to 0.025) and SLE patients (median=0.0025, range: 
0.0009 to 0.014).  B. Relative quantity of mRNA of PD-L1 to GAPDH in CD4+ T cells 
from healthy controls (average=0.00045, range: 7.2x10-5 to 0.00086), GPA patients on 
conventional therapies (average=0.00017, range: 0.00014 to 0.00022) (P=0.0024), GPA 
patients under B cell depletion therapy (median=0.00025, range: 0.00015 to 0.00057) 
(P=0.046 and P=0.016 when compared to healthy controls and GPA patients on 
conventional therapies respectively) and SLE patients (median=0.00011, range: 5x10-5 
to 0.00063) (P=0.035).  C. Relative quantity of mRNA of PD-L2 to GAPDH in CD4+ T 
cells from healthy controls (average=0.00009, range: 0 to 0.00013), GPA patients on 
conventional therapies (median=0.00004, range: 0 to 0.00045) (P=0.023), GPA patients 
under B cell depletion therapy (median=0.00011, range: 2.5x10-5 to 0.00046) (P=0.025 
when compared with GPA patients on conventional therapies) and SLE patients 
(average=0.00012, range: 0 to 0.00031).  D. Comparison of relative quantities of mRNA 
of PD-1, PD-L1 or PD-L2 in CD4+ T cells. Relative quantity of mRNA of PD-1 was 
significantly higher than that of PD-L1 in CD4+ T cells (P<0.0001). Relative quantities of 
mRNA of PD-L1 was significantly higher than that of PD-L2 in CD4+ T cells (P<0.0001). 
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5.2.2.3 Expression of PD-1, PD-L1 and PD-L2 by CD8+ T cells in GPA 
patients, healthy and disease controls 
The average percentage of cells expressing PD-1 in CD8+ T cell population was 
1.52% in healthy controls.  An increase in PD-1 expression on CD8+ T cells from 
GPA patients on conventional therapies was observed when compared to healthy 
controls.  No such difference was observed in patients who clinically responded 
to B cell depletion therapy (Figure 5.2.7).  
              
Figure 5.2.7: Expression of PD-1 on CD8+ T cells from healthy controls, GPA 
patients and B cell depleted GPA patients.  Percentage of PD-1+ cells in CD8+ T cells 
from healthy controls (average=1.52, range: 0.86 to 3.23), GPA patients on conventional 
therapies (average=2.37, range: 1.43 to 3.81) and GPA patients under B cell depletion 
therapy (average=5.32, range: 0.22 to 20.01). 
 
The relative quantity of mRNA encoding PD-1 in CD8+ T cells of 16 GPA patients 
on conventional therapies, 13 healthy controls, 7 GPA patients following B cell 
depletion therapy and 11 SLE patients was quantified by RT-PCR.  No 
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significant difference was detected in either group of GPA patients or SLE 
patients compared with healthy controls (Figure 5.2.8 A).  
The relative quantity of mRNA encoding PD-L1 in CD8+ T cells was found to be 
lower in GPA patients and SLE patients compared to healthy controls.  A 
tendency for the relative quantity of PD-L1 mRNA in GPA patients on 
conventional therapies to be lower than those who were following B cell 
depletion therapy was observed.  However, the differences here were not 
significant (Figure 5.2.8 B). 
The relative quantity of mRNA encoding PD-L2 in CD8+ T cells from GPA patients 
on conventional therapies was significantly lower compared to age and gender 
matched healthy controls (Figure 5.2.8 C, P=0.029).  However, there was no 
difference in the relative quantity of mRNA encoding PD-L2 in CD8+ T cells from 
GPA patients following B cell depletion therapy compared to age and gender 
matched healthy controls.  The relative quantity of mRNA encoding PD-L2 on 
CD8+ T cells was the same in the two groups of GPA patients.  No difference in 
the relative quantity of PD-L2 mRNA in CD8+ T cells was detected in SLE patients 




Figure 5.2.8: Relative quantities of mRNA encoding PD-1 and PD-Ls in CD8+ T cells 
from healthy controls, GPA patients, B cell depleted GPA patients and SLE patients.   
A. Relative quantity of mRNA of PD-1 to GAPDH in CD8+ T cells from healthy controls 
(average=0.0051, range: 0.0007 to 0.014), GPA patients on conventional therapies 
(median=0.0058, range: 0.0007 to 0.065), GPA patients under B cell depletion therapy 
(median=0.0077, range: 0.0029 to 0.017) and SLE patients (median=0.0036, range: 
0.001 to 0.046).  B. Relative quantity of mRNA of PD-L1 to GAPDH in CD8+ T cells from 
healthy controls (average=0.00024, range: 0.00006 to 0.00042), GPA patients on 
conventional therapies (average=0.00016, range: 0.00007 to 0.00029), GPA patients 
under B cell depletion therapy (average=0.00020, range: 0.00008 to 0.0003) and SLE 
patients (average=0.00014, range: 0.00006 to 0.00026).  C. Relative quantity of mRNA 
of PD-L2 to GAPDH in CD8+ T cells from healthy controls (average=0.00007, range: 
0.00002 to 0.00017), GPA patients on conventional therapies (median=0.00003, range: 
0 to 0.00009) (P=0.0288), GPA patients under B cell depletion therapy 
(median=0.00004, range: 0 to 0.00008) and SLE patients (median=0.00005, range: 
0.00003 to 0.00012).  D. Comparison of relative quantities of mRNA of PD-1, PD-L1 or 
PD-L2 in CD8+ T cells. Relative quantity of mRNA of PD-1 was significantly higher than 
that of PD-L1 in CD8+ T cells (P<0.0001). Relative quantities of mRNA of PD-L1 was 
significantly higher than that of PD-L2 in CD8+ T cells (P<0.0001). 
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The level of mRNA encoding PD-1 in CD8+ T cells was significantly higher than 
that encoding PD-L1 (P<0.0001), which was significantly higher than that 
encoding PD-L2 (Figure 5.2.8 D, P<0.0001).   
5.2.2.4 Expression of PD-1, PD-L1 and PD-L2 by CD19+ B cells in GPA 
patients, healthy and disease controls 
The percentage of PD-1+ cells in CD19+ B cells was similar to that in CD4+ T cells 
and CD8+ T cells.  The average percentage was 1.19% in healthy controls 
(Figure 5.2.9 A).  No difference in the proportion of CD19+ B cells expressing 
PD1 was observed in GPA patients on conventional therapies compared to 
healthy controls.  There were no PD-1+CD19+ B cells detected in GPA patients 
who had clinically responded to B cell depletion therapy, but the B cell numbers 
in this group were very low (Figure 5.2.9 B).  
 
Figure 5.2.9: Expression of PD-1 on CD19+ B cells from healthy controls, GPA 
patients and B cell depleted GPA patients.  A. Comparison of PD-1 expression in 
CD4+ T cells (average=0.98, range: 0.16 to 1.88), CD8+ T cells (average=1.52, range: 0.86 
to 3.23), and CD19+ B cells (average=1.19, range=0.69 to 2.88) from healthy controls.  
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B. Percentage of PD-1+ cells in CD19+ B cells from healthy controls (average=1.19, 
range=0.69 to 2.88), GPA patients on conventional therapies (average=0.99, range: 0.22 
to 1.6). No PD-1+ CD19+ B cell was detected in GPA patients under B cell depletion 
therapy. 
As there were very few CD19+ B cell in GPA patients following B cell depletion 
therapy, only mRNA from GPA patients on conventional therapies, healthy 
controls and SLE patients was quantified by RT-PCR.  The relative quantity of 
mRNA encoding PD-1 in CD19+ B cells of GPA patients was quantified, and no 
significant difference was detected compared with healthy controls (Figure 
5.2.10 A).  The range of values for relative quantity of PD-1 mRNA in CD19+ B 
cells from SLE patients was wider than from healthy controls and GPA patients, 
but the difference was not significant.  
No significant difference was observed in the relative quantity of mRNA encoding 
PD-L1 in CD19+ B cells from GPA patients on conventional therapies compared 
to age and gender matched healthy controls (Figure 5.2.10 B).  No difference in 
the relative quantity of PD-L1 mRNA in CD19+ B cells was detected in SLE 
patients compared with healthy controls.  Similarly, no significant difference in 
the relative quantity of mRNA encoding PD-L2 in CD19+ B cells was detected 







Figure 5.2.10: Relative quantities of mRNA encoding PD-1 and PD-Ls in CD19+ B 
cells from healthy controls, GPA patients and SLE patients.  A. Relative quantity of 
mRNA of PD-1 to GAPDH in CD19+ B cells from healthy controls (average=0.0001, range: 
0.00005 to 0.00022), GPA patients on conventional therapies (average=0.00011, range: 
0.00002 to 0.0003) and SLE patients (average=0.0018, range: 0.00006 to 0.01).  B. 
Relative quantity of mRNA of PD-L1 to GAPDH in CD19+ B cells from healthy controls 
(average=0.00036, range: 0.00013 to 0.00074), GPA patients on conventional therapies 
(average=0.00057, range: 0.00007 to 0.003) and SLE patients (average=0.00034, range: 
0.00008 to 0.00095).  C. Relative quantity of mRNA of PD-L2 to GAPDH in CD19+ B 
cells from healthy controls (average=0.00002, range: 0 to 0.00007), GPA patients on 
conventional therapies (average=0.00004, range: 0 to 0.00018) and SLE patients 
(average=0.00009, range: 0 to 0.00031).  D. Comparison of relative quantities of mRNA 
of PD-1, PD-L1 or PD-L2 in CD19+ B cells. Relative quantity of mRNA of PD-L1 was 
significantly higher than that of PD-1 in CD19+ B cells from healthy controls and GPA 
patients (P<0.0001). Relative quantities of mRNA of PD-1 was significantly higher than 




The relative quantity of mRNA encoding PD-1, PD-L1 and PD-L2 in CD19+ B cells 
from all studied groups was further compared.  Different from that in total 
PBMC, CD4+ T cells and CD8+ T cells, the level of mRNA encoding PD-L1 was 
highest in CD19+ B cells from GPA patients and healthy controls (P<0.0001 when 
compared to either PD-1 or PD-L2), while the relative quantity of mRNA 
encoding PD-1 was higher than that encoding PD-L2 in all groups (Figure 5.2.10 
D, P=0.0003).  The range of data was very wide, especially for the SLE group. 
5.2.2.5 Expression of PD-1, PD-L1 and PD-L2 by CD14+ monocytes in 
GPA patients, healthy and disease controls 
The average of CD14+ monocytes expressing PD-1 was 10.92% (healthy 
controls), 10.98% (GPA patients under B cell depletion therapy) and 10.14% 
(SLE patients).  These percentages were significantly higher than the 3.76% 
observed in GPA patients on conventional therapies (Figure 5.2.11). 
                    
Figure 5.2.11: Expression of PD-1 on CD14+ monocytes from healthy controls, GPA 
patients, B cell depleted GPA patients and SLE patients.  Percentage of PD-1+ cells 
in CD14+ monocytes from healthy controls (average=10.92, range: 2.09 to 27.77), GPA 
patients on conventional therapies (average=3.76, range: 0.36 to 17.27) (P=0.019), GPA 
patients under B cell depletion therapy (average=10.98, range: 0.17 to 29.99) and SLE 
patients (average=10.14, range: 1.11 to 37.54). 
206 
 
The relative quantity of mRNA encoding PD-1 in CD14+ monocytes was 
quantified by RT-PCR.  No significant difference was detected in either of the 
two groups of GPA patients or SLE patients compared with healthy controls 
(Figure 5.2.12 A).  
The relative quantity of mRNA encoding PD-L1 in CD14+ monocytes was 
quantified by RT-PCR.  A lower relative quantity of mRNA encoding PD-L1 was 
observed in GPA patients on conventional therapies compared to healthy 
controls (Figure 5.2.12 B, P=0.052).  A significantly lower relative quantity of 
mRNA encoding PD-L1 in CD14+ monocytes was observed in GPA patients who 
had clinically responded to B cell depletion therapy, compared to healthy 
controls (P=0.023).  Further comparison of the two groups of GPA patients did 
not illustrate difference in the relative quantity of mRNA encoding PD-L1 in 
CD14+ monocytes (Figure 5.2.12 B, P=0.49).  No difference of relative quantity 
of PD-L1 mRNA in CD14+ monocytes from SLE patients was detected compared 




Figure 5.2.12: Relative quantities of mRNA encoding PD-1 and PD-Ls in CD14+ 
monocytes from healthy controls, GPA patients, B cell depleted GPA patients and 
SLE patients.  A. Relative quantity of mRNA of PD-1 to GAPDH in CD14+ monocytes 
from healthy controls (median=7x10-6, range: 0 to 0.000025), GPA patients on 
conventional therapies (median=4x10-6, range: 0 to 0.000019), GPA patients under B cell 
depletion therapy (median=7x10-6, range: 0 to 0.000024) and SLE patients 
(median=5x10-6, range: 0 to 0.000045).  B. Relative quantity of mRNA of PD-L1 to 
GAPDH in CD14+ monocytes from healthy controls (median=0.00049, range: 9.6x10-6 to 
0.0031), GPA patients on conventional therapies (average=0.00002, range: 3.7x10-6 to 
0.00004) (P=0.052), GPA patients under B cell depletion therapy (median=0.00001, 
range: 5.8x10-6 to 0.00003) (P=0.023 when compared to healthy controls) and SLE 
patients (average=0.00005, range: 5.6x10-6 to 0.00011).  C. Relative quantity of mRNA 
of PD-L2 to GAPDH in CD14+ monocytes from healthy controls (median=0.00003, range: 
3.4x10-6 to 0.00028), GPA patients on conventional therapies (median=0.00001, range: 
2.7x10-6 to 0.00011) (P=0.029), GPA patients under B cell depletion therapy 
(median=0.00001, range: 0 to 0.00007) and SLE patients (median=0.00002, range: 
0.00001 to 0.00013).  D. Comparison of relative quantities of mRNA of PD-1, PD-L1 or 
PD-L2 in CD14+ monocytes. Relative quantity of mRNA of PD-L1 was higher than that of 
PD-L2 in CD14+ monocytes (P=0.14). Relative quantity of mRNA of PD-L2 was 
significantly higher than that of PD-1 in CD14+ monocytes (P<0.0001).  
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A significantly lower relative quantity of mRNA encoding PD-L2 in CD14+ 
monocytes was observed in GPA patients on conventional therapies, compared 
to age and gender matched healthy controls (Figure 5.2.12 C, P=0.029).  
However, no significant difference in the relative quantity of mRNA encoding 
PD-L2 in CD14+ monocytes was observed in GPA patients following B cell 
depletion therapy, compared to age and gender matched healthy controls 
(P=0.54).  Further comparison of the two groups of GPA patients did not 
illustrate a significant difference in the relative quantity of mRNA encoding 
PD-L2 in CD14+ monocytes (P=0.31).  No difference in the relative quantity of 
PD-L2 mRNA in CD14+ monocytes was detected in SLE patients compared with 
healthy controls (Figure 5.2.12 C, P=0.84).  
The relative quantity levels of mRNA encoding PD-1, PD-L1 and PD-L2 in CD14+ 
monocytes from all studied groups were further compared.  Different from that 
in total PBMC and different lymphocyte subsets, the levels of mRNA encoding 
PD-L1 was higher than PD-L2 mRNA (P=0.14), and both mRNA encoding PD-L1 
and PD-L2 was significantly higher than that encoding PD-1 in all groups (Figure 




5.2.2.6 Comparison of mRNA relative quantities of PD-1, PD-L1 and 
PD-L2 by different cell types in GPA patients, healthy and disease 
controls  
The relative quantity of mRNA encoding PD-1, PD-L1 and PD-L2 was quantified 
in CD4+ T cells, CD8+ T cells, CD19+ B cells and CD14+ monocytes.  In the 
sections above differences within a cell type were analysed.  In this section, 
relative mRNA levels between cell types were compared.  The relative quantity 
of PD-1 mRNA was highest in CD8+ T cells, followed by CD4+ T cells then CD19+ 
B cells in all patient and healthy groups.  The relative quantity of PD-1 mRNA in 
CD14+ monocytes was more than 10 times lower than in other cell types 
(P<0.0001) in all groups studied (Figure 5.2.13 A).  
The relative quantity of PD-L1 mRNA in different cell types in healthy controls 
was compared.  No significant difference was observed in CD4+ T cells and 
CD19+ B cells from healthy control group (Figure 5.2.13 B).  Compared to CD4+ 
T cells, a significantly lower relative quantity of PD-L1 mRNA in CD8+ T cells was 
observed in healthy controls (P=0.0083), while the average relative quantity of 
PD-L1 mRNA in monocytes was significantly higher than in CD8+ T cells from 





Figure 5.2.13: Comparison of relative quantities of mRNA encoding PD-1 and 
PD-L1 in different immune cell types.  A. Relative quantity of mRNA of PD-1 in CD4+ 
T cells (average=0.0048, range: 0.00058 to 0.025), CD8+ T cells (average=0.0089, range: 
0.00069 to 0.065), CD19+ B cells (average=0.0007, range: 0 to 0.01) (P<0.0001 when 
compared with that in CD8+ T cells) and monocytes (average=8x10-6, range: 0 to 
0.00004) (P<0.0001 when compared with that in B cells) from all groups.  B. Relative 
quantity of mRNA of PD-L1 in total PBMC (average=0.00037, range: 7x10-6 to 0.0011), 
CD4+ T cells (average=0.00045, range: 7.2x10-5 to 0.00086), CD8+ T cells 
(average=0.00024, range: 0.00006 to 0.00042), CD19+ B cells (average=0.00036, range: 
0.00013 to 0.00074) and monocytes (average=0.00037, range: 9.6x10-6 to 0.0031) from 
healthy controls.  
 
The relative quantity of PD-L2 mRNA in different cell types was compared 
according to different patient groups.  A decreased tendency of relative quantity 
of mRNA encoding PD-L2 was observed in the subsequence of CD4+ T cells, CD8+ 
T cells, CD14+ monocytes and then CD19+ B cells from healthy controls (Figure 
5.2.14 A).  However, in GPA patients on conventional therapies and SLE patients, 
this tendency was CD4+ T cells, followed by CD19+ B cells then CD8+ T cells and 
then monocytes (Figure 5.2.14 B and D).  In GPA patients following B cell 
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depletion therapy, the relative quantity of PD-L2 mRNA was highest in CD4+ T 
cells, followed by CD8+ T cells and then CD14+ monocytes (Figure 5.2.14 C). 
      
Figure 5.2.14: Comparison of relative quantities of mRNA encoding PD-L2 in 
different immune cell types.  A. In healthy controls, the relative quantity of mRNA of 
PD-L2 in total PBMC (average=0.00014, range: 1.7x10-5 to 0.00034), CD4+ T cells 
(average=0.00009, range: 0 to 0.00013), CD8+ T cells (average=0.00007, range: 0.00002 
to 0.00017), CD19+ B cells (average=0.00002, range: 0 to 0.00007) and monocytes 
(average=0.00005, range: 3.4x10-6 to 0.00028).  B. In GPA patients on conventional 
therapies, the relative quantity of mRNA of PD-L2 in total PBMC (average=0.00008, 
range: 9.8x10-6 to 0.00026), CD4+ T cells (average=0.00008, range: 0 to 0.00045), CD8+ 
T cells (average=0.00003, range: 0 to 0.00009), CD19+ B cells (average=0.00004, range: 
0 to 0.00018) and monocytes (average=0.00002, range: 2.7x10-6 to 0.00011).  C. In GPA 
patients under B cell depletion therapy, the relative quantity of mRNA of PD-L2 in total 
PBMC (average=0.00008, range: 2x10-5 to 0.00024), CD4+ T cells (average=0.00019, 
range: 2.5x10-5 to 0.00046), CD8+ T cells (average=0.00004, range: 0 to 0.00008) and 
monocytes (average=0.00005, range: 0 to 0.00007).  D. In SLE patients, the relative 
quantity of mRNA of PD-L2 in total PBMC (average=0.00019, range: 9.1x10-6 to 0.0012), 
CD4+ T cells (average=0.00012, range: 0 to 0.00031), CD8+ T cells (average=0.00006, 
range: 0.00003 to 0.00012), CD19+ B cells (average=0.00009, range: 0 to 0.00031) and 
monocytes (average=0.00004, range: 0.00001 to 0.00013). 
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5.2.3 Expression of VISTA by PBMC, different lymphocyte subsets and 
monocytes in GPA patients, healthy and disease controls  
The relative quantity of mRNA encoding VISTA in PBMC, CD4+ T cells, CD8+ T 
cells, CD19+ B cells and CD14+ monocytes was quantified by RT-PCR.  cDNA 
was prepared from RNA isolated from 10 GPA patients on conventional therapies, 
10 healthy controls, 7 GPA patients following B cell depletion therapy and 9 SLE 
patients.  Consistent with results from the test experiment shown in table 5.2.1, 
the relative quantity of mRNA encoding VISTA was much higher than that 
encoding PD-1, PD-L1 and PD-L2 in all cell types studied (Figure5.2.15).  
There was no significant difference in the relative quantity of VISTA mRNA in 
whole PBMC, CD4+ T cells, CD8+ T cells, CD19+ B cells and monocytes from GPA 
patients on conventional therapies, GPA patients following B cell depletion 










Figure 5.2.15: Relative quantities of mRNA encoding VISTA in different 
lymphocyte subsets and monocytes from healthy controls, GPA patients, B cell 
depleted GPA patients and SLE patients.  A. Relative quantity of mRNA of VISTA in 
total PBMC from healthy controls (average=0.12, range: 0.049 to 0.21), GPA patients on 
conventional therapies (average=0.09, range: 0.054 to 0.12), GPA patients under B cell 
depletion therapy (average=0.22, range: 0.025 to 0.62) and SLE patients (average=0.075, 
range: 0.024 to 0.13).  B. Relative quantity of mRNA of VISTA in CD4+ T cells from 
healthy controls (average=0.066, range: 0.013 to 0.12), GPA patients on conventional 
therapies (average=0.062, range: 0.041 to 0.099), GPA patients under B cell depletion 
therapy (average=0.068, range: 0.029 to 0.1) and SLE patients (average=0.045, range: 
0.0084 to 0.11).  C. Relative quantity of mRNA of VISTA in CD8+ T cells from healthy 
controls (average=0.068, range: 0.013 to 0.11), GPA patients on conventional therapies 
(average=0.068, range: 0.037 to 0.11), GPA patients under B cell depletion therapy 
(average=0.05, range: 0.023 to 0.077) and SLE patients (average=0.057, range: 0.011 to 
0.09).  D. Relative quantity of mRNA of VISTA in CD19+ B cells from healthy controls 
(average=0.0079, range: 0.0049 to 0.013), GPA patients on conventional therapies 
(average=0.0085, range: 0.0028 to 0.017), and SLE patients (median=0.0094, range: 
0.0036 to 0.13).  E. Relative quantity of mRNA of VISTA in CD14+ monocytes from 
healthy controls (median=0.31, range: 0.12 to 0.41), GPA patients on conventional 
therapies (average=0.28, range: 0.18 to 0.38), GPA patients under B cell depletion 
therapy (median=0.33, range: 0.16 to 0.63) and SLE patients (average=0.32, range: 0.2 
to 0.51).  
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The relative quantity of mRNA encoding VISTA in different cell types was further 
compared.  The relative amount of mRNA transcripts encoding VISTA was 
highest in monocytes, which was approximately 5 times more than in CD4+ T 
cells and CD8+ T cells (Figure 5.2.16, P<0.0001 respectively), while the relative 
quantity of VISTA mRNA was lowest in B cells which was 1/10 of that in CD4+ T 
cells (Figure 5.2.16, P<0.0001). 
             
Figure 5.2.16: Comparison of relative quantities of mRNA encoding VISTA in 
different lymphocyte subsets and monocytes.  Relative quantity of mRNA of VISTA 
in CD4+ T cells (average=0.06, range: 0.0084 to 0.12), CD8+ T cells (average=0.062, 
range: 0.011 to 0.11), CD19+ B cells (average=0.013, range: 0.0028 to 0.13) (P<0.0001 
when compared with that in CD4+ T cells) and monocytes (average=0.32, range: 0.12 to 
0.63) (P<0.0001 when compared with any of that in CD4+ T cells, CD8+ T cells and 





5.2.4 Main findings in this chapter: 
- Higher proportion of CD8+ T cells expressing PD-1 and lower percentage 
of CD14+ monocytes expressing PD-1 was observed in GPA patients on 
conventional therapies compared to healthy controls. 
- Lower relative quantity of mRNA encoding PD-L1 in whole PBMC, CD4+ T 
cells and CD14+ monocytes was observed in GPA patients on 
conventional therapies and GPA patients following B cell depletion 
therapy compared to healthy controls. 
- Lower relative quantity of mRNA encoding PD-L2 in CD4+ T cells, CD8+ T 
cells and CD14+ monocytes was observed in GPA patients on 
conventional therapies compared to healthy controls.  
- No significant difference in and relative quantity of mRNA encoding PD-1 





5.3.1 PD-1 in GPA 
The relative quantities of PD-1 mRNA in circulating cells from GPA patients has 
been described for the first time in this thesis.  A higher percentage of CD8+ T 
cells expressing PD-1 and a lower percentage of CD14+ monocytes expressing 
PD-1 were observed in GPA patients on conventional therapies compared to 
healthy controls.  No difference was observed in proportion of PD-1+cells in 
CD4+ T cells and CD19+ B cells between GPA patients and healthy controls.  No 
significant difference in the relative quantity of mRNA encoding PD-1 was found 
in all cell types studied between GPA patients and healthy controls.  
A significantly increased proportion of PD-1+ CD4+ T cells was observed in 
peripheral blood from GPA patients (average: 1.23, range: 0.7 to 2.85) compared 
to healthy controls (average: 0.69, range: 0.47 to 0.99) in chapter 4.  However, 
this difference was not seen the experiments carried out for the chapter, 
although the percentage of PD-1+CD4+ T cells (GPA: average: 1.11, range: 0.64 to 
1.66; healthy: average: 0.98, range: 0.16 to 1.88) was similar to that in chapter 4.  
Differences between the data might due to different staining Abs used or 
different patient cohorts.  PD-1 expressing CD4+ T cells in GPA patients have 
been discussed in chapter 4. 
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Changes in PD-1 expression by different subsets of lymphocytes in human 
diseases have been observed before.  Although low PD-1 expression was 
observed on un-stimulated CD8+ T cells in this study, PD-1 expression was 
reported to be up-regulated on CD8+ T cells from human blood after activation in 
vitro [417].  Other studies have reported PD-1 expression on peripheral 
lymphocytes from patients with autoimmune diseases.  Fewer PD-1 expressing 
CD4+ T cells and CD8+ T cells in peripheral blood, and lower expression level of 
PD-1 on antigen experienced T cells was observed in patients with SLE [418].  
Higher percentage of PD-1+ CD4+ T cells was observed in blood from patients 
with ankylosing spondylitis, and the proportion of PD-1 expressing T cells was 
inversely correlated with severity of disease outcomes [419].  One study has 
reported that PD-1 expression by peripheral blood T cells was undetectable, 
while PD-1+CD4+ T cells were enriched in synovial fluid from patients with 
rheumatoid arthritis [420].  PD-1 expression on CD4+ and CD8+ T cells was 
observed to be up-regulated in patients with stable but not active multiple 
sclerosis after stimulation [421].  Therefore the increased proportion of PD-1 
expressing CD8+ T cells and decreased proportion of PD-1 expressing monocytes 
in peripheral blood from GPA patients may contribute to failure of immune 
tolerance.    
Animal models have identified an association between PD-1 expression and 
autoimmune diseases.  Studies have shown that mice with PD-1 deficiency can 
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develop various autoimmune diseases.  PD-1 deficiency in different mouse 
models was reported to develop lupus-like autoimmune diseases [413], and 
more severe autoimmune disease [306, 307], diabetes [414, 422] and 
Ag-induced arthritis [423].  A previous study indicated that the level of PD-1 
transcripts is not consistent with the level of PD-1 protein expression in mice 
[239].  Although no difference in PD-1 mRNA in monocytes was observed in 
GPA patients, the deficiency of PD-1 protein expressed on monocytes in GPA 
patients may contribute to the autoimmune responses through providing less 
suppression.  
A previous study in mice has indicated that expression of PD-1 alone does not 
trigger apoptosis [239].  Interaction between PD-1 and its ligands has been 
shown to be related to autoimmune diseases in different animal models.  
Ligation of PD-1 expressed on activated lymphocytes with PD-L1 in addition to 
blocking ICOS-mediated co-stimulation, was shown to suppress the development 
of a lupus-like syndrome and nephritis in an autoimmune mouse model [424].  
Blockade of the PD-1/PD-L1 pathway was demonstrated to accelerate type 1 
diabetes in NOD mice [415], as well as break CD4+ T cell tolerance in NOD mice 
achieved by treatment with insulin [416].  Ligation of PD-1 with PD-L1/Fc 
fusion protein was reported to result in fewer infiltrated inflammatory cells and 
effectively improve disease in rat models for experimental autoimmune 
glomerulonephritis [425].  Autoreactive B cells in mice were demonstrated to 
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be suppressed by PD-1 ligation through PD-L1 and PD-L2 [284].  Therefore, 
although no difference of mRNA encoding PD-1 in lymphocytes and monocytes 
was observed from GPA patients in this thesis, PD-1/PD-L pathways might still 
contribute to the pathogenesis of GPA due to the deficiency of PD-1 ligands in 
different cell subsets. 
 
5.3.2 PD-L1 in GPA 
The relative quantity of PD-L1 in total PBMC, lymphocyte subsets and monocytes 
from GPA patients has been described for the first time in this thesis.   Lower 
relative quantities of mRNA encoding PD-L1 in whole PBMC, CD4+ T cells and 
CD14+ monocytes were observed in GPA patients on conventional therapies and 
GPA patients following B cell depletion therapy compared to healthy controls.  
Changes in PD-L1 expression by monocytes and DCs have been observed in 
inflammatory and autoimmune diseases.  One study has indicated that 
expression of PD-L1 on monocytes was deficient in patients with Crohn’s disease 
[426].  A reduction in PD-L1 expression on peripheral CD14+ cells has been 
observed in patients with active Multiple Sclerosis but not stable Multiple 
Sclerosis [421].  In contrast, some studies have reported that the expression of 
PD-L1 on monocytes and DCs is up-regulated in patients in remission but not 
patients with active SLE [427], while another study reported an increased 
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proportion of PD-L1+CD14+ monocytes in both SLE patients with active disease 
and those in remission [428].  
Animal models have identified an association between PD-L1 expression and 
autoimmune diseases.  Studies on mice have shown that PD-L1 deficiency can 
cause expansion of autoreactive T cells with diabetes [279, 280].   
Furthermore, studies on animal models and human samples have indicated that 
PD-L1 expressed by monocytes and DCs regulated Treg cell induction.  Some 
studies indicated that PD-L1 expressed on DCs in mesenteric lymph nodes 
promoted the generation of antigen-specific Treg cells in a mouse model [303].  
This was supported by a study on human peripheral DCs which demonstrated 
that blockade of PD-L1 on DCs inhibited Treg cell expansion after M. tuberculosis 
infection [429].  Therefore the deficiency of PD-L1 mRNA in CD14+ monocytes 
from GPA patients might lead to less suppression of the immune response and 
also cause a reduction in iTreg cell generation. 
The interaction between PD-L1 on DCs and Treg cells may be bi-directional.  
Although TGF-β produced by Treg cells has been demonstrated to down-regulate 
PD-L1 expression on monocytes in SLE patients [430], Treg cells were 
demonstrated to promote the maturation of DCs and up-regulate PD-L1 
expression on DCs which had reduced capacity to stimulate effector T cells [431].  
Therefore the lower frequency of Treg cells found in GPA patients described in 
chapter 4 might contribute to the shortage of PD-L1 in monocytes as well.  
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PD-L1 has also been reported to be expressed on Treg cells [283, 284, 431].  
Although some studies found that Treg cells do not suppress immune responses 
via PD-1/PD-L pathways [432], PD-L1 deficient Treg cells were shown to be 
defective in inhibiting alloreactive Th1 cells in a mouse model [283].  Moreover, 
a recent study illustrated that Treg cells suppress autoreactive B cell responses 
directly through interaction between PD-L1/PD-L2 expressed on its surface and 
PD-1 expressed on B cells in mice [284].  This information together implies that 
the reduction of Treg cells and PD-L1 mRNA in GPA patient may contribute to the 
pathogenesis of GPA by multiple pathways. 
PD-L1 expression by CD4+ T cells may play an important role in regulating 
immune responses.  Some animal studies have shown that PD-L1 expressed by 
naive T cells is required for DC maturation during microbial infection [433].  
Therefore a shortage of PD-L1 mRNA in CD4+ T cells in GPA patients might result 
in failure of DC maturation and then lead to impaired interaction between DCs 
and B cells which could eventually cause autoantibody production.  
Studies of animal models have shown that in addition to PD-1, PD-L1 can also 
interact with co-stimulatory molecule B7-1, and down regulate T cell responses 
[277].  Therefore the deficiency of PD-L1 in GPA patients may contribute to the 
failure of immune tolerance by pathways other than PD-1/PD-L1 pathway alone.  
PD-L1 has been shown to be expressed on many different cell types in mouse 
models and has different functions.  PD-L1 expression has been detected in 
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many organs in mouse, including thymus, spleen, cardiac endothelium and 
pancreatic islet [302].  PD-L1 expressed on non-hematopoietic cells has been 
shown to limit tissue damage during chronic virus infection in mice [434].  In a 
mouse model of autoimmune diabetes, PD-L1 expressed on islet cells has been 
demonstrated to inhibit tissue destruction mediated by CD4+ T cells [435].  
PD-L1 expressed in tissue has been shown associated with human autoimmune 
disease and transplant tolerance as well.  Increased PD-L1 expression on 
inflamed epithelial cells in salivary gland has been detected in patients with 
Sjögren’s Syndrome [393].  PD-L1 expressed on brain endothelial cells has been 
found to inhibit T cell transmigration in patients with multiple sclerosis [299], 
while high expression of PD-L1 on keratinocytes has been shown to suppress 
allo-reactive immune responses through inducing Treg cells [436].  Therefore it 
would be interesting to study the expression of PD-L1 on non-hematopoietic 
cells, especially cardiac endothelium cells as it may contribute to the 
pathogenesis of vasculitis, in GPA patients in the future.  
 
5.3.3 PD-L2 in GPA 
The relative quantity of PD-L2 in whole PBMC, lymphocyte subsets and 
monocytes from GPA patients has been described for the first time in this thesis.  
Lower relative quantities of mRNA encoding PD-L2 in CD4+ T cells, CD8+ T cells 
223 
 
and CD14+ monocytes were observed in GPA patients on conventional therapies 
compared to healthy controls.  The relative quantity of mRNA encoding PD-L2 
in CD4+ T cells was higher in GPA patients following B cell depletion therapy 
than those on conventional therapies.  
Like the PD-1/PD-L1 pathway, the interaction between PD-L2 and PD-1 has been 
reported to regulate T cell responses and affect T cell differentiation in animal 
models.  In 2001, PD-L2 was reported to be the second ligand for PD-1, and the 
interaction between PD-L2 and PD-1 was shown to inhibit T cell proliferation 
and cytokine production in mouse models [291].  Further study indicated that 
like the PD-1/PD-L1 pathway, the PD-1/PD-L2 pathway also down-regulates 
CD4+ as well as CD8+ T cell responses in mice [247].  This was further 
confirmed by PD-L2 blockade in experimental autoimmune encephalomyelitis 
(EAE) mice, which results in T cell expansion and accelerated and more severe 
disease [306].  Moreover, PD-L2 was also reported to regulate the generation of 
inducible Treg cells in mice.  One study demonstrated that PD-L2 deficient DCs 
induce fewer Treg cells in mesenteric lymph nodes in a mouse model [303]. 
The PD-1/PD-L2 pathway has been shown to regulate T cell responses in 
humans as well.  Studies of peripheral blood from healthy human donors have 
illustrated that the PD-1/PD-L2 pathway down-regulates T cell proliferation and 
cytokine production [304, 305].  As discussed above, PD-L2 was also involved in 
regulating autoreactive B cell responses, as the expression of PD-L1 and PD-L2 
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on Treg cells were both required for inhibiting autoreactive B cell proliferation in 
mice [284].  Therefore the deficiency of PD-L2 mRNA in T cells and monocytes 
from GPA patients might result in less suppression of T cell responses, failure to 
suppress antoreactive B cell responses, and may contribute to the reduction of 
inducible Treg cells observed in chapter 4. 
Although PD-1/PD-L2 interaction has been demonstrated to suppress immune 
responses in mouse models as well as human studies, the mechanism of 
inhibition has been reported to be different from that in PD-1/PD-L1 pathway.   
One study demonstrated that although either PD-L1 or PD-L2 deficiency resulted 
in EAE mouse model, PD-L1 deficient mice developed more severe disease than 
PD-L2 deficient mice, and inflammatory cytokines produced in lymph nodes 
from PD-L1 deficient mice was more than in PD-L2 deficient mice [307].  
Another study reported PD-L1 and PD-L2 negatively regulated immune 
responses in experimental animal models of autoimmune kidney disease via 
different mechanisms, as different cell infiltrate and antibody deposits were 
observed from PD-L1 deficient and PD-L2 deficient mice [437].  Moreover, one 
recent study reported the molecular mechanisms of binding to PD-1 were 
different in PD-L1 and PD-L2 in human [438].  Therefore the deficiency of 
mRNA encoding PD-L1 and PD-L2 found in GPA patients might contribute to the 
disease pathogenesis through different pathways.  
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Although PD-L2 expression by un-stimulated peripheral lymphocytes was not 
observed in this study, expression of PD-L2 by activated cells from peripheral 
blood in humans has been described by others.  One study indicated that PD-L2 
is inducibly expressed by activated CD4+ and CD8+ T cells from human blood.  
An increased relative quantity of PD-L2 mRNA was also observed in activated 
CD4+ T cells [294].  PD-L2 expression by peripheral blood monocytes was 
reported to be up-regulated in multiple sclerosis patients treated with IFN-β 
[295].  Therefore, it would be interesting to isolate and culture lymphocytes 
from GPA patients, and then study the PD-L2 expression on those cells after 
stimulation in the future.  
The expression of PD-L2 in tissues has also been described in autoimmune 
mouse models and human studies.  One study observed PD-L2 expression on 
inflammatory infiltrating cells in brains from EAE mice [302].  In humans, 
PD-L2 was found to be expressed by macrophages and DCs in livers from 
patients with autoimmune liver diseases.  The relative quantity of PD-L2 mRNA 
was observed to be higher as well in livers from patients with autoimmune liver 
diseases compared to normal controls [296].  In addition, another study 
demonstrated that PD-L2 is expressed by renal tubular epithelial cells in the 
kidneys from patients with lupus nephritis [297].  Therefore it would be 
interesting to study the expression of PD-L2 in inflammatory tissues in GPA 
patients in the future. 
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5.3.4 VISTA in GPA 
The relative quantity of VISTA in whole PBMC, lymphocyte subsets and 
monocytes from GPA patients has been described for the first time in this thesis.  
No significant difference in the relative quantity of mRNA encoding VISTA was 
found in all cell types studied.  
VISTA has been reported to be homologous to PD-L1 while not interacting with 
PD-1 in mice.  It has also been shown to negatively regulate T cell-mediated 
immune responses in EAE mice [311].  Different from B cells from spleens in 
the mouse, a small amount of mRNA encoding VISTA was observed in human 
peripheral blood.  However, no difference in the relative quantities of VISTA 
mRNA was found in whole PBMC, different lymphocyte subsets, or monocytes 
from GPA patients compared to healthy controls.  There is therefore no 
evidence to suggest that VISTA is involved in the pathogenesis of GPA.  
 
5.3.5 PD-1, PD-L1, PD-L2 and VISTA in SLE 
Significantly lower relative quantity of mRNA encoding PD-L1 in CD4+ T cells, 
but not other cell types, was observed in patients with SLE compared to healthy 
controls.  No significant difference in the relative quantities of mRNA encoding 




Previous studies have shown a reduction in the percentage of PD-1 expressing 
CD4+ T cells and CD8+ T cells, with an increase in the proportion of PD-L1 
expressing monocytes in SLE patients [418, 427, 428].  However, no difference 
in either proportion of PD-1+ CD4+ T cells or mRNA encoding PD-1 was found in 
any lymphocyte subsets or monocytes from SLE patients in our study.  This may 
be because of either the limited sample numbers involved in this study or the 
lack of correlation between encoding mRNA level and protein expressed.  In our 
study, a reduction in mRNA encoding PD-L1 in CD4+ T cells, while no difference 
in monocytes was found in SLE patients.  This may be because SLE is a disease 
with various symptoms and a range of subtypes.  Patients involved in our study 
were not sub-divided since they were used as disease controls for the study of 
GPA.  It would be interesting to study the expression of PD-1 and its ligands 
PD-L1 and PD-L2 by lymphocytes and monocytes from well defined subtypes of 





- Although no difference in mRNA encoding PD-1 was observed in 
peripheral blood lymphocytes and monocytes from GPA patients, PD-1 
may still be involved in the pathogenesis of GPA through reduced 
PD-1/PD-Ls signals. 
- The shortage of mRNA encoding PD-L1 in circulating CD4+ T cells and 
CD14+monocytes from GPA patients may contribute to the disease 
pathogenesis in multiple pathways. 
- The deficiency of mRNA encoding PD-L2 in peripheral CD4+ T cells, CD8+ 
T cells and CD14+ monocytes from GPA patients may also contribute to 
the disease pathogenesis. 
- No difference in mRNA encoding VISTA in circulating lymphocyte subsets 
and monocytes from GPA patients was observed implies that VISTA is not 











Overview and potential future directions 
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The aim of this thesis was to investigate the immunology in GPA and to increase 
understanding of this disease, as immunological features of GPA are not well 
studied.   
In chapter 3 of this thesis, chronic activated B cells surrounded by abundant B 
cell survival factors and autoantibody target neutrophils without the presence of 
organized lymphoid structure were observed in lesions from GPA patients.  
This suggests that B cells in lesions from GPA patients could be stimulated by 
sustained PR3 expression, and their survival could be supported by local BAFF 
and APRIL production.  In addition, B cells in the lesion might not be a 
component of any circulating B cell subsets that could migrate to the target 
tissue, as no evidence for this was observed in the study of B cell clonality.  This 
suggests that B cell responses and autoantibody production in lesions from GPA 
patients is independent of circulating B cells.  Once B cells migrate to the lesion, 
they may be supported by abundant local BAFF and APRIL to survive.   
No difference in proportions of different circulating B cell subsets that might 
have the potential to migrate to lesions was found in GPA patients compared to 
healthy controls.  This suggests that unlike B cells in lesions, circulating B cells 
in peripheral blood from GPA might not contribute directly to the pathogenesis 
of GPA.  Later studies of circulating TFH cells and Treg cells in peripheral blood 
from GPA patients on conventional therapies and GPA following BCD therapy 
suggests that B cells might contribute to the pathogenesis of GPA through 
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affecting frequencies of circulating TFH cells and Treg cells.  Altering frequencies 
of such immunomodulatory T cell subsets may break the balance between 
up-regulating and down-regulating inflammation in GPA. 
In chapter 4 of this thesis, higher frequency of circulating TFH cells while lower 
frequency of Treg cells was observed in peripheral blood from GPA patients on 
conventional therapies compared to controls.  However, BCD treated GPA 
patients were no different to healthy controls in the frequencies of these T cell 
subsets.  This suggests that the frequencies of circulating TFH cells and Treg cells 
in peripheral blood might be B cell dependent, and the changes found in GPA 
patients might contribute to the pathogenesis of GPA.   
The increased proportion of circulating TFH cells in peripheral blood from GPA 
patients might lower the threshold for autoreactive B cells to survive.  In 
addition, although no organized lymphoid structure was found in most lesions 
from GPA patients, PD-1+ T cells were observed in the lesions mixed with B cell 
infiltrates.  These cells could have the functional capacity of TFH cells and may 
provide help to local autoreactive B cells.   
Although the frequencies of Treg cells in peripheral blood from GPA patients on 
conventional therapies were found to be decreased, the suppressive capacity per 
Treg cell was found to be the same as it in healthy controls.  This suggests that 
the failure to control autoimmune responses in GPA might partly be due to 
changes in frequency of Treg rather than functional deficiency.  The pathogenic 
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pathway through Treg and TFH cells in GPA and the possible explanation for how 
B cell depletion therapy works in GPA is hypothesised in figure 6.1. 
 
Figure 6.1 Hypothesis of pathogenic pathway through Treg and TFH cells and the 
possible mechanism of B cell depletion therapy in GPA.  Top: In healthy individuals, 
TFH cells interact with B cells in GCs, provide help for B cell survival and Ab production.  
The frequencies of Treg cells and cTFH cells in peripheral blood are inversely correlated.  
The functional link between Treg cells and B cells is not clear yet.  Bottom Left: In GPA 
patients, there are more TFH cells which provide more help to B cells and result in less 
competition for B cells producing low affinity Abs to survive.  Fewer Treg cells in GPA 
patients will lead less suppression to immune responses.  Therefore B cells in GPA 
patients could produce autoantibodies and release them to peripheral blood.  Bottom 
Right: When GPA patients are treated with rituximab, B cells are depleted; the 
frequencies of TFH cells reduce, while Treg frequencies increase to normal level which 
provides suppression for immune responses.  Therefore the patients are clinically 
improved. 
As the frequencies of circulating TFH cells and Treg cells were inversely 
correlated in human peripheral blood, in the future it could be possible to 
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longitudinally investigate these changes in GPA patients before and after 
receiving BCD treatment to see whether this ratio changes in a single patient 
during treatment and determine if this could be developed as a biomarker for 
disease relapse in GPA.  This study could also attempt to link the frequencies of 
circulating TFH and Treg cells to the BVAS disease activity score.   
The reasons for the increased frequencies of circulating TFH cells and decreased 
frequencies of Treg cells in peripheral blood from GPA patients are not clear.   
Likewise, the mechanism of dependence of frequencies of circulating TFH cells 
and Treg cells on B cells in peripheral blood is not clear.  Whether it is affected 
by B cells directly or through other mediating molecules is not known.  The 
study of PD-1/PD-Ls in chapter 5 of this thesis might provide clues to enable to 
address these questions. 
In chapter 5 of this thesis, decreased levels of mRNA encoding PD-L1 and PD-L2 
were found in circulating T cells and monocytes from GPA patients compared to 
healthy controls.  Therefore, although no difference in mRNA encoding PD-1 
was observed in peripheral blood lymphocytes and monocytes from GPA 
patients, PD-1 may still be involved in the pathogenesis of GPA through reduced 
activity of PD-1/PD-L pathways.   
Previous studies have reported that PD-L1 can promote Treg differentiation 
while inhibiting TFH cell development through interacting with PD-1 expressed 
on antigen presenting cells [166, 282].  Therefore, increased frequencies of 
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circulating TFH cells and decreased frequencies of Treg cells found in peripheral 
blood from GPA patients might due to a deficiency of PD-L1 protein on T cells 
and monocytes.  This could be further investigated in the future.  As all data 
obtained in this thesis is generated from freshly isolated cells, future study could 
measure expression of and manipulation of PD-1 and PD-Ls in response to 
stimulation in vitro.  The hypothesis of abnormal frequencies of Treg and cTFH 
cells caused by deficiency of PD-L1 in GPA patients is shown in Figure 6.2. 
 
Figure 6.2 Hypothesis of PD-L1 deficiency affects Treg and cTFH cell frequencies 
in GPA patients.  Signal through PD-L1 and PD-1 promotes Treg cell differentiation 
and inhibits TFH cell development in healthy people. While in GPA patients, the 
deficiency of PD-L1 on monocytes would lead to failure of promoting Treg and inhibiting 
TFH developments which results in less Treg cells and more TFH cells in GPA patients.  
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Time and funding did not permit these experiments, but the data generated in 
this thesis has identified a number of pathways that appear highly relevant to the 
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Granulomatosis with polyangiitis involves sustained
mucosal inflammation that is rich in B-cell survival
factors and autoantigen
Yuan Zhao1, Edward Odell2, Lee Meng Choong3, Francesca Barone4,
Paul Fields5, Bridget Wilkins6, Fahim M. Tungekar6, Pritash Patel7,
Jeremy D. Sanderson7, Shirish Sangle3, David D’Cruz3,* and Jo Spencer1,*
Abstract
Objective. Granulomatosis with polyangiitis (GPA) is a rare chronic autoimmune disease that may be
triggered by upper airway infection. ANCAs specific for PR3 that is expressed by activated neutrophils
and macrophages are associated with GPA. Our aim was to investigate regional immune mechanisms that
might induce or support the autoimmune response in GPA.
Methods. Biopsy samples from 77 patients including 8 with GPA were studied by immunohistochemistry.
B-cell homing subsets in blood samples from 16 patients with GPA and 11 healthy controls were studied
by FACS. The distribution of B-cell clones was searched in paired biopsies and blood samples from one
patient by analysing immunoglobulin heavy chain gene (IGH) junctional sequences.
Results. Activated B cells were located alongside PR3-expressing cells and B-cell survival factors BAFF
and APRIL in mucosa from patients with GPA. We detected APRIL production by the granulomas and
giant cells. B cells were proliferating in all cases and persistent for 5 years in biopsies obtained from one
patient. However, there was no evidence of B-cell clones from the mucosal biopsies circulating in per-
ipheral blood in GPA or any numerical or proportional change in B-cell subsets expressing markers of
regional homing in blood in GPA.
Conclusions. Our study illustrates chronically activated B cells alongside autoantigens and B-cell survival
factors in the mucosa in GPA.
Key words: granulomatosis with polyangiitis, B cells, granuloma, APRIL, immunoglobulin genes.
Introduction
Granulomatosis with polyangiitis (GPA) is a rare,
multi-organ inflammatory disease that may affect lungs,
bronchi, oral or nasal mucosa, eyes, kidneys, nerves,
brain, joints and skin [1, 2]. GPA is associated with the
production of autoantibodies to neutrophil cytoplasmic
antigens (ANCAs) in particular antibodies to the protei-
nase 3 (PR3) autoantigen expressed by neutrophils and
activated macrophages [36]. Friederich Wegener first
observed that patients with this disorder almost univer-
sally had upper airway disease especially affecting the
facial sinuses, and he proposed that the disease was
initiated in the upper airways [7, 8]. It has been suggested
that Staphylococcus aureus infection may be associated
with the pathogenesis of GPA and persistent S. aureus
nasal carriage is associated with a risk of disease relapse
[9, 10]. The chronological sequence of upper airway
symptoms followed by systemic manifestations, including
a high incidence of thromboembolic events [11], is con-
sistent with the notion that GPA may evolve as a conse-
quence of upper airway inflammation and that other
systemic, potentially life-threatening symptoms are a
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direct consequence of the inflammation and activity of
pathogenic autoantibodies.
The immunological features of the mucosal microenvir-
onment in GPA have not been studied extensively.
Classical features of the disease include a mixed infiltration
of acute and chronic inflammatory cells, vasculitis, granu-
lomas and small numbers of giant cells [1214]. It has been
shown that B cells are present in the nasal mucosa in GPA
and that the immunoglobulins they express are encoded by
genes that are mutated in their immunoglobulin variable
regions, a feature of germinal centre (GC) origin [15, 16].
Despite this, conventional germinal centres have not been
identified as a consistent feature of the inflamed airway
mucosa in GPA, though GC-like structures have been
described [17]. B cells in normal oro-nasal mucosa and
bronchial mucosa have been identified in organized lymph-
oid structures termed nasal-associated lymphoid tissue
(NALT) or bronchus-associated lymphoid tissue (BALT), re-
spectively [18]. In addition, isolated activated B cells can
be identified beneath the stratified/pseudostratified epithe-
lium in oral mucosa that are increased in frequency and are
associated with plasma cell differentiation in local inflam-
matory responses [19].
In this study, we have characterized the B-cell infiltrate in
mucosa in GPA. We have related the distribution of B cells
to the distribution of cells expressing or binding the PR3
autoantigen and to the local production of B-cell survival
factors, B-cell activating factor (BAFF) and a proliferation-
inducing ligand (APRIL) by immunohistochemistry. We
observe that large activated B cells in GPA exist alongside
an abundance of cells expressing PR3. The B cells in GPA
mucosa express BAFF receptor and are therefore poten-
tially able to receive survival signals from locally produced
BAFF. APRIL is expressed abundantly by many cell types
in GPA mucosa, but most notably by the granulomas and
giant cells that are a feature of the disease.
Immunoglobulin heavy chain gene (IGH) analysis allows
the identification of B-cell clonality by comparison of junc-
tional sequences that are unique to each B cell and its
clonal progeny. By immunoglobulin variable region gene
analysis, we observed evidence for local and sustained
B-cell clones in the upper bronchial mucosa in GPA in a
single case studied. We also studied subsets of blood
lymphocytes and saw no evidence for preferential expan-
sion of cells associated with any anatomically defined
circulation pathways. By IGH analysis, there was no evi-
dence of the B-cell clones identified in the mucosa circu-
lating in the blood.
Overall, our study supports the concept that the
mucosa in GPA is a niche containing chronically activated
B cells and autoantigen. A local autoantibody response as
described previously [20] could be sustained by the abun-
dance of local B-cell survival factors.
Materials and methods
Tissues
Paraffin blocks of inflamed mucosal biopsies from 77 pa-
tients, including 8 patients with clinically confirmed GPA,
were selected to include a range of characteristics from
mild lymphocytic infiltrates considered within normal
histological limits through to marked inflammation
(detailed location of the tissue sampled and the diagnoses
are included in supplementary Table S1, available as sup-
plementary data at Rheumatology Online). The group of
patients with orofacial granulomatosis (OFG) were con-
sidered to be an important control group because
this is a chronic granulomatous mucosal lesion, but it is
not associated with acute inflammation or autoimmunity.
Specimens were graded according to the inflammatory
infiltrate present to produce a semi-quantitative score
(Nil, Mild and Marked). This was undertaken blind by
two authors (P.P. and E.O.).
In addition, peripheral blood mononuclear cells (PBMCs)
were isolated with Ficoll-Paque from fresh blood samples
donated by 16 patients with GPA (M:F ratio 1:1, age be-
tween 25 and 73 years, average age 53 years) and 11
healthy controls (M:F ratio 1:1, age between 22 and 68
years, average 45 years). The details of patients’ clinical
information are listed in supplementary Table S2, available
as supplementary data at Rheumatology Online.
Flow cytometry (FACS)
PBMCs were isolated and incubated with fluorochrome-
conjugated mAbs on ice for 40 min. To isolate Beta7low
CLA+ CCR10 B cells, PBMCs were stained with
CD19-PE (BD Biosciences 10 ml/100ml), Beta7-PeCy5
(BD Biosciences 10 ml/100 ml), CLA-FITC (Biolegend,
15 ml/100 ml), CCR10-APC (R&D Systems, 7 ml/100 ml).
After staining, cells were washed and resuspended in
sterile PBS and immediately separated into different
subpopulations with the BD FACSAria I cell sorter or BD
FACSCanto.
Immunohistochemistry
Paraffin-embedded tissue sections (5 mm) were submitted
to antigen retrieval by heating retrieval solution (DAKO,
Glostrup, Denmark) at 95C for 40 min. Endogenous per-
oxidase and alkaline phosphatase were blocked. Sections
were single stained for CD20, APRIL, BAFF, BAFF-R, PD1,
CD57, IgD, IgG, IgA, IgM and IgE and double stained for
CD138 with CD20, Ki67 with CD20, neutrophil elastase
with CD20, PR3 with CD20, PR3 with neutrophil elastase
and E-selectin with CLA using the EnVision single and
double stain systems (DAKO). After staining, sections
were counterstained with haematoxylin.
Analysis of immunoglobulin gene sequences
IGH from blood cells was amplified from the variable
(IGHV) to constant (IGHC) regions. IGH from paraffin-
embedded biopsy sections was amplified from the frame-
work region 3 (FR3) to the joining (J) region. Semi-nested
PCR was applied (details in supplementary Table S3,
available as supplementary data at Rheumatology
Online). To search the clone relationships between biop-
sies and different circulating blood subsets, clone-specific
primers were applied to all blood subsets and biopsies
from the same patient using the FR3-IGHJ PCR program.
2 www.rheumatology.oxfordjournals.org
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All primers used are listed in supplementary Table S4,
available as supplementary data at Rheumatology Online.
Ethics approval
This study was approved by the National Research Ethics
Service (Approval no. 10/H0715/3). All patients donated
blood and agreed to allow access to biopsy and tissue
samples that were surplus to clinical investigation after
fully informed written consent.
Statistical methods
Data sets are expressed with average values and com-
parisons were made using the MannWhitney test.
Statistical analysis was carried out using GraphPad
Prism4.
Results
B cells and plasma cells as components of
chronic/acute inflammation in GPA
B and T cells were consistently present in mucosal biop-
sies from eight patients with GPA. B cells in most cases
tended not to be components of any organized lymphoid
structure but were scattered submucosally, and the infil-
trate showed no evidence of GC formation. One nasal
biopsy from a patient with GPA contained abundant orga-
nized mucosa-associated lymphoid tissue (MALT), but the
affected mucosa in the remaining cases had no evidence
of GC formation. The B cells in GPA had properties of
activated cells; they did not express IgD but were large
cells with extensive dendritic processes that extended
and made contact with many adjacent cell types.
Approximately 5% expressed the Ki67 nuclear prolifer-
ation antigen. This description of B-cell morphology,
phenotype and proliferative behaviour does not fit easily
within the current schemes of B-cell biology. These cells
were therefore compared with those seen in a range of
inflammatory conditions of different levels of severity
involving mucosal surfaces, including those around the
oral cavity and upper airways. This B-cell subset was in-
distinguishable from that consistently seen in other biop-
sies of nasal and oral mucosa stained as controls,
demonstrating that the presence of this B-cell subset
was not a disease-specific observation. Unlike the con-
trols, used in this study, however, the B-cell infiltrate in
GPA was generally intimately mixed with acute inflamma-
tory cells that included cells expressing the GPA-asso-
ciated autoantigen PR3 and neutrophil elastase.
The plasma cell and B-cell infiltrates tended to occupy
adjacent areas of mucosa. Plasma cells were often
observed in the infiltrate that was predominantly B cells,
but B cells were rare in the plasma cell-dominated zones.
The majority of plasma cells expressed IgG rather than
IgM or IgA, consistent with the profile observed in the
control samples (Fig. 1).
Analysis of local B-cell clonality by Ig gene analysis
DNA was prepared from serial sections of diagnostic
biopsies from one patient (patient P5 in supplementary
Table S2, available as supplementary data at
Rheumatology Online) who donated surplus tissue follow-
ing surgical procedures in 2004, 2009 and 2010 and a
blood sample. Ten PCRs to amplify IGH from FR3 to J
were carried out from each of the biopsies. Clones with
the same junctional sequence from the same PCR were
considered to be the same sequence and were counted
as one. A total of 74 different rearrangements were iden-
tified; 40 from bronchial mucosa in 2004, 13 from bron-
chial tissue in 2009 and 21 from nasal mucosa in 2010.
The different numbers were a reflection of different B-cell
numbers in the different-sized tissue samples studied.
Clone-specific primers were then prepared to the V prox-
imal N-D sequence to specifically identify the clone in the
target DNA sample by PCR. Design ensured that some
non-templated sequence was present between the
clone-specific primer and the J segment primer to allow
confirmation of clonal identity by sequencing. Of 14 pri-
mers designed, 8 were found not to amplify
non-specifically in a DNA preparation of tonsil cells from
an unrelated individual and were considered to be poten-
tially clone specific. When PCR products of the correct
size were generated by clone-specific PCR, clonal identity
was confirmed by sequencing.
Although the B-cell population was polyclonal, these
methods identified three examples of B-cell clonal
FIG. 1 Examples of B lineage cells in paraffin sections of
GPA mucosa studied by immunohistochemistry.
(A) Single staining with CD20 (brown) identified B cells in
biopsies from GPA patients. (B) Double staining with
CD20 (pink) and CD138 (brown) identified B cells and
plasma cells occupying adjacent areas in GPA. Plasma
cells were present in the B-cell-dominated areas while B
cells did not tend to infiltrate plasma cell-dominated
areas. (C) Double staining of cell division antigen Ki67
(brown nucleus) and surface CD20 (in pink) identified B
cells that were proliferating in the biopsies. (D) Double
staining of CD20 (pink) and neutrophil elastase (brown)
identified that activated B cells were adjacent to neutro-
phils, the target of autoantibody ANCA, in GPA biopsies.
(E) Double staining of PR3 (in brown), the main target of
ANCA in GPA, and CD20 (pink).
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expansion in the inflamed mucosa. Two examples were
restricted to the 2009 biopsy. Remarkably, one clone was
observed to be present in bronchial tissue in both 2004
and 2009 (Fig. 2). The same method was also applied to
detect circulating B-cell clones in peripheral blood.
However, we did not observe any evidence that B-cell
clones in the lesion were circulating in peripheral blood.
Local production of B-cell survival factors in GPA
Since we saw evidence of local B-cell division and sus-
tained clonal expansion as described above, we investi-
gated the local distribution of B-cell survival factors APRIL
and BAFF and the BAFF receptor [2124], all of which can
be detected by immunohistochemistry in paraffin-
embedded tissue. APRIL was produced abundantly in
the B-cell microenvironment in GPA and in other control
mucosal biopsies. It was observed that granulomas and
giant cells, both of which are features of most cases of
GPA, contained abundant APRIL. Granulomas in OFG and
sarcoid also contained APRIL. Granulomas are, therefore,
a previously unrecognized source of APRIL that may con-
tribute to the support of the local B-cell response. The
B cells in GPA expressed the BAFF receptor, and cells
producing BAFF were also identified in the mucosa, indi-
cating that this pathway of promoting B-cell survival is
also relevant to the local response in GPA (Fig. 3).
Analysis of lymphocytes expressing regional homing
receptors in GPA
Evidence presented above is consistent with a local and
sustained B-cell response in the mucosa in GPA. We
investigated whether the chronic expansion of B cells in
the mucosa was associated with any changes in the pro-
portion of total lymphocytes or B cells in blood, which
express molecules that facilitate regional lymphocyte
homing. Cells that home to the nasal and bronchial
mucosa have been reported to express the cutaneous
lymphocyte antigen (CLA), which binds the endothelial
antigen E-selectin, but not the chemokine receptor
CCR10 [2528].
We confirmed the expression of E-selectin by flat endo-
thelium in mucosal biopsies in GPA. We then identified
cells expressing CLA, the receptor for E-selectin, either
among B cells or in the total lymphocyte gate by flow cyto-
metry. There was no difference between patients with
GPA and healthy controls in the proportion of B cells or
lymphocytes expressing CLA or any other lymphocyte
subset associated with regional homing (Fig. 4).
The clone-specific PCR method as described above
was applied to the B-cell subsets isolated from blood,
using primers designed to the CDR3 sequences observed
in the biopsy taken from the patient at the same time. No
evidence of the B-cell clones identified in the affected
mucosa was observed in the blood in any sorted subsets.
Discussion
In this study we observed that inflamed mucosa in GPA
contains chronically activated B cells intimately mixed
with cells expressing PR3, a characteristic target of
autoantibodies in most cases of GPA. The mucosal micro-
environment is rich in B-cell survival factors APRIL and
BAFF and the expression of APRIL by granulomas and
giant cells is described here for the first time. The
FIG. 2 IGH VDJ junction sequences from a patient with GPA.
(A) and (B) are alignments of sequences of VDJ obtained from different DNA samples of a biopsy obtained in 2004. The
presence of the same sequence in different PCRs confirms B-cell division and local presence of members of a B-cell
clone. (C) One VDJ rearrangement was identified in both the 2004 and the 2009 biopsies from this patient, implying that
this B-cell clone was persistent in the lesion for at least 5 years.
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combination of mixed acute and activated chronic inflam-
matory cells, alongside survival factors including APRIL
produced by granulomas and giant cells, were only seen
in GPA.
The B cells observed in GPA were indistinguishable as a
population from recently identified subepithelial dendritic
B cells in oral mucosa [19]. In GPA and a varied panel of
controls, B cells were activated cells that lack IgD, contain
a small but consistent proliferating fraction and have
irregular cytoplasmic processes that extend and contact
diverse adjacent cells. They are not associated with any
follicular structures but are present in increased numbers
and exist alongside a plasma cell component in inflamma-
tion. Such cells are not a general feature of the physio-
logical process of plasma cell differentiation from B cells.
For example, the lamina propria of the normal gut, a site of
plasma cell differentiation, does not have a significant
population of cells that resembles those observed in the
mucosa described here. In GPA, the most common Ig
isotype observed was IgG, consistent with the profile
observed in the diverse set of control tissues.
Local B-cell division observed by immunohistochemis-
try was supported by the detection of clonally related cells
in a single bronchial biopsy studied by Ig gene analysis.
Clonally related cells were detected in a polyclonal B-cell
background by comparison of CDR3 sequences. The
presence of a clonal population of B cells persisting for
5 years in one patient suggests that B-cell stimulation is
chronic.
In GPA, the B cells were often intimately associated with
cells expressing PR3. Some PR3-positive cells were
clearly neutrophils, but not all. It is possible that the abun-
dance of PR3 antigen locally provides an immunological
stimulus to potentially initiate or sustain the chronic B-cell
anti-PR3 response. However, some cases studied were
negative for autoantibodies to PR3. This demonstrates
that while this juxtaposition could possibly support the
generation of autoantigen reactive B cells, this does not
necessarily occur.
B-cell responses that result in GC formation are gener-
ally T-cell dependent [29]. T-cell involvement places strin-
gent regulation on the discrimination between self and
non-self as a consequence of thymic education [30, 31].
The chronic B-cell activity but lack of GC formation in
most disease-relevant mucosal microenvironments in
GPA might indicate that the anti-PR3 response in the
mucosa could be driven in a T-cell independent way.
B-cell survival factors APRIL and BAFF were present in
the nasal mucosa in GPA. We observed for the first time in
this study that granulomas and giant cells are both signifi-
cant potential sources of APRIL. It is possible that the
granulomas, that are also linked to macrophage fusion
and giant cell formation, may subsequently provide a
source of factors to support an aberrant B-cell response.
This observation is relevant to granulomatous diseases
other than GPA and is therefore not restricted to this auto-
immune condition. Studies have not observed correlation
between concentrations of APRIL in serum and ANCA
titres [32], and the relevance of serum BAFF to
ANCA status and vasculitis remains unclear in a study of
GPA serum BAFF varied inversely with ANCA levels
[3234]. It is not known if BAFF and APRIL produced in
mucosa acts locally or if it may contribute to the serum
pool of B-cell survival factors.
The B cells in mucosal lesions in GPA have been
observed to have mutated IGHV genes, yet in the majority
of cases no GC formation was observed in the mucosa
[15, 16]. We therefore considered that the B-cell fraction
that localizes to the mucosa might be expanded as a
population in blood in GPA as part of a migratory
continuum. It is also possible that recruitment to an in-
flammatory site might result in depletion of a subset of
inflammatory cells from the blood. When we analysed
the subsets of total lymphocytes or B cells in blood that
expressed markers associated with tissue-specific
FIG. 3 Paraffin-embedded biopsies studied by immuno-
histochemistry to identify local B-cell survival factors.
(A) Single staining of BAFF-R (in brown) identified the
distribution of B cells that expressed receptor for survival
factor BAFF in biopsies from GPA patients. (B) Single
staining of APRIL (in brown) illustrated the B-cell survival
factor APRIL production in GPA. Giant cells producing
APRIL were observed in GPA. (C) Single staining of APRIL
(in brown) in OFG. A granuloma containing a giant cell
producing APRIL is shown here. (D) Double staining of
APRIL (brown) and CD68 (pink) illustrated the APRIL
was produced by the macrophages that comprise the
granulomas in sarcoidosis. (E) Single staining of BAFF
(in brown) identified the production of B-cell survival
factor BAFF in GPA.
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homing, no differences between GPA and healthy controls
were apparent.
Overall our data are consistent with the hypothesis that
a chronic, local B-cell response in inflamed mucosa, in
the presence of abundant PR3 antigen and supported
by locally produced B-cell survival factors BAFF and
APRIL, could support the production of the autoan-
tibodies that are associated with life-threatening systemic
symptoms in GPA.
Rheumatology key messages
. B cells in the mucosa in GPA are mostly isolated,
activated cells.
. In a single case studied, local mucosal B cells
included long-lived clones.
. B-cell survival factor APRIL produced by granu-
lomas could promote B-cell survival in granuloma-
tous lesions.
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